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Abstract 
High concentrations of large very low density lipoproteins (VLDL1) give rise to 
atherogenic dyslipidaemia, which is usually associated with insulin resistant 
conditions (e.g. obesity) and increases the risk for cardiovascular disease (CVD). 
Isotopic tracer methods for determining VLDL1 kinetics are costly, time-consuming, 
labour intensive and need experience and skill to calculate the kinetic parameters.  
The aim of this thesis was to develop a simpler and cost-effective method of 
obtaining triglyceride-rich lipoproteins (TRL) kinetic data, based on the fact that 
chylomicrons (CM) or CM-like particles (e.g. Intralipid) compete with large VLDL1 
for the same lipoprotein lipase (LPL)-mediated catalytic pathway.  From this method, 
it was possible to determine VLDL1-triglyceride (TG) and -apolipoprotein (apo) B 
production rates and the Intralipid-TG clearance rate (as a surrogate measure of CM 
clearance).  Kinetic data obtained from this method agreed with values and 
relationships obtained from stable isotope methods.  The protocol is relatively quick, 
inexpensive, and transferable to non-specialist laboratories. 
As a first application, the ‘Intralipid method’ was used to investigate the effects of 
hyperinsulinaemia and hyperglycaemia due to glucose ingestion on VLDL1-TG and -
apoB production rates and Intralipid-TG clearance rate.  This showed that hepatic 
VLDL1 production is suppressed in response to hyperinsulinaemia and that the 
change in Intralipid-TG clearance rate with hyperinsulinaemia correlated 
significantly with HOMA-estimated insulin resistance (HOMAIR).  In addition, 
alanine aminotranferase (ALT) concentrations (a marker for liver fat), within normal 
range, predicted the extent of hepatic VLDL1 suppression. 
Secondly, the Intralipid method was used to investigate the mechanisms responsible 
for the hypotriglyceridaemic effect of a moderate exercise session (120 min walking 
at 50% V
.
O2max) in overweight/obese middle-aged men; the section of the population 
at high risk of CVD in whom exercise-for-health guidelines are targeted.  This 
showed that the exercise-induced reduction in plasma TG was due to increased 
VLDL1-TG and -apoB clearance, rather than decreased hepatic production.  Exercise 
XIX  
also increased Intralipid-TG clearance rate, but to a lesser extent than VLDL1, 
suggesting an increased affinity of VLDL1 for LPL-mediated lipolysis post-exercise. 
Taken together, the Intralipid method is a relatively simple, safe and cost-effective 
method to determine in VLDL1-TG and -apoB production rates and Intralipid-TG 
clearance rates.  It is also sensitive enough to detect physiological changes in TRL 
kinetics.  
 
XX  
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1.  Introduction and Literature Review 
1.1 
1.2 
1.2.1 
Introduction 
This chapter aims to establish a scientific rationale for the experimental studies 
described in this thesis.  It starts with a brief overview of lipoprotein classification 
and metabolism.  This is followed by an in-depth review of very low density 
lipoprotein (VLDL) metabolism and regulation, with special emphasis on the effects 
of elevated concentrations of VLDL in the formation of atherogenic dyslipidaemia. 
In addition, the effects of hyperinsulinaemia and moderate exercise on VLDL 
production are also discussed.  Finally, methods used for measuring VLDL kinetics 
are reviewed. 
Lipoprotein Metabolism 
Classification and Properties of Lipoproteins 
Lipids, being insoluble in water, need to be combined with proteins for transport in 
the blood.  The resulting particles are lipoproteins and the protein moieties are 
known as apolipoproteins (apo) (Gurr et al., 2002).  The Lipoprotein particle 
consists of a hydrophobic core of triglycerides (TG) and cholesteryl esters (CE), 
surrounded by a monolayer surface of the amphipathic (both hydrophilic and 
hydrophobic) phospholipids (PL), small amounts of free cholesterol and proteins 
(Ginsberg et al., 2005).  Lipoproteins differ according to the ratio of lipid to protein 
within the particle as well as the proportions of lipids, they form a continuum of 
particles varying in composition, size, density and function (Gurr et al., 2002; 
Ginsberg et al., 2005).  It is convenient, therefore, to classify plasma lipoproteins 
into different density classes and to separate and isolate them by ultracentrifugation 
(Gurr et al., 2002).  These are: chylomicrons (CM), very low density lipoproteins 
(VLDL), intermediate density lipoproteins (IDL), low density lipoproteins (LDL) 
and high density lipoproteins (HDL) (Table 1.1).  It should be noted, however, that 
these classes are not homogenous and there is a wide variety of particle size and 
chemical composition within each class.  The major apolipoproteins are described in 
Table 1.2.  
      Table   1.1: Composition and characteristics of the human plasma lipoproteins (Gurr et al., 2002; Ginsberg et al., 2005; Packard & Shepherd, 1997) 
Composition (%) 
Class  Density 
(g.ml
-1) 
Svedberg
Floatation
Rate (Sf) 
Diameter 
(nm)  Apolipoproteins Function 
Protein TG CHOL* PL 
Chylomicrons  <0.95 >400  80-1000  AI, AII, AIV, B-48, CI, 
CII, CIII, E 
Transport of 
dietary fat  2 80-95 2-7  3-9 
VLDL  0.95-1.006  20-400  30-80  B-100, CI, CII, CIII, E  Transport of 
endogenous fat  8 55-80  5-15  10-20 
IDL  1.006-1.019 12-20  25-35  B-100,  CI,  CII, CIII, E  -  19  20-50  20-40  15-25 
LDL  1.019-1.063 0-12  18-25  B-100 
Transport of 
CHOL to 
periphery 
22 5-15  40-50  20-25 
HDL  1.063-1.210 –  5-12 AI, AII, AIV, CI, CII, 
CIII, D, E 
Reverse transport 
of CHOL  40 5-10  15-25  20-30 
      * Free and esterified cholesterol (CHOL). 
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Table   1.2: Characteristics of the major apolipoproteins (Gurr et al., 2002; Ginsberg et al., 2005) 
Apolipoprotein MW  Major site of 
synthesis  Function 
apo A-I  28 000  Liver, intestine  Structural component of HDL; activates LCAT 
apo A-II  17 000  Liver, intestine  May inhibit HL activity; inhibits AI/LCAT 
apo A-IV  44 500  Intestine  Activates LCAT; possibly facilitates transfer of apos between HDL and chylomicrons 
apo A-V  39 000    Associated with lower TG levels; facilitates LPL 
apo B-48  241 000  Intestine  Structural component of chylomicrons 
apo B-100  513 000  Liver  Necessary for secretion of VLDL from liver; structural protein of VLDL, IDL and LDL; ligand 
for the LDL receptor 
apo C-I  6 600  Liver  Activates LCAT; may inhibit hepatic uptake of chylomicrons and VLDL remnants; may inhibit 
CETP 
apo C-II  8 800  Liver  Activates LPL (essential cofactor) 
apo C-III  8 800  Liver, intestine  Inhibits LPL and hepatic uptake of chylomicrons and VLDL remnants 
apo E  34 000 
Liver (60-80%), 
other tissues 
including adipose 
tissue 
Ligand for LDL receptor, LDL receptor-related protein and proteoglycans 1. Introduction and Literature Review 
Lipoproteins can also be classified according to their major lipids content into TG-
rich lipoproteins (TRL), which include chylomicrons and VLDL, and cholesterol-
rich lipoproteins, which include LDL and HDL (Sparks & Sparks, 1994).  
Lipoprotein metabolism is a complex process to which new insights are continually 
being added.  TRL metabolism is divided into the exogenous and endogenous lipid 
transport pathways.  The exogenous pathway involves the delivery of dietary lipids 
(cholesterol, TG and PL) from the small intestine to the liver and peripheral tissues, 
while the endogenous pathway involves the delivery of lipids from the liver to 
peripheral tissue.  As far as cholesterol metabolism is concerned, the exogenous and 
endogenous pathways are collectively known as forward cholesterol transport, 
whereas HDL metabolism is also known as the reverse cholesterol transport as it 
removes cholesterol from peripheral tissues.  
1.2.2  Exogenous Lipoprotein Metabolism 
After ingestion of a meal, dietary TG and cholesterol are absorbed into the small 
intestine cells where they are packed into nascent apoB-48-containing chylomicrons 
(Ginsberg et al., 2005) with a Svedberg flotation rate (Sf) of >400 (Gurr et al., 2002) 
(Figure 1.1).  The newly synthesised chylomicrons enter the circulation through the 
lymphatic system and via the superior vena cava, where they acquire apoC-II, apoC-
III and apoE (Ginsberg et al., 2005).  Chylomicrons also contain apoA-I and apoA-
IV (Alaupovic, 1991).  The TG content of chylomicrons is then hydrolysed by 
lipoprotein lipase (LPL) (section 1.2.5) situated on the capillary endothelium of 
predominantly adipose and muscle tissues (Fielding & Frayn, 1998; Goldberg, 1996).  
While apoC-II acts as activator for LPL (Olivecrona & Beisiegel, 1997), both apoC-
III (Wang et al., 1985) and apoE (Jong et al., 1997) act to inhibit lipolysis by LPL.  
However, it is the balance of apoC-II and apoC-III that determines, in part, the 
efficiency with which LPL hydrolyses chylomicron TG (Ginsberg et al., 2005; Chan 
et al., 2008).  The released non-esterified fatty acids (NEFA) from chylomicrons are 
either taken up by adipose tissues, re-incorporated into TG and stored, or by muscle 
tissue where they can be used for energy (Ginsberg et al., 2005).  Some dietary 
NEFA will also ‘spillover’ into the circulation (Barrows et al., 2005).  As a result of 
lipolysis, a new particle called ‘chylomicron remnant’ is formed with some attached 
LPL molecules (Saxena et al., 1989).  However, it should be noted that the majority 
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of chylomicrons do not form small chylomicron remnants, rather they show signs of 
being marginated to the vascular endothelium and removed as very large 
chylomicron remnants long before they reach the size of VLDL (i.e. Sf 60-400 or the 
Sf 20-60 range) (Karpe et al., 1997).  Chylomicron remnants are relatively enriched 
in CE, both diet- and HDL-derived, which is transferred in exchange for TG, 
mediated by cholesteryl ester transfer protein (CETP) (Cooper, 1997; Ko et al., 1994; 
Chung et al., 2004).  They are also enriched in apoE and apoB and depleted of apoA-
I and apoCs (Cooper, 1997; Ginsberg et al., 2005).  The normal physiological 
function of chylomicron remnants is to return bile cholesterol to the liver by an 
enterohepatic circulation (Redgrave, 2004), while its residual TG content is an 
important source of hepatic fatty acids (FA), accounting for ~73% of newly 
synthesised hepatic VLDL in mice (Jung et al., 1999).  
Hepatic uptake of remnant particles (Figure 1.2) is thought to start when they are 
sequestered in the liver perisinusoidal space (space of Disse), where they undergo 
further processing by hepatic lipase (HL) and LPL (both of which may remain 
associated with the particle) and acquire apoE.  LPL, HL and apoE can potentially 
serve as ligands for a group of hepatic scavenger receptors, which endocytoses the 
particles, leading to their lysosomal catabolism.  Endocytosis of remnant particles 
occurs via the apoB/apoE-recognizing LDL receptor (LDLR) or LDL receptor-
related protein (LRP) in association with heparan sulfate proteoglycans (HSPGs) or 
independently by proteoglycans that are secreted into the space of Disse (MacArthur 
et al., 2007; Havel & Hamilton, 2004; Mahley & Ji, 1999). 
Another member of the LDLR family that functions as a peripheral apoE-recognising 
remnant lipoprotein receptor is the VLDL receptor (VLDLR).  It is expressed 
abundantly in FA-active tissues (heart, skeletal muscle and adipose) and binds TRLs 
but not LDL (Takahashi et al., 2004).  It is likely that VLDLR functions in concert 
with LPL and has been reported to play a major role in chylomicron metabolism by 
enhancing LPL-mediated TG hydrolysis in mice (Goudriaan et al., 2004).  
©Iqbal A.R. AlShayji (2008)    5 1. Introduction and Literature Review 
T TG G   
C CE E   
E
S Sm ma al ll l   
I In nt te es st ti in ne e
T Th ho or ra ac ci ic c 
D Du uc ct t   
L Ly ym mp ph h   
 
T TG G   
C CE E   
E
C
A
A Ap po oB B- -4 48 8   
 
T TG G   
C CE E    A
S Sk ke el le et ta al l   
M Mu us sc cl le e   
A Ad di ip po os se e   
T Ti is ss su ue e 
L LP PL L
N NE EF FA A   
   
H HD DL L   
A
E
C
C CE ET TP P   
C CE E 
T TG G   
C Ch hy yl lo om mi ic cr ro on n 
C Ch hy yl lo om mi ic cr ro on n 
R Re em mn na an nt t 
N NE EF FA A   
L Li iv ve er r   
P Pl la as sm ma a 
N NE EF FA A   
L LP PL L
 
Figure   1.1: Chylomicron Metabolism. Dietary triglycerides (TG) and cholesteryl esters (CE) are 
absorbed into the small intestine and packed as chylomicrons, which also contain apoB-48 and apoA-I 
proteins.  Chylomicrons are secreted into the circulation through the lymphatic system, where they 
acquire apoCs and E (apoC-II acts as an activator for the lipoprotein lipase enzyme (LPL) and apoE is 
needed for receptor recognition by the liver).  Chylomicron-TG is hydrolysed by LPL situated on the 
capillary endothelium of mainly adipose tissues and skeletal muscles, providing the underlying tissue 
with non-esterified fatty acids (NEFA).  Some dietary NEFA may ‘spillover’ in the circulation during 
hydrolysis by LPL.  Chylomicron-TG is also removed from the particle in exchange for CE from high 
density lipoprotein (HDL).  This is catalysed by the action of cholysteryl ester transfer protein 
(CETP).  The result is a slightly smaller and CE-enriched particle called ‘chylomicron remnant’.  It is 
also depleted in apoCs and apoA-I. The majority of chylomicron remnants are removed from plasma 
long before they reach the size of VLDL particles range.  Remnant particles are taken up by the liver 
by a number of receptors (see Figure 1.2). 
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Figure   1.2: Model of possible hepatic uptake of TRL remnants. Hepatocytes and endothelial cells 
produce membrane-bound heparan-sulfate (HS) proteoglycans (HSPGs) and secrete proteoglycans 
into the space of Disse.  After lipolytic processing of lipoproteins in the circulation by lipoprotein 
lipase (LPL; blue triangles), apoE-enriched (black circles) remnant lipoproteins enter the space of 
Disse through fenestrations in the endothelium.  Remnant lipoproteins are thought to be sequestered 
near the hepatocyte cell surface via apoE-HS binding or lipase-HS bridging on secreted HSPGs.   
Lipoproteins are further processed in the space of Disse by transfer of soluble apoE (grey circles) and 
by hepatic lipase (HL; red triangles) bound via HS.  ApoE, HL, and LPL can potentially serve as 
ligands of TRLs.  Endocytosis of lipoprotein particles occurs via LDL receptor (LDLR; blue) or LDL 
receptor-related protein (LRP; purple) in association with HSPGs or independently by proteoglycans.  
[Figure and legend reproduced with permission from Journal of Clinical Investigation (MacArthur et 
al., 2007).] 
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1.2.3   Endogenous Lipoprotein Metabolism 
The major bulk of endogenous plasma TG is carried by VLDL, which is continually 
synthesised and secreted by the liver (Packard & Shepherd, 1997).  The VLDL 
particle contains one molecule of apoB-100 (Elovson et al., 1988) and approximately 
5-25,000 TG molecules in its core (Bjorkegren et al., 1998).  It also contains apoCs 
and apoE (Packard & Shepherd, 1997).  There are at least two major subclasses of 
VLDL particles: large TG-rich VLDL1 (Sf 60-400) and smaller, more dense VLDL2 
(Sf 20-60), which have more cholesterol and a lower ratio of apoCs and apoE to 
apoB (Packard & Shepherd, 1997; Packard et al., 1984).  In normolipidaemic 
subjects, about 75% of the variation in plasma TG seems to be determined by the 
VLDL1 concentration (Tan et al., 1995).  Once in the circulation, the TG content of 
VLDL1 is rapidly removed by LPL-mediated hydrolysis (Karpe et al., 2007) and the 
action of CETP, which facilitates the transfer of TG from TRLs (mainly VLDL) to 
HDL in exchange for CE from HDL to apoB-containing lipoproteins (VLDL, IDL 
and LDL) (Stein & Stein, 2005; Ko et al., 1994).  As VLDL1 particles become 
progressively depleted in TG, they may either attain the same size and TG content as 
VLDL2 particles, or continue its delipidation to form IDL.  This is further aided by 
the lipolytic action of HL, which is also involved in the hydrolysis of IDL-TG.  As a 
result, LDL appears as the terminal particle (Packard et al., 1984).  During the 
transition of VLDL to IDL and IDL to LDL, a portion of the surface PL, apoCs and 
apoE are transferred to HDL (Verges, 2005). 
Approximately 10% of VLDL1 particles undergo complete delipidation to LDL, 
while the remaining cease delipidation in the VLDL or IDL density range forming 
remnant particles that persist in the circulation for considerable periods before being 
removed from plasma (Packard & Shepherd, 1997; Packard et al., 1984).  On the 
other hand, almost all VLDL2 particles will be effectively delipidated to LDL (Gaw 
et al., 1995; Packard et al., 1984). Similarly, not all IDL particles are delipidated to 
LDL, some are cleared by the liver (Packard & Shepherd, 1997) along with TRL 
remnant particles, possibly by the clearance pathway as chylomicron remnants (see 
Figure 1.2).  
LDL is the main cholesterol-carrying lipoprotein in plasma with each particle 
containing one molecule of apoB-100.  Generally about 65% of the total plasma 
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cholesterol is carried in LDL in man (Wang & Briggs, 2004) and its major role is to 
supply tissues with cholesterol, which is paramount for every cell for the synthesis 
and maintenance of cell membranes.  LDL particles are removed from plasma by the 
LDLR with LDL2 particle exhibiting the highest affinity (Packard & Shepherd, 
1997).  While 70% of the LDLRs are located on hepatic cells, 30% are located on the 
other cells of the body (Verges, 2005).  
1.2.4  HDL Metabolism 
The movement of lipids via chylomicrons, VLDL, IDL and LDL provides the 
peripheral cells with FA (fuel) and cholesterol (necessary for synthesis and 
maintenance of cell membranes).  While this ‘forward’ movement of TG is balanced 
by the metabolic consumption of NEFA as a source of fuel, there is no analogous 
(i.e. catabolic) mechanism for the metabolic disposal of cholesterol.  This is 
accomplished by ‘reverse’ cholesterol transport by HDL particles (Tulenko & 
Sumner, 2002).  Over the last several decades, epidemiological studies have revealed 
that levels of LDL-cholesterol are directly associated with risks of CVD, while an 
inverse relationship existed between HDL-cholesterol and the risk of the disease 
(Wang & Briggs, 2004).  
HDL particles are synthesised and secreted, mainly by the liver, as nascent or lipid-
poor disc-shaped particles (pre-β HDL) containing apoA-I and small amount of PL 
(Wang & Briggs, 2004; Tulenko & Sumner, 2002).  This lipid-poor apoA-I avidly 
absorbs free cholesterol and PL from peripheral cells mediated by ATP-binding 
cassette A1 (ABCA1) transporter on the ‘donor’ cells plasma membrane (Wang & 
Briggs, 2004).  The free cholesterol, being amphipathic, is absorbed onto the surface 
of the small HDL, which is progressively esterified by lecithin cholesterol 
acyltranferase (LCAT; bound to HDL and activated by apo A-I) and stored in the 
core of HDL (Tulenko & Sumner, 2002; Wang & Briggs, 2004).  The continuous 
addition of cholesterol converts pre-β HDL to larger spherical HDL3.  Together with 
the action of phospholipid transfer protein (PLTP) which transfers phospholipids to 
HDL (mostly HDL3) particles from VLDL/LDL (van Tol, 2002), HDL3 is converted 
to the much larger HDL2 particles (Wang & Briggs, 2004; Verges, 2005).  This stage 
of cholesterol transfer from cells to the HDL3 is mediated either by cell-surface 
receptors scavenger receptor class B type I (SR-BI) or passive diffusion, both distinct 
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from that mediated by ABCA1 (Wang & Briggs, 2004).  In addition, HDL 
accumulates apoC-II and apoE from VLDL and IDL, which serve as a reservoir of 
apolipoproteins, especially apoC-II which is needed for the activation for LPL 
(Tulenko & Sumner, 2002). 
The TG content of HDL is hydrolysed by HL, while removal of cholesterol from 
HDL3 particles occurs through CETP-mediated neutral lipid (TG and CE) exchange 
between HDL and apoB-containing lipoproteins.  Because the bulk of cholesterol 
removal is accomplished by shuttling to these particles, their uptake by the liver is 
essential for the disposal of HDL cholesterol (Tulenko & Sumner, 2002; Wang & 
Briggs, 2004).  The degradation of the larger HDL2 occurs directly by CE-selective 
uptake by the liver mediated by SR-B1.  The apoA-I from the degradation is either 
recycled for new HDL formation or cleared by the cubulin, a receptor highly 
expressed in kidney and yolk sac (Wang & Briggs, 2004). 
Figure 1.3 summarises the endogenous lipoprotein metabolism. 
1.2.5  Lipoprotein Lipase  
Lipoprotein lipase (EC 3.1.1.34) is a key enzyme for the hydrolysis of circulating TG 
(Fielding & Frayn, 1998; Preiss-Landl et al., 2002).  It is synthesized by 
parenchymal cells, then transferred to the luminal surface of endothelial cells, where 
it is bound to HSPG (Goldberg, 1996).  LPL is distributed in a variety of tissues, with 
the highest concentrations occurring in adipose tissue and muscle (Wong & Schotz, 
2002) [cardiac and skeletal (Preiss-Landl et al., 2002)].  However, substantial LPL 
activity is also detectable in differential machrophages, brain, placenta, lung, spleen, 
pancreatic β-cells and steroidgenic tissue (Preiss-Landl et al., 2002).  LPL functions 
to supply the underlying tissue with FAs derived from the TG-rich core of circulating 
chylomicrons and VLDL (Olivecrona et al., 1997).  However, chylomicrons have 
been shown to be the preferred substrate for LPL (Potts et al., 1991; Fisher et al., 
1995), as they may bind to LPL with an affinity of 50 times higher than VLDL 
(Xiang et al., 1999).  In addition, it has been shown that about forty LPL molecules 
may act on a TRL particle simultaneously to achieve the rates of TG hydrolysis 
observed (Scow & Olivecrona, 1977).  After hydrolysis of TG, the TG-depleted 
particle detaches along with some LPL molecules that may dissociate from the 
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endothelium and leave attached to the remnant particle (Goldberg, 1996; Fielding & 
Frayn, 1998).  There is a continual turnover of LPL at the endothelial site of action, 
with replacement of the dissociated LPL molecules by newly secreted molecules 
from within the tissue.  LPL circulating attached to lipoprotein particles may play an 
important role in their eventual receptor-mediated uptake (Fielding & Frayn, 1998) 
(see Figure 1.2). 
The apoC-II associated with the TRL particle acts as an activator of the enzyme 
(Goldberg, 1996; Olivecrona & Beisiegel, 1997) and apoE, which is a strong 
heparan-binding protein, anchors TRLs to the HSPG on the surface of the endothelial 
cells (Goldberg, 1996).  In contrast, apoC-III is the principal plasma inhibitor of 
VLDL lipolysis; it inhibits LPL as well as interfering with remnant lipoprotein 
clearance (Shachter, 2001; Havel et al., 1973).  
The regulation of LPL is tissue-specific in such a way that its expression correlates 
highly with both the need for, and the uptake of, lipid fuels by the tissue. For 
instance, in the fed state, when energy is abundant, LPL is downregulated in skeletal 
muscle and heart and activated in white adipose tissue which facilitates the lipolysis 
of TRL-TG in the latter tissue, directing released NEFA for esterification and storage 
(Fielding & Frayn, 1998).  On fasting, however, the situation is reversed, with 
suppression in adipose tissue and upregulation in muscle, increasing TRL-TG 
lipolysis in muscle, so that the resultant NEFAs are directed to the tissue in which 
they are needed as an oxidative fuel (Fielding & Frayn, 1998; Ruge et al., 2005).  
Such changes in LPL expression are mediated predominantly through the action of 
hormones, such as insulin, glucocorticoid, and adrenaline (Mead et al., 2002) as well 
as cytokines, fatty acids and glucose (Preiss-Landl et al., 2002).  Insulin is of 
particular interest because it plays a central role linking dyslipidaemia and insulin 
resistance, the defining feature of the metabolic syndrome (Howard, 1999). This will 
be discussed further in section 1.5. 
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Figure   1.3: Overview of the general aspects of endogenous lipoprotein metabolism. The grey 
lines represent hepatic uptake of lipoproteins and lipoprotein remnants.  The major bulk of 
endogenous triglycerides (TG) is secreted by the liver in the form of VLDL1 particles, of which apoB-
100 protein forms an integral part on the surface of the particle.  Once in the circulation, TG in the 
core of VLDL1 is hydrolysed by the action of lipoprotein lipase (LPL) which provides non-esterified 
fatty acids (NEFA) to adipose tissue and skeletal muscle.  VLDL1 also loses some of its TG content to 
HDL in exchange for cholesteryl esters (CE) via the action of cholesteryl ester transfer protein 
(CETP).  The continual removal of TG from VLDL1 gives rise to smaller VLDL2, which is also 
produced by the liver.  VLDL2 is either taken up by the liver or delipidated further by the action of 
hepatic lipase (HL) to form IDL then LDL.  Unlike other apolipoproteins, apoB-100 stays with the 
particles as they are delipidated.  LDL is the main cholesterol (CHOL)-carrying lipoprotein which 
provides cholesterol to peripheral tissues.  HDL, on the other hand, is also secreted by the liver and 
acts as a ‘reverse’ cholesterol carrier, from peripheral tissues to the liver.  LDL is taken up by the liver 
by the apoB/E recognising LDL receptor (LDLR).  Remnant (smaller) lipoprotein particles are also 
taken up by the liver in a similar manner to chylomicron remnants (Figure 1.2) by hepatic receptors, 
such LDLR and LDL receptor-related protein (LRP). 
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1.2.6  Integration of TRL Metabolism 
In the fasted state, the continually secreted VLDL (particularly the larger VLDL1) 
particles by the liver are the major substrates for LPL (Fisher et al., 1995), providing 
endogenous fat to peripheral cells.  However, after ingestion of a meal, the newly 
formed chylomicrons, being the preferred substrate for LPL (Potts et al., 1991; 
Fisher et al., 1995), will compete with VLDL1 for the same LPL-mediated catalytic 
pathway (Brunzell et al., 1973; Karpe et al., 1993a).  As the percent TG hydrolysed 
by LPL in TRL subfractions was chylomicrons > VLDL1 > VLDL2, it was proposed 
that increasing the size and TG content of a lipoprotein particle increases its 
susceptibility to hydrolysis by LPL (Fisher et al., 1995).  Another possible 
explanation for this preferential lipolysis of chylomicrons compared with VLDL 
might be due to transient changes in VLDL1 composition in the postprandial state.  
Both VLDL1 and VLDL2 are enriched in cholesterol, apoE, apoC-I and apoC-III in 
the postprandial state, but depleted in apoC-II (Bjorkegren et al., 1997).  While 
apoC-II acts as activator for LPL (Olivecrona & Beisiegel, 1997), both apoC-III 
(Chan et al., 2008) and apoE (Jong et al., 1997) act to inhibit lipolysis by LPL. 
As a result of this competition, the delipidation of VLDL1 particles is delayed and 
their concentration is increased as they accumulate in plasma after the appearance of 
chylomicrons (Karpe et al., 1993a) or chylomicron-like particles (Karpe & Hultin, 
1995; Bjorkegren et al., 1996) (Figure 1.4).  Indeed, the postprandial increase in the 
TRL particle number is mainly accounted for by VLDL, particularly VLDL1 (Karpe 
et al., 1993a).  VLDL2 particles, on the other hand, are not affected by this 
competition and, in fact, their concentrations are often lowered or unchanged 
postprandially (Bjorkegren et al., 1996; Karpe et al., 2007).  This is because, firstly, 
less VLDL1 is converted into VLDL2 and, secondly, VLDL2 is not a particularly 
good substrate for LPL (Fisher et al., 1995; Karpe et al., 2007).  
This competition and the preferential lipolysis by LPL between chylomicron-like 
particles and VLDL1 form the basis of work described in this thesis.  
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1.3 
1.3.1 
Hepatic Assembly and Secretion of VLDL 
The assembly of VLDL in the liver involves a number of complex processes which 
are still not fully understood. VLDL assembly is believed to take place in two major 
steps within two different compartments of the cell, rough endoplasmic reticulum 
(ER) and Golgi apparatus, and involves three different particles, pre-VLDL, VLDL2 
and VLDL1 (Olofsson & Borén, 2005).  It commences during the synthesis of apoB 
which is an integral part of the VLDL structure.  
Apolipoprotein B Structure 
Unlike other plasma lipoproteins, apoB is an amphipathic high molecular weight 
glycoprotein which is insoluble in aqueous solutions (Segrest et al., 2001; Kane, 
1983).  Because it binds irreversibly to TRLs and LDL, it is not transferable between 
lipoproteins (Kane, 1983; Davidson & Shelness, 2000).  There are two forms of 
apoB in mammals, which are encoded by the same gene (Davidson & Shelness, 
2000).  The full-length apoB, apoB-100, consists of 4536 amino acids, whereas 
apoB-48 corresponds to 48% of the protein from the N-terminal (Davidson & 
Shelness, 2000).  ApoB-48 is produced by a site-specific cytidine-to-uridine RNA 
editing reaction which converts a glutamine codon to a stop codon causing 
translational termination of (intestinal) apoB mRNA at residue 2152 (Davidson & 
Shelness, 2000; Olofsson & Borén, 2005).  In humans, apoB-100 is expressed in the 
liver, forming VLDL, while apoB-48 is expressed in the small intestine, forming 
chylomicrons. 
The apoB protein has a pentapartite structure consisting of one globular N-terminal 
structure, followed by two amphipathic β-sheets alternating with two amphipathic α-
helical domains (NH2-βα1-β1-α2-β2-α3-COOH) (Segrest et al., 2001).  The βα1 
domain (the N-terminal 1000 residues) is a globular structure that bears structural 
homology with the lipid-binding pocket of microsomal TG transfer protein (MTP) 
(an ER luminal protein with lipid transfer activity – see below) and the lamprey 
vitellogenin (an egg yolk lipoprotein) (Segrest et al., 2001).  Thus, apoB, MTP and 
vitellogenin are considered members of the same gene family collectively known as 
large lipid transfer proteins (LLTPs).  Although vitellogenin was presumed to be the 
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ancestral member, recent evidence suggests that MTP may be the oldest LLTP 
family member (Shelness & Ledford, 2005).  
The amphipathic β-sheet domains of apoB interact irreversibly with the neutral lipid 
core, while the α-helical domains, which are similar to those found in soluble 
apolipoproteins, may form strong but reversible binding to the lipoprotein surface 
(Davidson & Shelness, 2000).  The β2-region contains the LDL receptor-binding 
domain, needed for binding and hepatic endocytosis of LDL particles, and resembles 
the receptor binding domain of apoE, another LDLR ligand.  As this domain is in the 
truncated C-terminal region of apoB-48, chylomicrons depend on apoE to bind to the 
LDLR (Segrest et al., 2001).  
1.3.2  Assembly of VLDL 
The intracellular assembly of VLDL (Figure 1.5) starts in the rough ER during the 
biosynthesis of apoB, which is lipidated co-translationally; i.e. while the C-terminal 
portion of apoB is still being synthesised on the ribose of the ER, the N-terminal 
portion is translocated across the ER and is assembled as a small lipoprotein particle 
(Olofsson & Borén, 2005; Dashti et al., 2007).  ApoB interacts co-translationally 
with MTP, which catalyses the addition of lipids [in the order of TG > CE > 
diacylglycerol > cholesterol > PL (Rava et al., 2005)] to the growing apoB molecule.  
This results in the formation of a primordial HDL-sized lipoprotein particle, pre-
VLDL, which is retained in the cell by interaction with chaperones and other ER 
proteins (Olofsson & Borén, 2005; Shelness & Sellers, 2001).  It has been recently 
shown that MTP is not required for the initiation of this step as the first N-terminal 
1000 amino acid residue (apoB:1000) has the capacity to fold forming a PL-rich 
‘lipid-pocket’, independently of the structural requirement and lipid-transfer activity 
of MTP  (Manchekar et al., 2004; Dashti et al., 2007).  It is currently unclear at 
which point in VLDL assembly that MTP is required.  In addition to its lipid transfer 
activity, MTP facilitates the co-translational translocation of apoB across the ER 
lumen (Blasiole et al., 2007) and prevents its degradation as apoB will be sorted to 
proteasomal degradation if it misfolds or is underlipidated (Fisher & Ginsberg, 2002; 
Hussain et al., 2003).  Pre-VLDL is lipidated further to become VLDL2, or sorted to 
degradation.  This conversion of pre-VLDL to VLDL2 may explain why the MTP 
©Iqbal A.R. AlShayji (2008)    16 1. Introduction and Literature Review 
activity is needed for the secretion of apoB-100 after the translation is completed 
(Rustaeus et al., 1998; Olofsson & Borén, 2005). 
The apoB-100 containing VLDL2 particle exits the ER at specific exit sites carried by 
two vesicle proteins: a GTPase referred to as SAR1 and a coat protein called 
coatamer protein II (COPII) (Gusarova et al., 2003; Olofsson & Borén, 2005), which 
fuse to become ER-Golgi intermediate compartment (ERGIC).  It is converted to 
bona fide VLDL1 by post-translational acquisition of TG in the Golgi apparatus 
(Shelness & Sellers, 2001; Olofsson & Borén, 2005).  This lipidation differs from 
that which gives rise to VLDL2 and requires that apoB has reached the size of apoB-
48.  In addition, it is dependent on ADP ribosylation factor 1 (ARF-1), a small GTP 
binding protein which plays a role in the membrane trafficking between the ER and 
the Golgi apparatus (Asp et al., 2000; Asp et al., 2005).  It has been suggested that 
this ‘maturation’ step of VLDL1 may involve the formation of lipid droplets in the 
lumen of the secretory pathway, which fuse with apoB to form VLDL1 (Olofsson & 
Borén, 2005).  Further, this conversion of VLDL2 to VLDL1 seems an additional step 
for TG secretion from the liver as it is not necessary for the secretion of apoB 
(Olofsson & Borén, 2005).  The liver has been shown to secrete both VLDL1 and 
VLDL2 particles (Packard et al., 2000).  Interestingly, this stepwise assembly and 
secretion of VLDL explains the time delay between the biosynthesis of apoB-100 
and the major addition of lipids to the VLDL1 particles, which was estimated as ~15 
min (Adiels et al., 2005a).  
1.4 
1.4.1 
Regulation of VLDL Production 
The secretion of VLDL has been shown to be mainly dependent on fatty acids and 
insulin.  
Role of Fatty Acids 
The liver has the capacity to store TG in order to accommodate plasma fatty acids, 
which are surplus to immediate energy requirements, thereby neutralising any 
potential ‘lipotoxicity’ to peripheral tissue.  There are three potential sources of fatty 
acids which enter the hepatic TG storage pool: de novo lipogenesis (DNL), plasma 
NEFA [originating from adipose tissue and ‘spillover’ from dietary fat lipolysis 
(Barrows et al., 2005)] and remnant lipoproteins (Gibbons et al., 2000).  A healthy 
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liver uses different sources of FAs in the fasted and fed states (Barrows & Parks, 
2006).  It is estimated that during fasting, ~77% of VLDL-TG is derived from 
recycling adipose FAs and ~4% from DNL.  With feeding, 44% come from adipose 
FAs, 15% from uptake of chylomicron remnants, 10% from dietary NEFA spillover 
into plasma and 8% from DNL (Barrows & Parks, 2006), with dietary FAs appearing 
in VLDL within 90 min of food intake (Heath et al., 2003). 
 
 
Figure   1.5: The Intracellular assembly of VLDL. (Numbers in parentheses refer to corresponding 
numbers in the figure.)  The assembly process starts in the rough endoplasmic reticulum (ER) by the 
biosynthesis and concomitant (cotranslational) translocation of apoB-100 to the lumen of this 
organelle (1).  ApoB-100 interacts cotranslationally with the microsomal triglyceride transfer protein 
(MTP) and is lipidated to form a primordial particle (pre-VLDL) (2).  Alternatively, apoB-100 fails to 
be lipidated and misfolds resulting to degradation (3).  The protein is unfolded and retracted to the 
cytosol, ubiquinated, and sorted to proteasomal degradation (3 and 4).  Pre-VLDL is converted to 
VLDL2 late in the ER compartment (5).  VLDL2 exits the ER at specific exit sites of this organelle by 
Sar1/Cop II vesicles (6), which fuse to become the ER–Golgi intermediate compartment (ERGIC) (7). 
ERGIC fuses with Cis-Golgi (8).  In the Golgi apparatus, VLDL2 is converted to VLDL1 by the 
addition of a bulk load of triglycerides (9).  This lipidation process differs from that which gives rise 
to pre-VLDL and VLDL2.  The formation of VLDL1 may involve the formation of a lipid droplet in 
the lumen of the secretory pathway (10), the mechanism of which may follow that of cytosolic lipid 
droplets (11 and 12).  The formation of the cytosolic droplets also involves a fusion step (12).  [Figure 
and legend with permission from Current Opinion in Lipidology (Adiels et al., 2006a).] 
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It has been suggested that this hepatic TG pool is metabolically active with a rapid 
turnover such that extracellular FAs entering the cell are either oxidised in the 
mitochondrion or esterified into TG in the ER and then transferred to the cytosolic 
storage pool.  TG required for VLDL synthesis is recruited from this pool by a 
process of lipolysis to give FAs (Gibbons et al., 2000).  This may explain the 
findings of Malmstrom et al. (1999) who reported that acute NEFA flux is not 
accompanied by concomitant changes in the production of total VLDL-apoB 
(Malmstrom et al., 1999).  In fact, reducing NEFA concentrations using acipimox 
(an antilipolytic agent) caused a shift from VLDL1 to VLDL2 production, without 
affecting total VLDL-apoB production (Malmstrom et al., 1998), suggesting an 
important role of fatty acid availability for the assembly and secretion of VLDL1. 
Conversely, earlier studies which did not isolate VLDL subfractions indicate that 
acutely raising plasma NEFA concentrations could increase both VLDL-TG and 
VLDL-apoB production (Lewis et al., 1995), thus suggesting a role for FAs in the 
stimulation of TG and apoB synthesis.  This assumption is supported by animal 
studies, where chronic administration of intravenous albumin-bound oleic acid 
doubled hepatic secretion of apoB-100 (without changes in apoB mRNA levels), 
suggesting that FAs might act as both a stimulus for TG synthesis, thereby driving 
assembly of VLDL, and as a ‘signal’ for apoB assembly (Zhang et al., 2004b).   
Indeed, increased liver fat has been shown to increase the secretion of VLDL1-apoB-
100, and more – but not larger – VLDL1 particles are secreted (Adiels et al., 2006b). 
1.4.2  Role of Insulin 
Despite insulin’s induction of lipogenesis in the liver, it acutely suppresses hepatic 
VLDL production in normal weight, healthy subjects (Lewis et al., 1993) –   
specifically affecting the VLDL1 subclass (Malmstrom et al., 1998; Adiels et al., 
2007).  This effect is partly attributed to its induced reduction of NEFA flux to the 
liver, thus decreasing substrate availability for VLDL assembly (Coppack et al., 
1994).  However, other mechanisms are likely to play a role as this suppressive effect 
of insulin on VLDL1 production persisted even when compared with the action of 
acipimox (which caused a similar reduction in NEFA) (Malmstrom et al., 1998).  
Although these mechanisms are still elusive, some have been investigated.  Insulin 
inhibits the secretion of apoB (Sparks & Sparks, 1994) and insulin signalling (via 
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phospho-inositide 3-kinase) inhibits the maturation phase of VLDL assembly by 
preventing bulk lipid transfer to a VLDL precursor, thus enhancing the degradation 
of apoB (Brown & Gibbons, 2001).  In addition, it inhibits transcription (Lin et al., 
1995) and upregulation (Wolfrum & Stoffel, 2006) of the MTP gene, although it has 
been suggested that this is unlikely to account for the acute effect of insulin on 
VLDL production due to the long half-life of the MTP protein (4.4 days) (Lin et al., 
1995; Blasiole et al., 2007).  
In contrast, chronic hyperinsulinaemia, caused by insulin resistance, is associated 
with increased production of VLDL (Malmstrom et al., 1997a), specifically VLDL1 
(Adiels et al., 2007).  Possible mechanisms for this loss of the suppressive effect of 
insulin have been studied in a fructose-fed hamster model of insulin resistance 
(Taghibiglou et al., 2000).  These included increased cellular secretion of total and 
VLDL-TG, enhanced stability of nascent apoB, thereby reducing its post-
translational degradation and increased MTP mass (Taghibiglou et al., 2000).  In 
addition, insulin resistance also leads to loss of the acute insulin-mediated inhibition 
of apoB secretion (Chirieac et al., 2004).  In humans, central obesity and an 
increased liver fat content, which are usually associated with insulin resistance 
conditions, have been associated with the lack of insulin-induced suppression of 
VLDL1 production (Adiels et al., 2007) (see below). 
1.5  Defective TRL Metabolism and Atherogenic Dyslipidaemia 
The concept of atherogenicity of TG and TRL, especially in the postprandial state, 
was first introduced almost 30 years ago by Zilversmit (Zilversmit, 1979).  Since 
then, an increasing body of evidence has implicated hypertriglyceridaemia as an 
independent risk factor for cardiovascular disease (CVD), particularly coronary heart 
disease (CHD) (Cullen, 2000).  TRL are thought to have a role in the development 
and progression of atherosclerosis (Tanaka et al., 2001; Cullen, 2003) as TRL 
remnants have been found in human aortic atherosclerotic plaques (Nakano et al., 
2008).  In addition, elevated concentrations of VLDL1 particles are believed to start a 
chain of metabolic events that generate an ‘atherogenic lipoprotein phenotype’, also 
known as atherogenic dyslipidaemia.  
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1.5.1 
1.5.2 
Atherogenic Lipoprotein Phenotype 
The atherogenic lipoprotein phenotype is a cluster of lipoprotein abnormalities 
associated with insulin resistant states (Ginsberg et al., 2005), such as obesity 
(Bamba & Rader, 2007; Marsh, 2003; Chan et al., 2004a), type 2 diabetes (Marsh, 
2003; Taskinen, 2003) and the metabolic syndrome (Grundy, 2006; Kolovou et al., 
2005), and significantly contributes to increased risk of CVD (Avramoglu et al., 
2006; Watson et al., 2003). 
Such atherogenic dyslipidaemia manifests as increased concentrations of hepatic 
VLDL (causing hypertriglyceridaemia), small dense LDL (sdLDL), TRL remnants 
and low HDL concentrations (Grundy, 2006; Taskinen, 2003; Avramoglu et al., 
2006).  Importantly, it is the excess hepatic production of VLDL1 [the major 
determinant of plasma TG concentration (Hiukka et al., 2005)] but not VLDL2 
particles (Adiels et al., 2005b; Adiels et al., 2006b) that is associated with insulin 
resistance, indicating that VLDL1 and VLDL2 are independently regulated (Gill et 
al., 2004a; Packard & Shepherd, 1997). 
Elevated Levels of VLDL1, Insulin Resistance and Obesity 
Hepatic overproduction of VLDL (particularly the large VLDL1) has been associated 
with insulin resistance (Gill et al., 2004a; Johanson et al., 2004) and related 
conditions such as diabetes (Adiels et al., 2005b), the metabolic syndrome (Grundy, 
2006) and obesity (Mittendorfer et al., 2003a).  Of particular interest, abdominal 
obesity which is characterised by excess visceral and/or deep upper body 
subcutaneous adipose tissue accumulation and is strongly associated with obesity, 
insulin resistance and atherogenic dyslipidaemia (Després, 2007; Sniderman et al., 
2007).  Because visceral fat is more lipolytically active than subcutaneous fat in vitro 
(Mauriege  et al., 1987; Arner, 1998; Rebuffe-Scrive et al., 1989), it has been 
hypothesised that visceral fat accumulation results in a markedly increased flux of 
NEFA via the portal vein to the liver (Bjorntorp, 1990; Chan et al., 2004a), thereby 
increase substrate availability for hepatic VLDL formation (Kissebah et al., 1976).  
However, Nielsen et al (2004) demonstrated that although the release of NEFA from 
visceral fat depots into the portal vein increases with increasing visceral fat, it was 
much smaller than the amount derived from lipolysis of upper-body subcutaneous fat 
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(Nielsen et al., 2004).  Nevertheless, hepatic overproduction of VLDL1 particles has 
been found to be driven by increased liver fat content in man (Adiels et al., 2006b) 
and reduction in visceral adipose tissue is associated with decreased hepatic 
production of VLDL (Riches et al., 1999).  In addition, increased NEFA flux to the 
liver impairs hepatic extraction of insulin (Chan et al., 2004a).  Normally, insulin 
inhibits hepatic VLDL1 production, in the fed state, but this effect is lost in insulin 
resistant conditions and high liver fat content, leading to increased hepatic VLDL1 
secretion (Adiels et al., 2007).  
Furthermore, the clearance of VLDL1 and TRL particles and their remnants is 
impaired in insulin resistant conditions due to decreased LPL activity (Mead et al., 
2002), excess of apoC-III (an inhibitor of LPL) (Florez et al., 2006) and failure to 
bind to LDLR and LRP (Packard, 2003) or suppression of LDLR (Mamo et al., 
2001).  
1.5.3  VLDL1 and the Generation of Atherogenic Dyslipidaemia 
Whether due to hepatic overproduction or defective clearance, elevated levels of 
VLDL1, which give rise to a plasma TG concentration > 1.5 mmol.l
-1, are believed to 
start a sequence of events that result in the atherogenic lipoprotein phenotype 
(Packard, 2003; Taskinen, 2003).  Increased proportion of large LDL is a marker of 
efficient lipolysis of TG, which, in effect, will lower fasting and postprandial levels 
of TRL (Griffin, 1997).  However, the presence of VLDL1 gives rise to LDL 
particles (βLDL) with altered apoB-100 conformation which impedes binding of 
these particles to LDLR.  In addition, impaired clearance of VLDL1 particles (see 
above) will result in their accumulation in the circulation.  As a result, VLDL1 and 
βLDL particles have a prolonged residence time in the circulation, thereby increasing 
their likelihood of remodelling by CETP (Packard, 2003), which is increased in 
activity in insulin resistant states (Guerin et al., 2001).   Under these conditions, 
CETP promotes the acquisition of TG by LDL and HDL in exchange for CE from 
HDL to VLDL1 and LDL (Packard, 2003; Guerin et al., 2001). These TG-enriched 
LDL and HDL particles become favourable substrates for HL resulting in a reduction 
in particle size.  HL also has an enhanced activity in obesity and insulin-resistant 
states (Deeb et al., 2003).  This gives rise to (1) sdLDL with a prolonged residence 
time (~5 days) compared with the larger LDL derived from VLDL2 and IDL, which 
©Iqbal A.R. AlShayji (2008)    22 1. Introduction and Literature Review 
©Iqbal A.R. AlShayji (2008)    23 
has a residence time of ~2 days (Packard, 2003) and (2) small unstable HDL particles 
that are cleared rapidly from the circulation, resulting in low HDL cholesterol and 
apoA-I (Rashid et al., 2003) and loss of its protective potential against CVD (Wang 
& Briggs, 2004).  sdLDL is the most readily oxidised subfraction in the lipoprotein 
class (Tribble et al., 1992), increasing its atherogenic potential.  Figure 1.6 shows a 
schematic diagram of the mechanisms involved in the formation of atherogenic 
dyslipidaemia.  
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Figure   1.6: Schematic diagram of the mechanisms involved in the formation of atherogenic dyslipidaemia. Elevated concentrations of VLDL1 particles, producing 
plasma triglyceride (TG) concentrations > 1.5 mmol.l
-1, are believed to start a chain of reactions to generate an atherogenic lipoprotein phenotype (hypertriglyceridaemia, 
small dense (sd)LDL and low HDL).  VLDL1 accumulates in the circulation due to hepatic overproduction, coupled with decreased clearance due to low lipoprotein lipase 
(LPL) activity and/or excess of apoC-III (an inhibitor of LPL).  Lipolysis of VLDL1 gives rise to βLDL particles which have an altered apoB confirmation and, thus, fail to 
bind well to the LDL receptor (LDLR).  Consequently, VLDL1 and βLDL have a prolonged residence time in plasma.  This increases their likelihood of undergoing 
remodelling by cholesteryl ester transfer protein (CETP), which catalyses the transfer of TG from VLDL1 to LDL and HDL in exchange for cholesteryl esters (CE).  TG-
enriched LDL and HDL become good substrates for hepatic lipase (HL) which hydrolyses the TG content of these particles.  As a result, the atherogenic sdLDL and small 
unstable HDL particles are formed.  sdLDL is readily oxidised, thus, increasing its atherogenic potential, while the smaller HDL particles are cleared rapidly from the 
circulation resulting in low HDL concentrations and losing its protective potential against CVD. 
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1.6 
1.6.1 
1.6.2 
Effect of Exercise on TRL Metabolism  
Exercise as a Therapy for Dyslipidaemia  
Due to the well established role of TRLs in CVD in progression of atherosclerosis 
described above, interventions that have the potential to reduce fasting and/or 
postprandial TG concentrations have been investigated as valuable tools for lowering 
CVD risk.  Exercise has long emerged as an affordable, non-pharmaceutical method 
of improving lipoprotein metabolism.  Regular exercise training has been shown to 
reduce total TG [as well as VLDL-TG (Kraus et al., 2002)] concentrations, increase 
HDL cholesterol in adult men and women (Kraus et al., 2002; Kodama et al., 2007) 
and increase LDL particle size (Kraus et al., 2002; Altena et al., 2006).  In addition, 
exercise improves insulin sensitivity in men and women (Gill et al., 2002b), 
sedentary overweight/obese subjects (Houmard et al., 2004), hypertriglyceridaemic 
men (Zhang et al., 2006) and subjects with the metabolic syndrome (Zhang et al., 
2007) and type 2 diabetes (Alam et al., 2004).  Certainly, sedentary lifestyle has been 
associated with increased risk of obesity, metabolic deterioration, type 2 diabetes, 
CVD, cancer and all-cause mortality (Slentz et al., 2007).  In fact, a recent review on 
exercise training in patients with atheromatous CVD has found it to be a ‘true 
therapy’, reducing mortality by 25-35%, reducing clinical manifestations and 
complications (rhythm problems, thrombosis) and improving physical capacity, 
reintegration and quality of life (Casillas et al., 2007).  The following section focuses 
mainly on the effect of exercise on TRL metabolism.  
Impact of Endurance Training 
Compared with their untrained peers, endurance-trained men have reduced levels of 
postprandial lipaemia (Cohen et al., 1989; Ziogas et al., 1997; Merrill et al., 1989).  
In addition, a period of endurance training has been shown to decrease fasting and/or 
postprandial TG concentrations in normolipidaemic subjects (Weintraub et al., 
1989), overweight men and women with mild-to-moderate dyslipidaemia (Kraus et 
al., 2002) and older men and women (Halverstadt et al., 2007).  However, evidence 
suggests that this TG-lowering effect of exercise is due to short-term metabolic 
responses to recent exercise which is lost after a period of detraining.  For example, 
there was no difference between fasting or postprandial TG concentrations between 
endurance trained and untrained young adults (Herd et al., 2000) or untrained 
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middle-aged men (Tsetsonis et al., 1997) after at least 2 days of inactivity, or after an 
exercise training programme when post-training measurements were made 60 h after 
the last exercise session (Herd et al., 1998).   
1.6.3  Impact of a Single Exercise Session 
An increasing body of evidence shows that a bout of exercise (e.g brisk walking, 
jogging, cycling etc) reduces fasting and/or postprandial TG concentrations in   
different population groups including young adult men (Tsetsonis & Hardman, 
1996b; Zhang et al., 1998; Herd et al., 2001) and women (Tsetsonis & Hardman, 
1996b; Gill et al., 2002a), middle-aged men (Gill et al., 2001a; Gill et al., 2001b) 
and women (Tsetsonis et al., 1997), postmenopausal women (Gill & Hardman, 2000) 
and individuals with the metabolic syndrome (Zhang et al., 2006) and type 2 diabetes 
(Tobin et al., 2008), although responses are more heterogeneous in patients with type 
2 diabetes (Gill et al., 2007).  The percentage reductions in plasma TG 
concentrations following exercise are broadly similar (15-25%) across these groups, 
however, subjects with higher TG concentrations (e.g. centrally obese men) had a 
greater decrease in postprandial TG compared with subjects with lower TG (Gill et 
al., 2004b).  Furthermore, a single session of exercise has shown to acutely decrease 
VLDL (Gill et al., 2006) and VLDL-TG concentrations (Borsheim et al., 1999; 
Magkos et al., 2006; Morio et al., 2004). 
A session of exercise conducted before (Katsanos & Moffatt, 2004; Tsetsonis & 
Hardman, 1996b; Tsetsonis & Hardman, 1996a; Gill & Hardman, 2000; Gill et al., 
2001a; Gill et al., 2001b) or after (Katsanos & Moffatt, 2004; Hardman & Aldred, 
1995) ingestion of a fat meal has been reported to attenuate postprandial lipaemia.  
However, the weight of evidence (Zhang et al., 2004a; Zhang et al., 1998; Ferguson 
et al., 1998; Borsheim et al., 1999) suggests that the maximal TG-lowering effect of 
exercise appears to occur after a delay of approximately 12-18 h, rather than during 
or immediately post-exercise (Malkova & Gill, 2006).  For example, Zhang and 
colleagues (Zhang et al., 1998) reported a 21% greater reduction in postprandial TG 
when exercise was performed 12 h compared to 1 h prior to a meal and 49% lower 
than that performed after a meal.  However, this TG-lowering effect seems to be 
‘short-lived’ as exercising 24 h prior to the meal does not attenuate postprandial 
lipaemia (Zhang et al., 2004a).  
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1.6.4  Energy Expenditure and Energy Deficit 
The energy expended during exercise is a key determinant of the TG-lowering effect: 
the higher the energy expenditure, the bigger the reduction in postprandial lipaemia 
(Petitt & Cureton, 2003).  For instance, doubling energy expenditure by either 
doubling exercise intensity for the same duration [60 vs. 30% of maximal oxygen 
uptake (V
.
O2max) for 90 min] (Tsetsonis & Hardman, 1996a) or by doubling exercise 
duration at the same intensity (120 vs. 60 min at 50% V
.
O2max) (Gill et al., 2002a) 
essentially doubles the exercise-induced reduction to lipaemia.  In addition, 
postprandial TG concentrations are similarly reduced by different exercise settings 
(e.g. 180 min of walking at 30% V
.
O2max vs. 90 min at 60% V
.
O2max) when the same 
amount of energy is expended (Tsetsonis & Hardman, 1996b).  Similarly, a 2-h 
cycling at 60% V
.
O2max significantly decreased VLDL-TG and -apoB concentrations 
(Magkos  et al., 2006), whereas 1-h exercise of the same intensity had no effect 
(Magkos et al., 2007).  Of note, recently, Gormsen et al (2006) reported a significant 
positive correlation between VLDL-TG production and resting energy expenditure, 
suggesting that it should be taken into account when VLDL-TG production 
comparisons between groups are made (Gormsen et al., 2006). 
Furthermore, the exercise-induced improvement in insulin sensitivity appears to be 
related to duration and intensity of exercise (Houmard et al., 2004) and thus directly 
related to energy expenditure (Magkos et al., 2008).  It was proposed that exercise-
induced changes in a homeostasis model assessment-estimated insulin resistance 
(HOMAIR) are curvilinearly related to exercise energy expenditure with a threshold 
of ~3.77 MJ (900 kcal) for improvements in HOMAIR to be manifested (Magkos et 
al., 2008).  However, an inverse association was observed between the exercise-
reduced changes in baseline (i.e. resting) HOMAIR, suggesting that less exercise may 
be required to improve insulin sensitivity in insulin-resistant subjects than those with 
good insulin sensitivity at baseline (Magkos et al., 2008).  
The mechanisms by which exercise energy expenditure attenuates postprandial 
lipaemia are currently not known.  Interestingly, dietary-induced energy deficit of 
similar magnitude to that induced by a bout of exercise session results in a much 
smaller TG reduction (Gill & Hardman, 2000).  This implies that either the TG-
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lowering effect of exercise is not dependent on energy deficit and/or that exercise- 
and dietary-induced energy deficits are not metabolically equivalent.  However, a 
recent study investigating the effects of exercise, with or without energy 
replacement, on fasting and postprandial TG metabolism, demonstrated that the 
exercise-induced TG-lowering effect was only evident with an accompanying energy 
deficit (Burton et al., 2008).  This suggests that dietary-induced and exercise-induced 
energy deficits elicit different effects on postprandial metabolism.  This may be 
related to specific body tissues in which the energy deficits occur as exercise induces 
quantitatively larger muscle and hepatic substrate deficits than energy intake 
restriction (Burton et al., 2008). 
1.6.5 
1.6.6 
Intermittent versus Continuous Exercise 
Current exercise-for-health guidelines recommend the accumulation of physical 
activity throughout the day (Haskell et al., 2007).  Thus, it is important to understand 
whether small sessions of exercise spread throughout the day would be as beneficial 
in lowering TG concentrations as a single prolonged session of exercise.  A number 
of studies have been conducted to investigate the effects of intermittent and 
continuous exercise, such as 90-min session vs. three 30-min sessions (Gill et al., 
1998), 30-min vs. three 10-min exercise session (Murphy et al., 2000; Altena et al., 
2004) and even 30-min continuous exercise vs. ten 3-min bouts performed 
throughout the day (Miyashita et al., 2006).  All these studies consistently 
demonstrated that intermittent patterns of physical activity are effective in lowering 
TG concentrations as long as sufficient energy is expended, independently of the 
duration of the individual sessions.  
Potential Mechanisms Responsible for the Exercise-Induced TG 
Reduction 
Concentrations of TRLs in the circulation reflect the balance between rate of 
appearance and rate of clearance of intestinally-derived chylomicrons and 
hepatically-derived VLDL.  Thus, the reduction in plasma TG concentration 
following exercise could be due to disturbance in the balance of appearance and 
clearance rates of chylomicrons and/or VLDL.  
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1.6.6.1  Effect of Exercise on Chylomicron Metabolism 
The fact that maximal reduction in postprandial lipaemia is observed after a delay of 
number of hours, seems unlikely that the exercise-induced TG reduction is due to a 
reduction in gastrointestinal blood flow leading to potentially slower gut absorption 
and secretion of chylomicrons (Malkova & Gill, 2006).  This is supported by three 
pieces of evidence: (1) the peak time for chylomicron-TG concentrations is not 
delayed post-exercise (Gill et al., 2001a; Gill et al., 2006), (2) gastric emptying time, 
evident by peak time of ingested paracetamol concentration, is unaffected by prior 
exercise (Gill et al., 2001a; Gill et al., 2001b) and (3) chylomicron particle number is 
not affected by prior exercise (James et al., 2007).  
There is clear evidence that endurance-trained individuals have high clearance rates 
of chylomicron-like lipid emulsions compared with untrained peers (Cohen et al., 
1989; Podl et al., 1994), which is likely to reflect the increased post-heparin plasma 
LPL activity (reflecting overall LPL activity from all body tissues) observed in them 
(Podl et al., 1994; Kantor et al., 1984).  In addition, muscle LPL activity has been 
reported to increase over 200% in response to intense exercise sessions lasting for 
hours (Lithell et al., 1984; Sady et al., 1986).  
On other hand, recent studies investigating the effects of a more moderate exercise 
on LPL activity are equivocal.  While some studies reported a significant increase in 
plasma (Zhang et al., 2002), muscle and adipose tissue LPL activity after a moderate 
session of exercise (Perreault et al., 2004), others reported no significant difference 
in muscle (Herd et al., 2001) or post-heparin plasma LPL activity (Gill et al., 2003) 
or muscle LPL mass (Magkos et al., 2006) post-exercise.  Interestingly, however, in 
the absence of an exercise-induced effect on muscle LPL mass, a significant ~20% 
increase in plasma LPL concentrations has been observed (Magkos et al., 2006).  
Similarly, a significant correlation between LPL activity and the exercise-induced 
changes in fasting and postprandial TG has been observed without an effect on post-
heparin LPL activity post-exercise (Gill et al., 2003).  
1.6.6.2  Effect of Exercise on VLDL Metabolism 
Studies investigating the effect of moderate exercise on postprandial lipaemia 
demonstrated that the lipoprotein class most affected by prior exercise is VLDL 
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(Malkova et al., 2000), specifically VLDL1, rather than chylomicrons (Gill et al., 
2001a; Gill et al., 2006).  However, little is known about the mechanisms that 
regulate VLDL concentrations (i.e. production and clearance rates) in response to 
moderate exercise.  Certainly, there is no information available regarding the effect 
of exercise on large VLDL1.  
Malkova et al (2000) examined the influence of a prolonged session of prior exercise 
(running at ~60% V
.
O2max) on postprandial extraction of TG across the leg (Malkova 
et al., 2000).  Although they found no significant increase in total, chylomicron- and 
VLDL-TG uptake across the leg, TG clearance (defined as uptake divided by arterial 
concentration) – a marker for the efficiency of TG removal - was greater following 
exercise.  However, as absolute VLDL-TG uptake did not differ significantly 
between control and exercise conditions, it is unclear whether the lower VLDL-TG 
concentrations following exercise were due to increase efficiency of removal or a 
lower VLDL production rate (Malkova et al., 2000).  
Following exercise, there is an increase in circulating NEFA (Burton et al., 2008), 
which, theoretically, can increase hepatic VLDL secretion.  However, this is not the 
case, as there is no correlation between the change in NEFA concentration and 
VLDL-TG following exercise (Borsheim et al., 1999).  This may be explained by the 
concurrent increase in 3-hydroxybutyrate following exercise (Malkova et al., 2000; 
Burton et al., 2008), which a marker of hepatic fatty acid oxidation (Williamson & 
Whitelaw, 1978), suggesting a shift of the hepatic fatty acid flux towards β-oxidation 
and ketone body production and away from re-esterification and VLDL synthesis 
(Malkova & Gill, 2006).  
Due to the fact that chylomicrons are the preferred substrate for LPL and their 
presence prevents VLDL clearance (Fisher et al., 1995; Bjorkegren et al., 1997), it 
has been hypothesised that moderate exercise likely to reduce hepatic VLDL 
production, rather than increase its clearance (Malkova & Gill, 2006).  However, 
recent evidence suggests that a session of moderate exercise (e.g. walking or cycling 
for more than 1 h at 60% V
.
O2max) increases VLDL-TG clearance rates (Magkos et 
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al., 2006; Tsekouras et al., 2007) in healthy, lean, young men.  In addition, Magkos 
et al also reported a decreased production of VLDL-apoB (reflecting the number of 
particles being produced) post-exercise (Magkos et al., 2006), which may contribute 
to the exercise-induced reduction in VLDL concentrations.  It should be noted, 
however, that these findings may not necessarily be applicable to overweight or 
centrally obese individuals (at which exercise-for-health guidelines are targeted), as 
this condition is (1) associated with hepatic overproduction of VLDL1 due to their 
likely increased liver fat content (Adiels et al., 2006b) and (2) impaired ability to 
suppress hepatic VLDL production due to their likely insulin resistance (Adiels et 
al., 2007).  
1.6.7  Effect of ApoE Phenotype  
ApoE is a 299-amino acid glycoprotein which is an integral surface component of 
TRLs and some subclasses of HDL (Hatters et al., 2006).  It primarily functions as a 
ligand for receptor-mediated uptake of TRLs, but also modulates the activity of LPL, 
LCAT and CETP (Leon et al., 2004).  The apoE gene has three alleles (ε2, ε3, and 
ε4) that give rise to 6 different phenotypes (E2/2, E2/3, E2/4, E3/3, E3/4, and E4/4) 
(Davignon et al., 1988), with the E3 isoform being the most common (Hagberg et al., 
2000).  ApoE polymorphism has been shown to have a substantial influence on 
plasma lipids and lipoproteins, which could be explained by a number of 
mechanisms (Kolovou & Anagnostopoulou, 2007): (1) receptor-binding affinities of 
different apoE-containing lipoproteins, (2) dietary fat clearance, (3) differences in the 
clearance of LDL-apoB and (4) efficiency of intestinal cholesterol absorption.  
In the general population, the E2 isoform is associated with elevated levels of TG 
and apoE compared with the E3 isoform (Hagberg et al., 2000), which is caused by 
impaired clearance of remnant particles bearing the apo E2 isoform probably due to 
defective receptor recognition (Havel et al., 1980).  Homozygous E2/2 carriers can 
develop type III hyperlipoproteinaemia, which is characterised by the accumulation 
of chylomicron and VLDL remnants in fasting plasma (Kolovou & 
Anagnostopoulou, 2007).  On the other hand, the apo E4 isoform is typically 
associated with low TG levels compared with the apo E3 individuals (Davignon et 
al., 1988).  This is consistent with the fact that apo E4 subjects clear chylomicron 
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remnants into the liver more rapidly than E3/3 subjects and twice as fast as E3/2 
subjects (Weintraub et al., 1987).  
In contrast, studies investigating the effects of apoE polymorphism on (V
.
O2max), 
lipids and lipoproteins in response to endurance exercise training are conflicting.  
While a cohort study reported an improvement in lipid and lipoprotein profile in 
subjects homozygous for the E 3/3 , despite a small reduction in V
.
O2max, compared 
with E 2/3 and E 3/4 (Thompson et al., 2004), another reported no significant 
influence of apoE polymorphism on V
.
O2max in response to exercise (Leon et al., 
2004).  Conversely,  in  a  study  with  smaller  subject  number,  increases  in V
.
O2max (and HDL) in response to endurance exercise training, were in the order, apo 
E4 > apo E3 > apo E2 (Hagberg et al., 1999). 
However, to the best of the author’s knowledge, there is only one study investigating 
the effect of apoE polymorphism on lipoprotein responses to moderate exercise.  In a 
study including 38 men and 43 women, Gill et al (Gill et al., 2002b) reported no 
significant differences between subjects possessing the E3/2, E3/3 and E4/3 
phenotypes on the magnitude of the exercise-induced reduction in fasting or 
postprandial TG.  
1.7  Measurements of TRL Kinetics 
Lipoprotein metabolism is a complex system of tightly regulated and coordinated 
dynamic processes.  Measurements of plasma lipid and lipoproteins concentrations 
provide useful, yet limited information – ‘a snapshot of the various processes’ 
(Packard, 1995), which do not reveal the dynamics of the system.  This is achieved in 
vivo by the use of kinetic studies, in which labelled precursors are used to help 
characterise the metabolic pathways of lipoprotein metabolism (Packard, 1995; 
Barrett et al., 2006).  The system can be studied either in steady state (when the 
concentration of the substance of interest is constant) or in acute perturbation (non 
steady state, where a stimulus is applied and the return to steady state is monitored) 
(Packard, 1995). 
There are basically two study protocols for investigating the metabolism of apoB-
containing lipoproteins (i.e. VLDL1, VLDL2, IDL and LDL) (Demant & Packard, 
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1997).  Lipoproteins can be tracer-labelled exogenously by isolating them from 
plasma, labelling them with radioactive substance (e.g. radioiodine).  They are then 
re-injected into the donor subject and followed over time as they disappear from the 
plasma compartment.  Alternatively, a stable isotope amino acid (e.g. D3-leucine or 
D5-phenylalanine) is injected, either as a bolus or as a primed constant infusion, and 
incorporated into the newly synthesised apoB protein serving as an endogenous label 
(Table 1.3 shows the characteristics of each tracer and labelling method).  In either 
case, multiple plasma samples are collected during the first 12 h of tracer injection 
and daily thereafter in the fasted state for up to 10-14 days.  ApoB-containing 
lipoprotein fractions are then separated at each timepoint using cumulative gradient 
ultracentrifugation in salt solutions (Lindgren et al., 1972) and apoB is isolated by 
selective precipitation (Egusa et al., 1983).  In the case of radioactive tracer studies, 
the specific activity is calculated by measuring the radioactive tracer in a scintillation 
counter, whereas in the stable-isotope tracer studies, tracer enrichment is determined 
by gas chromatography mass spectrometry (GC-MS) (Demant et al., 1996).   
Multicompartmental modelling using the Simulation, Analysis And Modeling 
software (SAAM II; SAAM Institute, Seattle, WA) is used to calculate rates of 
production, delipidation and catabolism of apoB-containing lipoproteins (Packard et 
al., 1995).  
Although such methods provide valuable information about lipoprotein metabolism, 
they are difficult, time-consuming, expensive and labour-intensive.  Furthermore, the 
laboratory manipulations are complex and require the use of specialised equipment 
(see below). [Comprehensive reviews of kinetic methods can be found by (Barrett et 
al., 2006; Packard, 1995; Chan & Watts, 2006; Chan et al., 2004b).] 
1.7.1  Using Stable-Isotopes to Measure VLDL1 and VLDL2 Kinetics 
Recently, Adiels and colleagues (Adiels et al., 2005a) developed a 
multicompartmental model which permits the kinetics of apoB and TG to be assessed 
simultaneously in VLDL1 and VLDL2 fractions.  The method involves administering 
D3-leucine and D5-glycerol as bolus injections in the fasted state.  Several blood 
samples are taken before and for 8 h after the tracer injection while subjects are still 
fasting. Adiels et al. (Adiels et al., 2005a) reported a significant linear correlation 
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between TG and apoB production in VLDL1 and VLDL2, suggesting a coupling of 
the two processes governing the metabolism of these subfractions. 
Table   1.3: Characteristics of tracers [modified from (Packard, 1995)]. 
Advantages and disadvantages of endogenous versus exogenous tracers 
Exogenous Endogenous 
Labels specific lipoprotein apos or lipoprotein 
subfractions  Labels all lipoprotein apolipoproteins 
Labelled according to mass distribution  Labels according to production rate 
Measures synthesis indirectly by inference 
from steady state calculation 
Measures synthesis directly by tracer 
incorporation 
Tracer does not recycle  Tracer may recycle 
Urine data useful for assessing catabolism  Excretion data of little value 
Radioactive versus stable-isotope endogenous tracers 
Radioactive Stable  isotope 
Radiation hazard  Safe 
Limited applicability  Applicable to all, including women and 
children 
Limited repeatability  Can be repeated many times 
Easy to measure  Difficult to measure with sufficient precision 
Inexpensive apparatus and tracers  Capital cost high 
 
For purposes of this thesis, it is essential to appreciate the complexity of the stable-
isotope method, thus, Figure 1.7 shows a schematic summary of the laboratory 
techniques involved, which were developed and are still used in the Vascular 
Biochemistry Department (Glasgow Royal Infirmary, University of Glasgow).   
Briefly, VLDL1 and VLDL2 fractions are separated from plasma by cumulative 
gradient ultracentrifugation (Lindgren et al., 1972).  ApoB protein is precipitated 
using absolute isopropanol and delipidated using ethanol-ether (Egusa et al., 1983).  
Samples are then prepared (derivatised and fragmentised) for analysis of leucine and 
D3-leucine enrichment in hydrolysed apoB protein and plasma amino acids using the 
GC-MS (Demant et al., 1994).  In order to determine glycerol enrichment in TG, the 
isopropanol and ethanol-ether supernatants are treated with zeolite to precipitate PL 
and obtain TG.  Glycerol is then extracted by saponification using potassium 
hydroxide and ethanol (Witter & Whitner, 1972), then derivatised and fragmented for 
enrichement determination by the GC-MS (Beylot et al., 1987). 
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Figure   1.7: Schematic diagram of the stable-isotope laboratory protocol used to determine the 
kinetics of VLDL1- and VLDL2-TG and -apoB.  
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Based on the enrichment of leucine and glycerol in plasma, VLDL1 and VLDL2, and 
the known injected amounts of labelled leucine and glycerol, the kinetic parameters 
are determined using the modelling software SAAM II as previously described 
(Adiels  et al., 2005a).  Figure 1.8 shows the mathematical multicompartmental 
model used to assess the kinetics of glycerol and leucine in plasma and lipoprotein 
fractions, which is based on the apoB model originally described by Packard et al 
(Packard et al., 1995).  
Leucine pools 
Glycerol pools 
TG conversion
VLDL assembly
VLDL-apoB 
Delay 33 min 
VLDL-TG 
Delay 22 min 
VLDL1
VLDL2
IDL 
Liver
Plasma kinetic of 
ApoB and TG 
 
Figure   1.8: A diagram of the mathematical multicompartmental model (using SAAM II 
software) used to simultaneously determine the kinetics of apoB and TG in VLDL1 and VLDL2 
after a bolus injection of stable isotopes D3-leucine and D5-glycerol [Figure from (Adiels et al., 
2005a)]. 
 
1.7.2  Chylomicron Kinetics 
1.7.2.1  ApoB-48 Labelling with Stable-Isotopes  
Kinetics of apoB-48 containing lipoproteins are difficult with only a few studies 
reported using endogenously labelled stable-isotope tracer (primed constant infusion 
of [5,5,5-
2H3] leucine) (Welty et al., 1999; Welty et al., 2004; Lichtenstein et al., 
1992; Hogue et al., 2007).  This is because in the fasting state, apoB-48 
concentrations are generally too low for protein enrichment to be detected, whereas 
they vary postprandially (along with other lipoproteins) which makes interpretation 
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of tracer data very difficult (Barrett, 1998).  However, these obstacles were first 
overcome by Lichtenstein et al. (1992) by providing small hourly feeds of identical 
composition to the subjects (over a 20 h period) to ensure an ‘elevated’ steady state 
of chylomicron concentrations.  Recently, Bickerton et al. used a combination of 
stable isotope labeling to specifically label VLDL (using an intravenous infusion of 
[
2H2]palmitate) and chylomicrons (using a test meal containing [U-
13C]palmitate) to 
quantify the TG extraction across human skeletal muscle and adipose tissue 
(Bickerton et al., 2007).  However, it was reported that rapid recirculation of the 
label leads to loss of chylomicron specificity (Heath et al., 2003; Karpe et al., 2007).  
1.7.2.2  Retinol Palmitate 
Another commonly used, non-stable isotope, method to measure chylomicron 
metabolism involves the ingestion of retinol with a fat load, which is esterified into 
retinyl palmitate and secreted into the intestinal lymph in the core of the chylomicron 
particle.  The palmitate within the core remains with the particle as it undergoes 
lipolysis and becomes a remnant particle.  Thus, production and clearance rates of 
chylomicrons can be determined by monitoring the concentrations of plasma 
palmitate or chylomicron-associated palmitate (Barrett, 1998).  However, a major 
disadvantage of this approach is the exchange of core components between 
chylomicrons and other lipoproteins [e.g. 25% of retinyl palmitate may also be found 
in apoB-100 containing TRLs (Cohn et al., 1993)]. 
1.7.2.3  Chylomicron-Like (Lipid) Emulsions 
Intravenous lipid emulsions have been developed to supply patients with a balanced 
parenteral nutrition and to prevent or correct essential fatty acid deficiency.  They are 
TG-rich particles that are modeled on the endogenous chylomicrons and consist of a 
TG core, traditionally derived from vegetable oils (e.g. soybean, safflower, coconut, 
olive).  This TG is stabilised by a monolayer of PL derived from egg yolk 
(Olivecrona & Olivecrona, 1998; Carpentier & Dupont, 2000).  However, unlike 
chylomicrons, lipid emulsions contain no cholesterol or apolipoproteins (Olivecrona 
& Olivecrona, 1998).  Nevertheless, once in the circulation, these TG-rich particles 
rapidly acquire apoCs and apoE from plasma lipoproteins, mainly HDL (Iriyama & 
Carpentier, 1994); apoC-II is necessary for the action of LPL and apoE is important 
for receptor recognition.  
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Because the intravascular metabolism of these TG-rich particles resembles that of 
chylomicrons (Olivecrona & Olivecrona, 1998), they have been also used to study 
particular aspects of chylomicrons metabolism, both in vitro and in vivo.  After 
binding of emulsion particles to LPL situated on the endothelial cells of adipose and 
muscle tissues, a substantial amount of the TG content of these particles is 
hydrolysed and the released NEFAs are either taken by the adjacent tissue or spilled 
into the circulation (Evans et al., 1999; Carpentier & Dupont, 2000).  However, 
evidence suggests that lipolysis and particle removal may be simultaneous rather 
than sequential mechanisms like chylomicrons; i.e. emulsion particles may disappear 
from blood before they have become TG-depleted remnants.  This is because some 
remnants are not likely to leave the site of lipolysis (endothelial site) but be 
internalized together with HSPG/LPL or be delivered to adjacent specific lipoprotein 
receptors (Olivecrona & Olivecrona, 1998), including VLDLR (Carpentier & 
Dupont, 2000).  
Intralipid® (soybean oil) and Liposyn® (safflower oil) are two widely used 
commercial lipid emulsions, with the major difference in composition is their α-
linolenic acid content.  While Intralipid contains 8%, Liposyn has only 0.5% (Byrne, 
1982).  Intralipid emulsions have been used in intravenous fat tolerance tests to study 
TG clearance rate (see below).  Recently, Park and colleagues (Park et al., 2000; 
Park et al., 2001) have reported a new method to measure chylomicrons kinetics by 
labelling Liposyn with radioactive tracers.   
Redgrave and Maranhao (1985) prepared experimental lipid emulsions which, unlike 
the commercial ones, contain triolein, cholesteryl oleate, cholesterol and egg 
phosphatidyl-choline (Redgrave & Maranhao, 1985).  The particles are usually 
smaller than those in commercial emulsions and they contain no PL vesicles 
(Olivecrona & Olivecrona, 1998).  These emulsions have also been used in 
chylomicron kinetic studies, where the emulsion was double-labelled with 
radioactive cholesteryl esters and TG.  After intravenous injection into the subjects, 
determination of the plasma decaying curves of the labeled lipids allows the 2-step 
metabolism of chylomicrons to be followed (Oliveira & Maranhao, 2002). 
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1.7.2.4  Intravenous Fat Tolerance Test 
The intravenous fat tolerance test (IVFTT) provides a simple measure of postprandial 
TG clearance.  It was first introduced in the early 1960s by Carlson and Hallberg 
(Carlson & Hallberg, 1963) in dogs then in humans in 1965 (Hallberg, 1965).  In 
1972, Carlson and Rössner (Carlson & Rossner, 1972) provided an IVFTT protocol 
which involved the injection of a bolus dose of Intralipid (0.1 g TG per body mass) 
into a forearm vein, with blood being drawn from a contralateral antecubita vein at 5-
min intervals for 40 min.  The decline in plasma Intralipid-TG concentrations 
followed first-order kinetics (i.e. the clearance rate was directly proportional to the 
concentration).  Initially, Carlson and Rössner measured Intralipid-TG 
concentrations indirectly in plasma by measuring plasma turbidity using 
nephelometry (Carlson & Rossner, 1972), and although Rössner later reported a good 
reproducibility of this method for up to 6 months (Rossner, 1982), Sady and 
colleagues found better reproducibility using enzymatic TG quantification (Sady et 
al., 1986).  
1.8  Summary and Objectives  
This chapter attempted to briefly review current knowledge of lipid and lipoprotein 
metabolism, particularly TRLs.  Special emphasis was placed on VLDL1 assembly, 
metabolism, regulation and role in development of atherogenic dyslipidaemia.  In 
addition, the role of exercise as a potential therapeutic option to reduce VLDL 
concentrations, in an attempt to improve the atherogenic lipoprotein phenotype, was 
discussed.  Finally, the last section focused on the necessity of determining TRL 
kinetics; i.e. production and clearance rates, rather than concentrations, and the 
methods used to do so.  Of note, despite the well-established heterogeneity of VLDL 
and the independent regulation of VLDL1 and VLDL2, the majority of kinetic 
studies, especially those aimed at investigating TG kinetics, have focused on total 
VLDL, rather than VLDL1 and VLDL2 separately.  This is likely due to the difficulty 
in determining TG kinetics in VLDL subfractions compared with total VLDL.   
Although this obstacle has been recently overcome, the method still employed the 
use of stable-isotope tracers.  Although these methods are considered the ‘gold-
standard’ in kinetic studies and have been providing valuable information for a better 
understanding of lipoprotein metabolism, they are not widely available to most 
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laboratories due to their complexity and high cost.  Therefore, the aims of the present 
thesis are to develop and validate a relatively easy and cost-effective method of 
determining VLDL1 kinetics and use it to investigate the effects of hyperglycaemia 
and hyperinsulinaemia as well as moderate exercise on VLDL1 kinetics.  This is 
important as elevated concentrations of VLDL1, rather than VLDL2, are believed to 
be responsible for the generation of atherogenic dyslipidaemia.  In addition, it is 
essential to elucidate the mechanisms by which moderate exercise, a potential tool 
for lowering CVD risk, reduces plasma TG in obese/overweight middle-aged men; a 
typical population at which exercise-for-health guidelines are targeted. 
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2.  General Methods 
This chapter is divided into three main parts.  The first part describes the employed 
experimental procedures, many of which are common to several studies.  The second 
part explains a study conducted to compare between a chemical manual reaction and 
an antibody-based automated method for apoB determination in VLDL fractions.  
Finally, the third part describes a pilot study conducted to determine the 
concentration and dose of a glucose drink needed to sustain a steady 
hyperinsulinaemic and hyperglycaemic state.  
2.1  Subject Recruitment 
Apparently healthy subjects were recruited from within the University of Glasgow, 
Glasgow Royal Infirmary and Greater Glasgow area by personal contact as well as 
by local advertising using posters, web-based and radio announcements.  At least one 
week prior to the study, volunteers were interviewed and a subject information sheet 
about the study, including possible risks and discomforts (Appendices A1 & A2), 
was given and explained to them.  Volunteers were also encouraged to ask any 
questions before signing an informed consent (Appendices A1 & A2) and screened 
according to a health screen questionnaire (Appendices B1 & B2).  Their resting 
arterial blood pressure was measured and a venous blood sample was collected to test 
for their liver, renal, and thyroid functions.  For the glucose and exercise studies 
described in Chapters 4 and 5, subjects were also tested for fasting glucose. Common 
exclusion criteria were used as follows: 
a.  A history of known cardiovascular disease or abnormalities, including 
established CHD (e.g. MI, stroke, CABG), acute illness or active, chronic 
systemic disease 
b.  Uncontrolled hypertension (>160/90 mmHg on anti-hypertensive medication) 
c.  Taking any medication known to influence carbohydrate or lipid metabolism; 
d.  Anaemia (Hb <12 g.dl
-1 males, <11 g.dl
-1 females) 
e.  Current smoking (stopped for at least 6 months) 
f.  Frank diabetes (fasting blood sugar >7 mmol.l
-1) (Chapters 4 and 5) 
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g.  Abnormal renal, liver or thyroid function tests 
h.  Allergy to soybeans 
i.  Taking part in another study (within the last 3 months) 
Inclusion criteria were different for different studies.  These will be discussed in 
Chapters 4 and 5.  All study protocols were approved by the Research Ethics 
Committee of the North Glasgow University Hospitals NHS Trust. 
2.2 
2.2.1 
2.2.2 
2.3 
Anthropometry 
Height and Weight 
The heights and weights of subjects were measured using a weighing machine (D. 
Brash and Sons; Glasgow, UK) with an attached graduated metal plate.  Subjects 
stood barefoot with their heels together and wearing light clothing.  Height (m) and 
weight (kg) measurements were made to the nearest 0.1 unit. 
Waist and Hip Circumferences 
Waist and hip circumferences were measured using a flexible, inelastic tape measure 
(Supralip®160, West-Germany).  The waist circumference was measured on the 
horizontal plane midway between the costal margin and iliac crest with the 
abdominal muscles relaxed and the subject breathing shallowly.  The hip 
measurement was made horizontally around the maximum circumference of the 
buttocks.  The reported values are means of two to three measurements.  
Blood Sampling 
Venous blood was obtained via an indwelling cannula (Biovalve, 18G/1.2 mm, 
Vygon, France) placed in an antecubital vein, to which a 10 cm three-way stopcock 
(Connecta Plus 3, BD, Sweeden) was attached.  The cannula was kept patent by 
flushing with non-heparinised saline solution (0.9% NaCl).  Blood samples were 
collected directly in 10-ml tubes containing K3EDTA as an anticoagulant (BD 
Vacutainer Systems, Plymouth, UK).  Blood samples were then placed immediately 
in ice and centrifuged (GS-6KR, Beckman Instruments, Inc, California, US) within 
15-30 min of collection for 15 minutes at 3000 rpm and 4
o C.  
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EDTA plasma was pipetted into aliquots of 200 μl in 0.5 ml Eppendorf tubes (Treff 
Lab, Switzerland) and 2 × 350 μl in Apex tubes (2 ml, Alpha Laboratory Ltd, UK) 
and frozen immediately at -70
o C, for subsequent analysis of insulin, NEFA, glucose 
and lipid profile.  The remaining EDTA plasma was used for lipoprotein separation.  
This was either started on the same day of blood collection or the next morning.  In 
case of the latter, plasma was stored overnight at 4
o C. 
At the end of a successful lipoprotein separation, the remaining EDTA plasma was 
pipetted into aliquots of no less than 0.5 ml (to minimise any freeze drying effect) in 
1.5 ml Eppendorf tubes (Treff Lab, Switzerland) and stored at -70
o C. 
2.4 
2.4.1 
Blood Samples Analysis 
Lipoprotein fractions and EDTA plasma were separated and analysed in the Vascular 
Biochemistry Department of Glasgow Royal Infirmary, University of Glasgow.  The 
methods and techniques employed were taught to the author by researchers in the 
Vascular Biochemistry Department.  
Separation of VLDL1 and VLDL2 Lipoprotein Fractions 
VLDL1 (Sf 60-400) and VLDL2 (Sf 20-60) fractions were isolated from plasma using 
a modification of the cumulative ultracentrifugation density gradient technique 
described by Lindgren et al. (Lindgren et al., 1972).  
The density of 2 ml of plasma was adjusted to d 1.118 g.ml
-1 by the addition of 0.341 
g NaCl.  This was carefully layered over a cushion of 0.5 ml d 1.182 g.ml
-1 solution 
in an ultraclear Beckman SW 40 ultracentrifugation tube (Beckman Instruments Inc., 
UK) which had been coated with polyvinyl alcohol (Holmquist, 1982); this allowed 
the solutions to gravity feed down the side of the tubes smoothly without disturbing 
the formation of the gradient.  A discontinuous gradient was formed by overlayering 
d 1.0988 g.ml
-1 (1 ml), d 1.0860 g.ml
-1 (1 ml), d 1.0790 g.ml
-1 (2 ml), d 1.0722 g.ml
-1 
(2 ml), d 1.0641 g.ml
-1 (2 ml) and finally d 1.0588 g.ml
-1 (2 ml).  The density 
solutions were prepared from stock solutions 1.006 g.ml
-1 and d 1.182 g.ml
-1 of NaBr 
in 0.195M NaCl, 0.001% Na2EDTA and their densities were measured to 3 decimal 
places in a Paar Scientific densitometer (model DMA 35).  The centrifugation was 
carried out using a Beckman SW 40 rotor (Beckman Instruments Inc., UK) in a 
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Beckman L8-60M ultracentrifuge for 1.38 h at 39K rpm and 23
o C for separation of 
the VLDL1 fraction.  Rotors were decelerated without brakes and VLDL1 was 
removed in the top 1 ml using a finely drawn glass Pasteur pipette.  This volume was 
replaced by 1 ml of d 1.0588 g.ml
-1 and tubes were recapped and placed back in the 
centrifuge overnight for separation of VLDL2.  Various run times and speeds 
required for VLDL2 separation were previously calculated as shown in Table 2.1.  At 
the end of the run, 0.5 ml of VLDL2 fraction was aspirated in the same way as 
VLDL1.  Fractions were kept in tightly capped 2 ml Apex tubes (Alpha Lab Ltd., 
UK) at 4
o C for subsequent analysis.  
Table   2.1: Various times and speeds required for the separation of lipoprotein fractions using 
Beckman L8-60M Ultracentrifuge and SW 40 rotor. 
VLDL1   (ω
2t 9.81) VLDL2  (ω
2t 2.12) 
Time (h)  RPM  Time (h)  RPM 
1.38 39K  12.03  21.1K 
   14.52  19K 
   15.41  18.5K 
   16.34  18K 
   17.31  17.5K 
   18.08  17.2K 
   20.58  16K 
 
2.4.2  Spectrophotometric Assays 
Plasma analyses were carried out using commercially available enzymatic 
colorimetric kits.  Plasma glucose (Glucose hexokinase, Randox Laboratories Ltd, 
UK) and total and HDL cholesterol (CHOL and HDL-C, Roche Diagnostics, UK, 
respectively) were analysed in the fasted state. LDL cholesterol was calculated in the 
fasted state using the Friedewald equation [LDL cholesterol (mmol.l
-1) = total 
cholesterol (mmol.l
-1) – HDL cholesterol (mmol.l
-1) – (TG (mmol.l
-1)/2.2) 
(Friedewald  et al., 1972)].  TG (TG, Roche Diagnostics Limited, UK), NEFA 
(NEFA C, Wako Chemicals, USA) and glycerol (GLY, Randox Laboratories Ltd, 
UK) were analysed at all time points.  
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In  Chapter 5, PL (Phospholipids C, Wako Chemicals, USA) and FC (Free 
Cholesterol , Wako Chemicals USA) were measured in the VLDL1 fraction in all 
time points.  In addition, VLDL1-apoC-II, -apoC-III, and -apoE were also measured 
in the fasted state using commercial automated trubidimetric immunoassay kits, 
supplied by Wako Chemicals.  
All the above analyses were made by an automated clinical chemistry analyser 
(ILab
TM 600, Instrumentation Laboratory, USA) by Mrs. Josephine Cooney, Mrs. 
Elaine McDonald and Mrs. Elizabeth Murray (Department of Vascular Biochemistry, 
Glasgow Royal Infirmary). 
Serum ALT concentrations were measured at screening (General Biochemistry 
Laboratory, Glasgow Royal Infirmary) using commercially available enzymatic 
colorimetric kit (Alanine Aminotranferase, Abbott Laboratories, USA). 
2.4.3 
2.4.4 
2.4.5 
Insulin ELISA 
Insulin was measured in freshly frozen EDTA plasma using commercially available 
ELISA kits (Mercodia AB, Uppsala, Sweden).  The method is a solid phase two-site 
enzyme immunoassay.  The CV for the assay was < 4%. 
Apolipoprotein E Phenotyping 
ApoE phenotype was determined for each subject by Mrs Elizabeth Murray 
(Department of Vascular Biochemistry, Glasgow Royal Infirmary), by isoelectric 
focusing using Western blot techniques as described by Menzel (Menzel & 
Utermann, 1986) and Havekes (Havekes et al., 1987). 
Total Protein Determination (Lowry Method)  
Total protein content in lipoprotein fractions was measured using a modified Lowry 
method (Lowry et al., 1951).  This method involved the addition of 1 ml of Biuret 
reagent [100 ml of 2% Na2CO3 in 0.1 M NaOH (w/v), 1 ml of 2% NaK Tartrate 
(w/v), 1 ml of 1% CuSO4 (w/v), and 1 ml of 10% (w/v) sodium dodecyl sulphate (SDS)]  
to a total volume of 200 μl of sample (100 μl VLDL1 + 100 μl of distilled water or 
50 μl VLDL2 + 150 μl distilled water).  Samples were diluted or concentrated as 
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required.  One hundred microlitre of 1:1 Folins Ciocalteu reagent (Sigma-Aldrich 
Company Ltd., Irvine, Scotland) was then added and mixed immediately.  After 
incubation at room temperature for 30-60 min, the developed colour intensity was 
measured at an optical density of 750 nm using a Beckman DU 70 
Spectrophotometer.  The protein concentration was calculated using a standard curve 
of known concentrations.  Inter-assay precision was checked using 2 levels (100 μl 
and 200 μl) of human and bovine quality control (QC) materials.  The coefficients of 
variation (CVs) for the low QC were (human: 1.8%, bovine: 1.3%) and high QC 
were (human: 1.0%, bovine: 1.4%). 
2.4.6  Accuracy and Precision of Assays 
The accuracy and precision of the automated assays described section 2.4.2, except 
for glycerol, were monitored using quality control sera (Wako QC abnormal and 
normal, Wako Chemicals GmbH, Denmark; distributed by Alpha Laboratories, UK).  
Glycerol quality control was obtained from Randox Laboratories Ltd, UK.  In order 
to minimise intra-assay variation, all samples obtained for each subject were 
performed in the same analyser run for a given assay.  The CVs for the assays were 
2.9% for total cholesterol, 3.8% for TG, 2.8% for HDL-cholesterol, 5.2% for NEFA, 
2.0% for glucose, 1.9% for glycerol, 2.2% for free cholesterol, and 3.8% for PL. 
2.5  Bruce Protocol 
All subjects recruited for the exercise study described in Chapter 5 underwent a 
modified (ACSM, 2006) Bruce protocol (Bruce et al., 1973) under the supervision of 
a medical doctor: Dr Nicholas Barwell or Dr Lesley Hall, at the Institute of Diet, 
Exercise and Lifestyle (IDEAL) at the University of Glasgow.  A modified twelve 
lead electrocardiographic (ECG) monitoring was conducted throughout the test and 
arterial blood pressure was measured at rest and immediately after a Bruce protocol 
during recovery. 
2.6  Submaximal Exercise Test  
In the exercise study described in Chapter 5, subjects undertook a submaximal 
exercise test to estimate the gradient necessary to elicit an intensity corresponding to 
50% V
.
O2max.  The test consisted of a four-stage treadmill (Woodway Gmbh, Weil am 
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Rhein, Germany) walk (Figure 2.1) to determine the relationship between increasing 
gradient and the subjects’ V
.
O2  at their self-selected walking speed. V
.
O2max was 
estimated by extrapolation of the O2 uptake/heart rate relationship up to the subject’s 
predicted maximum heart rate: [220 – age] beat.min
-1 (ACSM, 2006).  Each stage 
was five minutes long with expired air samples being taken during the last minute of 
each stage.  Heart rates were recorded during the expired air collections as were 
perceived rates of exertion using the Borg scale (Borg, 1973).  The first stage of the 
test was on a level treadmill with gradient increasing by 2.0 to 3.0% in each 
subsequent stage.  The increase in gradient for each stage was established on an 
individual basis based on the subject’s heart rate response.  The relationship between 
V
.
O2 and treadmill gradient was determined for each subject and, together with the 
estimated V
.
O2max, the gradient necessary to elicit an intensity corresponding to 50% 
V
.
O2max was calculated.  
 
14
 
Figure   2.1: A schematic diagram of a 4-stage submaximal exercise test performed for subjects in 
Chapter 5.  The blue block represents an expired air sample and heart rate measurements. 
 
2.7  Monitoring of Heart Rate 
The subject’s heart rate (Chapter 5) was monitored continuously during exercise and 
the recovery period by short range telemetry (Polar S610i, Polar Electro, Finland). 
2.8  Measurement of Oxygen Uptake and Carbon Dioxide 
Production 
Oxygen uptake and CO2 production in Chapter 5 were determined at rest before and 
during exercise.  Samples of expired air were collected into 100 or 150 L Douglas 
Time (minutes)
Gradient 0% 
Gradient 3%
 0   4   5 
 91 0
15 
19 20
Gradient 6%
Gradient 9% 
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bags.  While wearing a nose clip, subjects breathed through a mouthpiece fitted to a 
lightweight large 2-way respiratory valve (2700 series, Hans Rudolph Inc. USA), 
which in turn was connected to a lightweight tube.  The tubing was terminated at a 
two-way valve which opened and closed the Douglas bag. All equipment was 
supplied by Cranlea & Co. Birmingham, England.  
An aliquot of expired air (measured using a flow meter) was removed from each 
Douglas bag to determine the fraction of O2 and CO2 using a gas analyser (Servomex 
4100, Servomex Group Ltd., East Sussex, England).  The analyser was calibrated 
before each use with certified reference gases (BOC Ltd, Surry, UK) and the 
reference gases were calibrated against a ‘gold standard’ reference gas to ensure 
consistency of results.  
The remaining volume of expired air in each Douglas bag was measured by 
evacuation through a dry gas meter (Harvard apparatus, supplied by Cranlea & Co. 
Birmingham, England).  The temperature of air in the Douglas bag was measured 
during evacuation using the same dry gas meter.  
Barometric pressure was measured using a barometer and the measured expired gas 
volumes were corrected to standard temperature and pressure (STPD) for a dry gas 
using the universal gas equation.  Inspired gas volumes were derived using the 
Haldane transformation (Consolazio et al., 1963) and O2 uptake, CO2 production, 
minute ventilation, respiratory exchange ratio and the ventilatory equivalent for 
oxygen were calculated.  Rates of substrate utilization expenditures were calculated 
via indirect calorimetry using the equations described by Frayn (Frayn, 1983) and 
energy expenditure was determined by multiplying the mass of substrates used by 
their respective energy densities.  
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2.9 
2.9.1 
Apolipoprotein B Measurements in VLDL1 and VLDL2 
Fractions – Comparison of a Manual and an Automated 
Method 
Introduction 
In the Vascular Biochemistry laboratory, for kinetic studies, apoB is usually 
measured in lipoprotein fractions using a standardised manual method, which is 
applicable to VLDL, IDL and LDL fractions.  ApoB is precipitated after the addition 
of an equal volume of absolute isopropanol (Egusa et al., 1983).  The supernatant is 
aspirated and its protein content is measured using a modified version of Lowry 
method (Lowry et al., 1951).  There is no apoB solubilisation in isopropanol and the 
precipitated apoB is virtually free of soluble apolipoproteins.  ApoB protein 
concentrations are measured by the difference between total protein content in 
lipoprotein and the protein measured in supernatant.  This method is standardised and 
widely used for the measurement of the relatively low concentrations of apoB in 
VLDL1 and VLDL2 fractions.  However, it is laborious, time consuming and, being a 
manual technique, is subject to personal error. 
Another method for measuring apoB concentrations is direct measurement using an 
automated in vitro immunoturbidimetric assay with the use of commercially 
available kits (see below).  Being an automated method, the immunoturbidimetric 
assay saves time, effort and potentially improves reproducibility.  However, these 
have been designed for apoB measurements in serum or plasma, where apoB 
concentrations are high and mainly represent apoB in the LDL fraction [85-90% of 
total apoB (Alaupovic, 1991)].  It was therefore unclear whether this method is 
suitable for the measurement of the low apoB concentrations in VLDL1 and VLDL2 
fractions. 
Therefore, the purpose of the present study was to compare the automated 
turbidimetry immunoassay method with the conventional precipitation one as an 
alternative method for the measurement of apoB protein in VLDL1 and VLDL2. 
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2.9.2  Materials and Methods 
2.9.2.1  Specimens and Separation of VLDL1 and VLDL2 fractions 
A total of 260 EDTA plasma samples were used to separate VLDL1 (Sf 60-400) and 
VLDL2 (Sf 20-60) fractions by a modification of the cumulative ultracentrifugation 
density gradient technique as previously described (section 2.4.1) 
2.9.2.2  Isopropanol Precipitation Method (Egusa et al., 1983) 
All VLDL1 and VLDL2 samples were brought to room temperature and 0.5 ml of 
absolute isopropanol was added to 0.5 ml of each sample in glass tubes (13/100 glass 
tubes, Labco Ltd., Buckinghamshire, UK).  After immediate vigorous mixing, 
samples were then incubated for at least 24 h at 4
o
 C, after which they were spun at 
3000 rpm and 4
o C for at least 30 min.  Immediately, the supernatant was carefully 
aspirated using a drawn-out Pasteur pipette, without drawing out any of the 
precipitated apoB.  
Total protein content in the VLDL1 and VLDL2 fractions and the non-apoB protein 
content of the supernatant were measured using the modified Lowry method as 
described earlier (section 2.4.5). 
2.9.2.3  Immunoturbidimetric Method 
The apoB content of the same samples was measured directly using commercially 
available kits (WAKO Apolipoprotein B-HA, Wako Chemicals GmbH, Denmark; 
distributed by Alpha Laboratories).  This method involved the specific combination 
of apoB in the sample with anti-human apoB antibodies in the reagent to yield an 
insoluble aggregate that causes increased turbidity.  The degree of turbidity is 
measured optically using an autoanalyser (ILab
TM 600, Clinical Chemistry System, 
Instrumentation Laboratory, USA).  The method in Vascular Biochemistry has been 
optimised for apoB measurements in lipoprotein fractions by increasing the volume 
of sample used in the assay from 3 μl to 12 μl (results were then multiplied by a 
factor of 0.25).  The supplied quality control was also diluted to account for the 
lower concentrations of apoB (WAKO 3 was diluted 1:5 to give a mean (range) 
concentration of 15.3 (12.3-18.4) mg.dl
-1, which is within the range of expected 
results). 
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2.9.2.4  Calculating ApoB %CV for Each Method 
VLDL1 and VLDL2 were separated from two subjects and each fraction was pooled 
together.  ApoB was measured in ten samples using the immunoturbidimetric method 
and the isopropanol-Lowry method.  Means, SDs and CVs were calculated for each 
method. 
2.9.3  Results 
Figure 2.2 shows VLDL1- and VLDL2-apoB concentrations (mg.dl
-1) measured by 
the immunoturbidimetry method in 260 samples plotted against that measured by the 
isopropanol precipitation method with the line of equality; the line all points would 
lie on if the two methods always gave exactly the same measurement.  The two 
methods correlate well for both fractions with R
2 (goodness-of-fit) of 0.88 for 
VLDL1 and 0.93 for VLDL2.  However, the isopropanol method measured values as 
~1.3 times higher than the immunoturbidimetric method for both VLDL1 and VLDL2 
fractions.  This was particularly apparent as the apoB concentrations increased. 
Figure 2.3 shows the percent difference between measurements by the two methods 
(isopropanol minus immunoturbidimetry) for each sample against their mean in both 
the VLDL1 and VLDL2 fractions.  This is done to explicitly show extreme or 
outlying observations and any lack of agreement between the two methods (Bland & 
Altman, 1999).  In addition, Figure 2.3 shows the 95% limits of agreement estimated 
as mean percentage difference ± 2 SD for each fraction, which define the range 
within which most differences between measurements by the two methods will lie 
(Bland & Altman, 1999).  This was: 0.8 ± 110.3% for VLDL1 and 9.1 ± 66.4% for 
VLDL2, giving rise to 95% limits of agreement between (-109.4% to +111.1%) for 
VLDL1 and between (-57.3% to +75.5%) for VLDL2.  From Figure 2.3, a cut-off 
value of ~3.0 mg.dl
-1 could be made, above which measurements between the two 
methods appeared to show better agreement for both VLDL1 and VLDL2 fractions 
compared to values less than 3 mg.dl
-1, where deviation around the mean was more 
scattered.  This is better illustrated in Figure 2.4, which shows the %difference 
(isopropanol minus immunoturbidimetry) in apoB concentrations plotted against the 
mean of two methods for values > 3.0 mg.dl
-1.  In this case, the deviation around the 
mean is evenly scattered, especially in the VLDL1 fraction, and the 95% limits of 
©Iqbal A.R. AlShayji (2008)    51 2. General Methods 
agreement (mean ± 2SD) became smaller: between -33.3% and 73.7% (20.2 ± 
53.5%, n = 65) for VLDL1 and between -17.5% and 53.0% (17.7 ± 35.3%, n = 84) 
for VLDL2.  In addition, it is clear from Figure 2.4A that there are two outliers in the 
VLDL1 fraction.  Although excluding these two measurements did not influence the 
mean percentage difference, it reduced the SD value (20.7 ± 37.5%) and 
consequently, the 95% limits of agreement (-16.8 to 58.2%).  
Finally, Table 2.2 shows the mean VLDL1- and VLDL2-apoB concentrations, SDs 
and CVs measured 10 times for each method in VLDL1 and VLDL2 fractions using 
pooled samples.  The apoB concentrations were lower in VLDL1 compared to 
VLDL2 and it is clear that the immunoturbidimetric method was more reproducible 
than the isopropanol method at such low concentrations (CV 3.4% vs. 9.9% for 
VLDL1 and 1.4% vs. 3.2% for VLDL2, respectively). 
 
Table   2.2: Calculated mean, SD and CV for apoB concentrations measured 10 times for the 
same sample using the two methods  
VLDL1-apoB (mg.dl
-1) VLDL2-apoB (mg.dl
-1) 
 
Immunoturbidimetric 
method 
Isopropanol 
method 
Immunoturbidimetric 
method 
Isopropanol 
method 
Mean  3.74 2.07 6.96 5.65 
SD  0.13 0.20 0.10 0.18 
CV  (%)  3.38 9.88 1.39 3.19 
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Figure   2.2: ApoB concentrations (mg.dl
-1, with linear-regression lines of ‘best-fit’ and equation 
of the line) in [A] VLDL1 and [B] VLDL2 fractions measured using an automated 
immunoturbidimetric method and by a manual isopropanol method with the line of equality. (n 
= 260) 
©Iqbal A.R. AlShayji (2008)    53 2. General Methods 
 
-300
-200
-100
0
100
200
300
- 10123456789 1 0 1 1 1 2
VLDL1-apoB concentrations (mg.dl
-1) - Mean of two methods
%
V
L
D
L
1
-
a
p
o
B
 
d
i
f
f
e
r
e
n
c
e
 
o
f
 
t
h
e
 
t
w
o
 
m
e
t
h
o
d
s
Mean
Mean + 2SD
Mean - 2SD
[A] 
 
-200
-150
-100
-50
0
50
100
150
200
0123456789 1 0 1 1 1 2
VLDL2-apoB concentrations (mg.dl
-1) - Mean of two methods
%
V
L
D
L
2
-
a
p
o
B
 
d
i
f
f
e
r
e
n
c
e
 
o
f
 
t
h
e
 
t
w
o
 
m
e
t
h
o
d
s
Mean
Mean + 2SD
Mean - 2SD
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Figure   2.3: A scatterplot of the percent difference in apoB concentrations (mg.dl
-1) between the 
two methods (isopropanol minus immunoturbidimetry) against their mean in [A] VLDL1 and 
[B] VLDL2, with 95% limits of agreement (mean ± 2SD): VLDL1 (0.8 ± 110.2%) and VLDL2 (9.1 
± 66.4%), n = 260. 
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Figure   2.4: A scatterplot of the percent difference (isopropanol minus immunoturbidimetry) for 
apoB concentrations > 3.0 mg.dl
-1 against the mean of the two methods in [A] VLDL1 and [B] 
VLDL2, with 95% limits of agreement (mean ± 2SD): VLDL1 (20.2 ± 53.5%, n = 65) and VLDL2 
(17.7 ± 35.3%, n = 85). 
 
©Iqbal A.R. AlShayji (2008)    55 2. General Methods 
2.9.4  Discussion 
Due to the low concentrations of apoB in VLDL fractions, the manual precipitation 
of apoB using isopropanol (Egusa et al., 1983) has historically been the preferred 
choice, followed by a modification of another manual method (Lowry et al., 1951) to 
determine the apoB protein concentrations in the fractions.  Being a chemical 
method, this technique is not affected by the size of the lipoprotein particle, the 
possible masking of the apoB epitopes or changes in time over standardisation of 
commercial apoB assays.  However, this method is time-consuming and requires a 
high degree of precision and skill in separating the non-apoB supernatant from the 
precipitated apoB protein, which may sometimes be difficult in cases of very high or 
very low apoB concentrations. 
Conversely, apoB can be measured directly using an automated immunoturbidimetric 
assay, with the use of commercially available kits.  The fact that this method is 
automated, makes it faster, allows for a minimal involvement of human error, and, 
consequently, better precision.  One possible shortcoming of this immunological 
method is that it relies on detecting certain epitopes on the apoB particle and, 
therefore, has the disadvantage of being dependent on the manufacturer’s choice of 
such epitopes, which could be subject to change at any time. 
Because of the large number of samples per trial used in this thesis and the relative 
difficulty of using the manual isopropanol method for apoB measurements, the two 
methods were compared using 260 samples from the VLDL1 and VLDL2 fractions.  
This was done to assess the possibility of replacing the isopropanol precipitation 
method with the automated immunoturbidimetric method.  
The present results show that the two methods agree well for both fractions with R
2 
values of ~0.9. This is especially true for apoB concentrations > 3.0 mg.dl
-1.  
Although the immunoturbidimetric method seems to give values ~20% lower than 
the isopropanol method, this is consistent and the deviation from the mean of the two 
methods still lies within the 95% limits of agreement.  However, the 
immunoturbidimetric method allows better precision and reproducibility than the 
manual isopropanol method, with CVs of 3.4% and 1.4% (compared to 9.9% and 
3.2%) in VLDL1 and VLDL2 fractions, respectively. In addition, being an automated 
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method, the immunoturbidimetry allows the feasibility and the ease of analysing 
large number of samples in a relatively short period of time, compared to the 
isopropanol method. 
In conclusion, it is inevitable to find some lack of agreement between different 
methods, but what matters is the amount by which methods disagree (Bland & 
Altman, 1999).  The automated immunoturbidimetry method correlated consistently 
and reasonably well with the manual isopropanol precipitation method, with better 
precision, reproducibility and ease of use for measurements of multiple samples.   
Therefore, the immunoturbidimetric method was chosen to measure apoB 
concentrations in this thesis. 
2.10 Glucose Pilot Study 
The purpose of this pilot study was to determine whether it was possible to maintain 
a ‘pseudo’ steady state of high circulating glucose and insulin concentrations by 
ingesting small amounts of a glucose solution at frequent intervals.  If this approach 
was feasible, it would represent a more straightforward and less invasive method of 
inducing hyperinsulinaemia and hyperglycaemia than invasively infusing glucose 
and/or insulin.  A number of different patterns of glucose ingestion were investigated 
to determine an appropriate protocol, which will be used in the study described in 
Chapter 4.  
2.10.1 Subjects and Methods 
Four subjects (2 women and 2 men – age (range) 20-33 years; body mass 55-95 kg; 
BMI 22.6-28.1 kg.m
-2) were included in this study after giving informed consent.  
Subjects reported in the morning to the metabolic suite at the Institute of Diet, 
Exercise and Lifestyle, at the University of Glasgow, after a 12-h fast. Subjects were 
cannulated in an anticubital vein and after a 10-min interval a baseline EDTA fasting 
blood sample was drawn.  A second baseline sample was taken 10 min later.  All 
blood samples were placed immediately in ice.  EDTA plasma was obtained after 
centrifugation for 10 min at 3000 rpm and divided into 5 aliquots in 1.5 ml 
Eppendroff tubes.  Aliquots were stored immediately at -20
o C for subsequent 
analysis of glucose, NEFA and insulin concentrations as previously described in 
sections 2.4.2 and 2.4.3. 
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The glucose drinks were prepared by dissolving the appropriate weight of glucose 
powder (Thornton and Ross Ltd., Huddersfield, England) in hot water and making 
the required volume up with cold water.  Approximately 5-6 ml of lemon juice per 
100 ml of water were added for taste. 
2.10.2 Protocol I 
The first protocol was designed to introduce a glucose concentration of 30% (w/v) 
(15 g in 50 ml) every 15 min for 2 h.  Two female subjects participated in this 
protocol (Table 2.3).  Blood samples were drawn every 15 min.  
Table   2.3: Characteristics of the two female subjects who participated in Protocol I 
Subject  Age (y)  Body mass (kg)  BMI (kg.m
-2) HOMA 
1  20 66.4  23.81  1.4 
2  33 55  22.6  1.6 
 
Figure 2.5 shows glucose, insulin and NEFA responses for the two subjects.   
Glucose concentrations increased slowly in subject 1 and immediately in subject 2 
before declining close to baseline at the end of 2 h.  Consequently, insulin 
concentrations increased in response to the glucose drink, but differently in the two 
subjects: while subject 1 had a delayed insulin response corresponding to glucose 
concentrations, subject 2 had a dramatic increase in insulin concentrations for the 
duration of the trial.  However, none of the two subjects reached any steady state 
during 2 h.  Similarly, NEFA concentrations declined slowly in subject 1 but 
dramatically in subject 2 over the course of trial in response to insulin.  NEFA 
concentrations were only suppressed at the end of the 2 h.  
Despite different responses in glucose and insulin concentrations, neither subjects 
reached a ‘pseudo’ steady state.  Because one subject had a delayed response, it was 
clear that an initial bolus glucose drink is needed to induce a more rapid response.  
Also, because the other subject had an exaggerated insulin response to the glucose 
drink, it might be beneficial to decrease its dose, and possibly increase its frequency 
to account for the reduced concentration. 
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2.10.3 
2.10.4 
Protocol II 
The second protocol started with a bolus drink of 20% glucose (30 g in 150 ml) 
followed by 20% glucose drink (5 g in 25 ml) every 10 min (instead of 15 min) for a 
period of 2 h.  Blood samples were taken at 15-min intervals.  One male subject 
participated in this protocol (aged 29 years, body mass 95 kg, BMI 28.1 kg.m
-2 and 
HOMA 1.4). 
Figure 2.6 shows glucose, insulin and NEFA responses during this protocol.  The 
bolus glucose drink successfully increased glucose and insulin concentrations shortly 
after ingestion.  However, the glucose drink, thereafter, was not sufficient to 
maintain a steady state of glucose and insulin as they started to decline after 90 min.  
In addition, the drink did not induce a desirable suppression in NEFA concentrations 
before the 2 h.  
Therefore, a bolus glucose drink seemed essential to induce a faster and immediate 
response in glucose and insulin concentrations.  However, a dose of 5 g glucose 
every 10 minutes did not seem sufficient to maintain elevated glucose and insulin 
concentrations.  Furthermore, it would be helpful to increase the observation time of 
the study to investigate whether a steady state could be reached and/or maintained for 
a longer period of time. 
Protocol III 
In this protocol, glucose drink concentration and the observation time were 
increased.  It started with 30% bolus glucose drink (30 g in 100 ml) followed by 60% 
glucose drink (15 g in 25 ml) every 15 min for 4 h.  These doses were chosen as it 
became obvious from the previous two protocols that a stronger glucose drink might 
be needed to achieve the desired ‘pseudo’ steady state and suppress NEFA at a time 
shorter than 2 h.  One subject participated in this protocol (aged 22 years, body mass 
80.5 kg, BMI 27.8 kg.m
-2 and HOMA 4.0). 
Figure 2.7 shows glucose, insulin and NEFA responses during the 4-h observation 
period for this protocol.  Glucose and insulin concentrations increased quickly in 
response to the bolus glucose drink, which caused a desirable, fast reduction in 
NEFA concentrations.  However, the glucose drink caused abrupt responses in both 
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glucose and insulin concentrations.  In addition, there was tendency for insulin 
concentrations to continually increase during the 4 h. It is uncertain, however, 
whether this increase is related to the subject’s HOMA of 4.0, which may indicate 
insulin resistance, or whether it was caused by the increased glucose drink 
concentration. 
2.10.5 Conclusion 
From these protocols, it was obvious that (1) a bolus glucose drink was needed to 
trigger an immediate insulin response, (2) providing 5 g of glucose every 10 minutes 
was not sufficient to maintain elevated levels of glucose and insulin, while providing 
15 g glucose every 15 minutes produced abrupt responses and (3) although NEFA 
concentrations started to decline immediately in response to insulin, it took about 60 
min to be suppressed almost completely in the last protocol. 
In conclusion, taking these findings into account, it was decided that the final 
protocol for the glucose ingestion would be; a bolus glucose drink of 25% (w/v) (30 
g of glucose in 120 ml), followed by 25% glucose drink (10 g in 40 ml) every 15 min 
for the duration of the trial.  The glucose ingestion protocol would start an hour prior 
to the Intralipid infusion described in Chapter 4 to ensure adequate suppression of 
NEFA concentrations. 
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[C] 
Figure   2.5: [A] glucose, [B] insulin and [C] NEFA response (n = 2) for the glucose pilot - 
Protocol I: 30% (w/v) glucose (15 g in 50 ml) every 15 min for 2 h. The solid lines represent 
subject 1, while the dotted lines represent subject 2. 
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[C] 
Figure   2.6: [A] glucose, [B] insulin and [C] NEFA response (n = 1) for the glucose pilot - 
Protocol II: a bolus drink of 20% (w/v) of glucose (30 g in 150 ml) followed by a 20% glucose 
drink (5 g in 25 ml) every 10 min for 2 h. 
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Figure   2.7: [A] glucose, [B] insulin and [C] NEFA response (n = 1) for the glucose pilot - 
Protocol III: a bolus glucose drink of 30 g (in 100 ml) followed by 15 g of glucose (in 25 ml) 
every 15 min for 4 hours. 
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3.  Development of a Novel Method to 
Determine VLDL1 Kinetics 
3.1  Introduction 
A large body of evidence suggests that increased circulating concentrations of TRLs 
increase the risk of atherosclerosis (Malloy & Kane, 2001; Tanaka et al., 2001).  This 
is particularly evident in the postprandial state (Karpe, 1999; Schneeman et al., 
1993).  However, the measurement of a high TRL concentration provides no 
information regarding the mechanisms responsible for this elevation; i.e. increased 
rate of synthesis and/or reduced rate of catabolism.  As it is important to understand 
the mechanisms responsible for increased TRL concentrations in different metabolic 
states, both to advance basic scientific understanding and to help guide therapeutic 
treatments, studies investigating kinetics of TRL can yield useful data.  Such an 
approach has, for example, revealed that the dyslipidaemia associated with insulin 
resistance and type 2 diabetes is largely due to an overproduction of hepatically 
derived large VLDL1 (Sf 60-400) (Watson et al., 2003; Adiels et al., 2005a).  These 
studies typically use precursors labelled with stable or radioactive isotope tracers to 
measure the synthesis of lipids and apolipoproteins directly (Adiels et al., 2005a; Gill 
et al., 2004a; Packard et al., 2000; Packard, 1995).  Although these techniques yield 
detailed kinetic data, they are costly, time consuming, labour-intensive and require 
the use of specialised equipment and techniques in research laboratories.  
The aim of the present study was, therefore, to develop a relatively straightforward 
method of obtaining TRL kinetic data.  The method relies on the fact that 
chylomicrons compete with VLDL1 particles for the same catalytic pathway; i.e. 
hydrolysis of their TG content by the action of LPL.  Previous studies (Karpe & 
Hultin, 1995; Bjorkegren et al., 1996) have shown that VLDL1 accumulates in 
plasma after fat ingestion or intravenous infusion of a lipid emulsion (e.g. Intralipid) 
due to the presence of the newly secreted chylomicrons or chylomicron-like 
particles, which are the preferred substrate for LPL because of their larger size and 
TG content (Fisher et al., 1995).  Indeed, using stable isotope methods, Björkegren et 
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al. demonstrated that infusion of Intralipid prevents over 90% of VLDL1 catabolism 
(Bjorkegren et al., 1996).  It was therefore hypothesized in the present study that it 
would be possible to calculate the production rates of VLDL1-TG and -apoB from 
the rate of their accumulation during an infusion of Intralipid.  The former would be 
a measure of lipid production while the latter would represent the rate of VLDL1 
particle production, as there is one apoB molecule per VLDL1 particle (Elovson et 
al., 1988).  Furthermore, using this approach, it is possible to calculate the rate of 
Intralipid-TG clearance (a surrogate measure of TRL-TG clearance) from either the 
steady-state Intralipid-TG concentration during infusion (Rang et al., 2003) or from 
the exponential decay in Intralipid-TG concentration post-infusion (Rossner, 1974).  
Here the author reports the development and validation of this ‘Intralipid method’ to 
determine TRL kinetics.  
3.2 
3.2.1 
Material and Methods  
Subjects 
Ten non-smoking healthy subjects (7 males and 3 females) were included in this 
study after giving written informed consent.  All subjects had normal thyroid, liver 
and renal function and none had acute illness, a history of known cardiovascular 
disease and hypertension, nor were under medication known to influence 
carbohydrate or lipid metabolism.  The subject information sheet, consent form and 
health screen for the present study are shown in Appendices A1 and B1.  Two 
subjects had the E3/2 apoE phenotype, seven had the E3/3 phenotype and one had 
the E4/3 phenotype.  The subjects’ characteristics are shown in Table 3.1.  Subjects 
were requested not to exercise for three days before their study days as this is known 
to affect TRL metabolism (Gill & Hardman, 2003).  In addition, they were asked to 
weigh and record their dietary intake for two days prior to the Intralipid test and this 
diet was replicated in those subjects who underwent a second Intralipid test.  The 
study protocol was approved by the Research Ethics Committee of the North 
Glasgow University Hospitals NHS Trust. 
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Table   3.1: Subjects' physical and metabolic characteristics (n=10).  
 Mean  Range 
Age (years)  33.5  (20.0 – 55.0) 
Body mass index (kg.m
-2) 25.9  (20.8  –  34.7) 
Waist circumference (cm)  85.1  (65.0 – 113.5) 
Waist/hip ratio  0.84  (0.71 – 1.04) 
Triglycerides (mmol.l
-1) 1.36  (0.40  –  4.43) 
Total cholesterol (mmol.l
-1) 4.15  (2.85  –  5.90) 
HDL cholesterol (mmol.l
-1) 1.30  (0.75  –  1.85) 
LDL cholesterol (mmol.l
-1) 2.20  (1.22  –  4.00) 
Glucose (mmol.l
-1) 5.5  (4.3  –  8.0) 
Insulin (mU.l
-1) 8.92  (2.78  –  24.81) 
HOMAIR 2.41  (0.56  -  8.82) 
NEFA (mmol.l
-1) 0.51  (0.34  –  0.70) 
ALT (U.l
-1) 23  (16-38) 
 
3.2.2  Intravenous Intralipid Test 
Each subject reported to the Clinical Investigation Suite in the Department of 
Vascular Biochemistry in Glasgow Royal Infirmary after an overnight fast of 12 h.  
Transportation to the hospital was provided for the subjects, when needed, to ensure 
that they arrived in a rested state.  A cannula was introduced into an antecubital vein 
in both arms; one for administration of Intralipid (purified soybean oil emulsion, 
Fresenius Kabi Ltd., Warrington, UK) and the other for blood sampling.  The 
cannulae were kept patent by flushing with non-heparinised saline solution (0.9% 
NaCl).  Ten min after cannulation a first baseline blood sample was obtained.   A 
second baseline blood sample was obtained 10 min later.  
The intravenous Intralipid test used was a modification of that described by 
Björkegren and collegues (Bjorkegren et al., 1996).  A bolus dose of 20% Intralipid 
(0.1 g.kg
-1 body mass) was injected within one min.  This was followed immediately 
by a constant continuous infusion of 10% Intralipid (0.1 g.kg
-1.h
-1).  This dose was 
chosen as Björkegren et al. reported that the rate of rise of VLDL1-apoB during 
Intralipid infusion was no greater for a 0.2 g.kg
-1.h
-1 infusion dose compared with 0.1 
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g.kg
-1.h
-1, suggesting that the lower dose was sufficient to saturate LPL and prevent 
measurable VLDL1 catabolism (Bjorkegren et al., 1996).  However, experiments 
with the 0.2 g.kg
-1.h
-1 dose were also performed in the present study to confirm that 
this was the case in the author’s hands (see below).  Initially, the infusion period was 
120 min, however, during development of the technique this was subsequently 
shortened to 75 min after it became clear that a 75-min infusion was long enough to 
induce a sufficient measurable rise in VLDL1-TG and -apoB.  Figure 3.1 shows an 
example of a subject during an Intralipid trial. 
Blood samples were obtained at 15-min intervals during the infusion.  Further blood 
samples were drawn 2.5, 5, 10, 15, 20, 30, 45, 60 and 75 min post-infusion.  Initially, 
the post-infusion period was 3.25 h.  However, this was subsequently shortened to 75 
min when it became clear that this was sufficient to calculate the Intralipid-TG 
clearance rate using the exponential decay.  All samples were obtained directly into 
10-ml potassium EDTA tubes (BD Vacutainer Systems, Plymouth, UK) and placed 
immediately in ice before centrifuging for 15 min at 3000 rpm and 4
o C. 
Aliquots of plasma were frozen immediately at -70
o C, as described in section 2.3, 
for subsequent analysis of insulin, NEFA, glucose, TG, and total and HDL-
cholesterol.  The remaining plasma was stored overnight at 4
oC prior to separation of 
Intralipid and lipoproteins. 
3.2.3  Increasing the Intralipid Infusion Rate 
Five subjects (2 females and 3 males, age 23-47 y [range], BMI 20.8-28.7 kg.m
-2, 
fasting TG 0.47-2.45 mmol.l
-1) underwent a second test using a higher infusion dose 
(0.2 g.kg
-1.h
-1) of 10% Intralipid with the same 0.1 g.kg
-1 bolus dose.  This was 
carried out to determine whether an Intralipid infusion dose of 0.1 g.kg
-1.h
-1 was 
sufficient to completely prevent measurable lipolysis of VLDL1 by LPL, and 
therefore enable determination of VLDL1-TG and -apoB production rates from their 
rises in concentration.  If the infusion rate of 0.1 g.kg
-1.h
-1 was sufficient to saturate 
LPL and block lipolysis of VLDL1, the 0.2 g.kg
-1.h
-1 dose would not result in higher 
calculated production rates of VLDL1-TG or -apoB compared to the 0.1 g.kg
-1.h
-1 
dose.  The order of testing was randomized.  Other than the higher infusion dose, all 
conditions of the tests were the same.  
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Figure   3.1: A picture of a subject during an Intralipid trial.  A cannula is placed in an anticubital 
vein in each arm; one for the Intralipid infusion of 0.1 g.kg
-1.h
-1 (right arm) using an IVAC Signature 
Edition Gold pump (ALARIS Medical Systems, Inc.) and one for blood sampling (left arm).  An intial 
bolus Intralipid dose (0.1 g.kg
-1 body mass) was given in the right arm via a three-way stopcock 
immediately before starting the infusion.  (Published with permission from the subject). 
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3.2.4  Intralipid (Sf > 400) Separation from Whole Plasma 
Two ml of plasma were overlayered with 4 ml of 1.006 g.ml
-1 density solution  in 
ultra-clear centrifuge tubes and spun at 10,000 rpm and 4
o C for 30 min (Lindgren et 
al., 1972) using Beckman L8-60M Ultracentrifuge and Beckman 50.4 rotor 
(Beckman Instruments Inc., UK).  Intralipid (d <1.006 g.ml
-1) was removed in the 
top 2 ml (IL-1) for subsequent measurements of TG using commercially available 
kits as described in section 2.4.2.  TG concentration was also measured in the middle 
1.5 ml fraction (IL-2) to verify complete separation of Intralipid.  The final 
Intralipid-TG concentration was calculated as the addition of these two fractions [IL-
1 + (IL-2 × 1.5/2)].  In addition, glycerol was measured in these IL-1 and IL-2 
fractions (section 2.4.2) to determine the amount of free glycerol.  The final 0.5 ml of 
the density solution was discarded and the remaining 2 ml Intralipid-free plasma was 
used for separation of VLDL1 and VLDL2.  The CV for the Intralipid-TG separation 
was 6.9%. 
3.2.5  VLDL1 and VLDL2 Separation 
VLDL1 (Sf 60-400) and VLDL2 (Sf 20-60) were isolated from plasma using a 
modification of the cumulative ultracentrifugation density gradient technique as 
previously described in section 2.4.1.  TG concentrations were then measured in the 
VLDL1 and VLDL2 fractions in all time points and apoB concentrations were also 
measured directly by immunoturbidimetry as described in section 2.9.2.3.  The CVs 
for separation of VLDL1-TG and -apoB were 5.0% and 3.4%, respectively and for 
VLDL2-TG and -apoB were 5.8% and 1.4%, respectively. 
3.2.6  Fasting Plasma Analysis 
Plasma glucose, insulin, total and HDL cholesterol concentrations were analysed in 
the fasted state and TG and NEFA concentrations were analysed at all time points.  
LDL cholesterol was calculated in the fasted state using the Friedewald equation 
(Friedewald et al., 1972).  Serum ALT concentrations were measured at screening.  
All analyses were done as previously described in section 2.4.2. 
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3.2.7 
3.2.8 
Correction for Glycerol 
Enzymatic kits for TG analysis measure the glycerol that is hydrolyzed from TG by 
LPL.  As Intralipid contains free glycerol as an excipient, it has been reported that it 
overestimates the true TG concentrations of Intralipid (Howdieshell et al., 1995).  
Therefore, all Intralipid-TG measurements were corrected for free glycerol and are 
reported as ‘true’ TG concentrations [true TG concentration (mmol.l
-1) = measured 
TG (mmol.l
-1) - glycerol (mmol.l
-1)].  Glycerol concentrations were also measured in 
5 subjects in the VLDL1 fraction during infusion and were found to be negligible 
(influencing VLDL1-TG concentrations by less than 1%). 
Kinetic Data Calculations  
The clearance rates of Intralipid-TG and production rates of VLDL1-TG and -apoB 
were calculated as described below using examples from individual subjects. 
3.2.8.1  Calculating VLDL1-TG and VLDL1-ApoB Production Rates 
The production rates (mg.h
-1) of VLDL1-TG and -apoB were calculated from the 
gradient of the linear rise in their pools (total mg in plasma) over time (min) 
multiplied by 60 min.  Pool sizes (mg) were calculated as concentrations in mg.dl
-1 
multiplied by plasma volume [4% of body mass (Packard et al., 1984)] in decilitres. 
Figure 3.2A represents the linear increase in TG pool (mg) in the VLDL1 fraction of 
subject No.3 (female, 55 y, 84.5 kg) with R
2 (goodness-of-fit) value of 0.97 and a 
gradient of 35.8.  Thus, the VLDL1-TG production rate of this subject would be (35.8 
× 60) 2147.4 mg.h
-1 (609.9 mg.kg
-1.d
-1).  Similarly, from Figure 3.2B, the VLDL1-
apoB production rate of the same subject was (0.85 × 60) 50.9 mg.h
-1 (14.5 mg.kg
-
1.d
-1).  
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Figure   3.2: Changes in [A] VLDL1-TG and [B] VLDL1-apoB pools (mg) over time in a female 
subject No. 3 (55 yr, 84.5 kg) during infusion of 10% Intralipid (0.1 g.kg
-1.h
-1).  An initial bolus 
dose of 20% Intralipid (0.1 g.kg
-1 body mass) was given at 0 min. 
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3.2.8.2  Calculating VLDL1-TG and VLDL1-ApoB Fractional Synthetic and 
Catabolic Rates 
The fractional synthetic rate (FSR) is defined as the rate of incorporation of a 
precursor into a product per unit of product mass (Foster et al., 1993), which can be 
calculated as: 
FSR =     initial rate of change in product                                    (Eq. 1) 
          initial precursor concentration 
 
In this method, the FSR of VLDL1-TG and -apoB (pools.d
-1) can be calculated from 
the gradient of the linear rise in their pool (mg) over time (min) divided by fasting 
pool size (mg) then multiplied by 60 and 24 (to account for number of minutes in 1 
day).  However, since the system is in a steady state in fasting conditions, where 
synthesis of VLDL1 equals its clearance, FSR will also be equivalent to the fractional 
clearance rate (FCR) in the fasted state (Foster et al., 1993). 
Subject No. 3 had a VLDL1-TG and -apoB fasting pool sizes of 1669.5 and 61.7 mg, 
respectively.  According to the equation of the line in Figure 3.2A, the subject’s 
VLDL1-TG FSR and FCR were (35.8 ÷ 1669.5 × 60 × 24) 30.9 pools.d
-1.  Similarly, 
from Figure 3.2B, VLDL1-apoB FSR and FCR were 19.8 pools.d
-1. 
3.2.8.3  Calculating Intralipid-TG Clearance Rate 
Assuming that all TG clearance is Intralipid-TG clearance, it is possible to determine 
Intralipid-TG clearance rate in two ways:  
3.2.8.3.1  The Steady-State (SS) Method 
The clearance rate of Intralipid-TG can be calculated from the steady-state 
concentration during infusion using the following equation (Rang et al., 2003): 
Clearance rate (ml.min
-1) =     infusion rate (mg.min
-1)      (Eq. 2) 
steady state concentration (mg.ml
-1) 
 
In this method, steady state is defined as being achieved when the final 3 values of 
the Intralipid-TG concentrations differed by less than 13.8% (i.e. two times the CV 
for the separation of the Intralipid fraction and measurement of the TG.  This 
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represents the 95% confidence interval for the measured value).  Figure 3.3A shows 
the concentration of Intralipid-TG ± 13.8% during a 75-min infusion for subject No.8 
(female, 23 y, 52.0 kg, BMI 20.8 kg.m
-2).  The steady state concentration, i.e. the 
mean of the last 3 points of infusion, is 0.86 mmol.l
-1 (0.76 mg.ml
-1).  Since this 
subject’s body mass is 52.0 kg, the infusion rate of 0.1 g of 10% Intralipid per kg of 
body mass per h equals: 
0.1 g.h
-1   ×   52.0 kg  =   5.2 g.h
-1  =   5200 mg.h
-1  =   86.67 mg.min
-1 
       kg 
 
From equation (2): 
    Clearance rate  =  86.67 mg.min
-1   =  113.7 ml.min
-1 
                0.76 mg.ml
-1 
 
Assuming plasma volume [4% of body mass, (Packard et al., 1984)] for this subject 
was 2080 ml, the clearance rate can also be expressed in pools.d
-1 as follows:  
 
Intralipid-TG clearance rate  = 113.7 ml.min
-1  × 60 min × 24 h  =  78.9 pools.d
-1 
        2080 ml 
3.2.8.3.2  The Exponential (Exp) Method 
After stopping the intravenous infusion, Intralipid-TG declines exponentially 
following first-order kinetics as described by Rössner (Rossner, 1974).  Figure 3.3B 
shows the Intralipid-TG concentrations (mmol.l
-1) post-infusion over time (min) 
curve for the same female subject (No.8) on a semi-log scale.  (In this case, data for 
the first 45 min post-infusion were used for calculation, as beyond this Intralipid-TG 
concentrations approached zero increasing the error associated with an exponential 
curve fit).  The equation of the fitted line is: 
y = k e
–bt           ( Eq. 3) 
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Figure   3.3: Intralipid-TG concentrations (mmol.l
-1) [A] during infusion and [B] post-infusion of 
0.1 g.kg
-1.h
-1 of 10% Intralipid for a female subject (23 y, 52.0 kg).  An initial bolus dose of 20% 
Intralipid (0.1 g.kg
-1 body mass) was given at 0 min.  The Y-axis error bars are ± 13.8% (i.e. the 
95% confidence interval for the measured Intralipid-TG concentration). 
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where k is the proportionality constant, t is the time, and b is the exponential decay 
constant, which in turn is defined as: 
   b  =          clearance rate (ml.min
-1)              (Eq. 4) 
plasma distribution volume (ml) 
 Hence,  
Clearance rate (ml.min
-1) =  b × plasma volume (ml)      (Eq. 5) 
or      in  pools.d
-1 = b × 60 min × 24 h 
 
Since the b value from Figure 3.3B is 0.056 and the subject’s plasma volume was 
2080 ml, then from equation (5): 
Intralipid-TG clearance rate   = 0.056 × 2080 ml = 116.5 ml.min
-1  
or   = b × 60 min × 24 h =  80.6 pools.d
-1  
Figure 3.4 shows a schematic diagram of the Intralipid method protocol.  (For 
comparison purposes with the stable-isotope method see Figure 1.7). 
3.2.9  Intralipid Recovery 
In order to assess the recovery of plasma-Intralipid in the Intralipid fraction (Sf 
>400), EDTA plasma was spiked with Intralipid to produce an Intralipid-TG 
concentration in plasma of ~1.5 mmol.l
-1 and ~4 mmol.l
-1.  These reflect approximate 
Intralipid-TG concentrations at the 0.1 g.kg
-1.h
-1 and 0.2 g.kg
-1.h
-1 infusion doses.  
For each Intralipid concentration, samples of spiked plasma were divided into 10 
aliquots and the Intralipid fractions were separated as described in section 3.2.4.  TG 
and glycerol concentrations were measured in plasma before and after addition of the 
Intralipid (to calculate the actual Intralipid-TG concentration), as well as in the 
separated Intralipid fractions.  The Intralipid recovery was calculated as follows: 
% recovery  =   separated Intralipid-TG    ×    100      (Eq. 6) 
       actual Intralipid-TG 
where actual Intralipid-TG = total TG (plasma with Intralipid) – TG (Intralipid-free 
plasma). 
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Figure   3.4: Schematic diagram of the 'Intralipid Method' protocol 
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3.2.10 
3.3 
3.3.1 
Statistical Analyses 
Statistical analyses were performed using MINITAB for Windows (Version 13.1, 
MINITAB Inc., State College, PA) and STATISTICA (Release 6.0, StatSoft, Inc, 
USA).  Normality was checked for all the data using the Anderson-Darling test.  
When data did not approximate a normal distribution, these were log-transformed, 
specifically TG, glucose, insulin, HOMAIR, production rates of VLDL1-TG 
(expressed in both mg.h
-1 and mg.kg
-1.d
-1) and VLDL1-apoB (expressed in mg.h
-1), 
Intralipid-TG clearance rate and VLDL1-apoB FSR required transformation.  Time 
trends were tested using one-way ANOVA with repeated measures.  Paired t-tests 
were used to compare between the Intralipid-TG clearance rates calculated from the 
steady state and the exponential decay and between the kinetic data obtained from 
the low and high Intralipid doses.  HOMA [calculated as insulin (mU.l
-1) × glucose 
(mmol.l
-1)/22.5] was used as a validated surrogate measure of insulin resistance 
(Matthews et al., 1985).  Relationships between HOMA-estimated insulin resistance 
(HOMAIR), NEFA, BMI, waist circumference and kinetic parameters were assessed 
using Pearson product-moment correlations.  Significance was accepted at the P 
<0.05 level. Data are presented as mean ± SEM unless otherwise stated.  It was not 
possible to perform a power calculation for this study as the method was still in the 
developmental stage and thus no data on the reliability of the method were available 
at this stage. 
Results 
Plasma, Intralipid, VLDL1- and VLDL2-TG Concentrations During 
and Post-Infusion 
Figure 3.5A shows the mean plasma-, Intralipid-, VLDL1- and VLDL2-TG responses 
in 10 subjects during 75-min Intralipid infusion (0.1 g.h
-1.kg
-1 body mass).  Plasma-
TG concentrations were increased to ~2-3 times the fasting value during the infusion.  
Similarly, mean Intralipid-TG concentrations increased in response to the bolus dose 
(P <0.001).  VLDL1-TG concentrations rose linearly during the infusion (P <0.001), 
but VLDL2-TG did not change significantly during the course of the infusion (P = 
0.14). 
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After stopping the infusion, the plasma- and Intralipid-TG concentrations decreased 
exponentially (both P <0.001, Figure 3.5B).  VLDL1-TG continued to rise for ~20 
min (P <0.001) before plateauing and subsequently decreasing.  In subjects where 
the post-infusion period was extended, VLDL1-TG returned to baseline 
concentrations within 105-135 min (an example of an earlier Intralipid trial is shown 
in Figure 3.6).  The mean VLDL2-TG concentrations remained unchanged for the 75 
min post-infusion observation period. 
Plasma
 
Figure   3.5: Plasma-, Intralipid-, VLDL1- and VLDL2-TG concentrations (mmol.l
-1) [A] during 
infusion of 0.1 g.kg
-1.h
-1 of 10% Intralipid and [B] for 75 min post-infusion.  An initial bolus dose 
of 20% Intralipid (0.1 g.kg
-1 body mass) was given at 0 min. N = 10, values are mean ± SEM. 
 
3.3.2  VLDL1- and VLDL2-ApoB Concentrations During Infusion 
The mean apoB concentration in the VLDL1 (Sf  60-400) fraction increased steadily 
from fasting levels throughout the infusion and was significantly higher than baseline 
within 15 min (P <0.001).  On the other hand, mean VLDL2-apoB concentrations 
declined significantly (P <0.001) during 75 min of infusion. Total (VLDL1 + 
VLDL2) VLDL-apoB concentrations rose slightly but significantly (P <0.05) during 
infusion (Figure 3.7).  There was no significant change in the VLDL1 or VLDL2 
TG/apoB ratio (expressed in mol:mol) over the 75 min of infusion (P = 0.21 and P = 
0.16, respectively) (Figure 3.8). 
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Figure   3.6: An example of a full 135min-Intralipid trial during development of the method. 
[Top]  Plasma-, Intralipid-, VLDL1- and VLDL2-TG and [Bottom] VLDL1- and VLDL2-apoB 
concentrations during and post-infusion for a female subject (34 y, 55.2 kg).  A bolus dose of 20% 
Intralipid (0.1 g.kg
-1 body mass) was injected at zero min, followed immediately by a constant 
infusion of 10% Intralipid (0.1 g.kg
-1.h
-1) for 120 min.  The dotted line represents the end of infusion.  
VLDL1 kinetics for this subject were calculated from the first 75 min of infusion: VLDL1-TG and 
VLDL1-apoB production rates were 711.2 and 20.7 mg.h
-1 and fractional catabolic rates were 56.3 and 
20.0 pools.d
-1, respectively.  Intralipid-TG clearance rate was calculated only from its exponential 
decay post-infusion as 146.9 pools.d
-1, as no steady state was achieved during infusion. 
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Figure   3.7: VLDL1-, VLDL2- and total VLDL-apoB concentrations (mg.dl
-1) during infusion of 
10% Intralipid (0.1 g.kg
-1.h
-1).  An initial bolus dose of 20% Intralipid (0.1 g.kg
-1 body mass) was 
given at 0 min.  N = 10, values are mean ± SEM. 
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Figure   3.8: VLDL1- and VLDL2-TG/apoB ratios during infusion of 10% Intralipid (0.1 g.kg
1.h
-
1).  An initial bolus dose of 20% Intralipid (0.1 g.kg
-1 body mass) was given at 0 min.  N = 10, 
values are mean ± SEM. 
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3.3.3  Kinetic Data 
Table 3.2 shows the production rates and FSR of VLDL1-TG and VLDL1-apoB as 
well as the clearance rates of Intralipid-TG calculated for each subject (n = 10) as 
previously described.  Fasting VLDL1-TG and VLDL1- and VLDL2-apoB 
concentrations are also presented. 
3.3.3.1  VLDL1-TG and VLDL1-ApoB Production Rates  
The mean ± SEM (range) production rates for VLDL1-TG and -apoB were 1076.7 ± 
224.7 (446.0 – 2563.2) mg.h
-1 and 25.4 ± 3.9 (12.0 – 50.9) mg.h
-1, respectively.  
These corresponded to 333.6 ± 49.1 (198.5 – 609.9) mg.kg
-1.d
-1 and 8.1 ± 0.9 (4.4 – 
14.5) mg.kg
-1.d
-1, respectively.  
3.3.3.2  VLDL1-TG and VLDL1-ApoB Fractional Synthetic and Catabolic 
Rates 
The mean ± SEM VLDL1-TG and -apoB FSRs, which are equal to the VLDL1-TG 
and -apoB FCRs in the fasted state (Foster et al., 1993), were 30.2 ± 5.7 (6.5 – 57.8) 
pools.d
-1 and 21.1 ± 5.1 (2.2 – 56.2) pools.d
-1, respectively.  
3.3.3.3  Intralipid-TG Clearance Rate 
The Intralipid-TG clearance rates calculated for individual subjects by two methods 
as described above (i.e. SS and Exp) are shown in Table 3.2.  Eight out of the 10 
subjects reached the defined steady state during infusion.  The mean ± SEM 
Intralipid-TG clearance rates in these 8 subjects did not differ significantly between 
the two calculation methods (52.4 ± 8.6 pools.d
-1 for SS vs 55.3 ± 9.2 pools.d
-1 for 
Exp, P = 0.45) and the values obtained were strongly correlated (r = 0.96, P <0.001).  
However, since not all subjects reached a steady state, the Intralipid-TG clearance 
rates mentioned hereafter will refer to that calculated using the exponential method.  
 19.8 
10.3 
13.7 
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Table   3.2: Fasting concentrations, apoE phenotypes and individual lipoprotein kinetic parameters calculated using the ‘Intralipid method’ (0.1 g.kg
-1.h
-1 infusion 
dose) (n=10).  
Exp, exponential decay; FCR, fractional catabolic rate; FSR, fractional synthetic rate; SS, steady state. 
Subjects 3, 5 and 8 were female subjects. 
** Subject did not reach a steady state. 
§ As FSR equals FCR in under steady state conditions, the VLDL1-TG and -apoB FSR values are equal to the FCR values in the fasted state.
Fasting Concentrations  Production Rates  Intralipid-TG 
Clearance Rate  FSR
§  Subjects 
 
(apoE 
phenotype) 
VLDL1-
TG 
VLDL1-
ApoB 
VLDL2-
ApoB  VLDL1-TG VLDL1-ApoB SS  Exp  VLDL1-
TG 
VLDL1-
ApoB 
  mmol.l
-1 mg.dl
-1 mg.dl
-1 mg.h
-1 mg.kg
-1.d
-1 mg.h
-1 mg.kg
-1.d
-1 pools.d
-1 pools.d
-1 pools.d
-1 pools.d
-1 
1   (3/3)  0.76 0.8  1.6 625.0  241.1  17.1 6.6  **  79.8 30.2 22.0 
2   (3/2)  0.83 1.1  2.9 719.9  214.6  14.8 4.4 82.6 66.1 25.8 
3   (3/2)  1.81 1.8  6.8  2147.4  609.9  50.9 14.5 56.9 56.4 30.9 
4   (4/3)  0.40 0.8  0.9 642.3  235.3  12.0 4.4 72.8 96.5 57.8 
5   (3/3)  0.54 1.1  2.2  711.2  309.2  20.7 9.0  **  146.9 56.3  20.0 
6   (3/3)  4.43 10.6  7.7  2563.2  593.2  40.2 9.3  17.3 18.1  6.5  2.2 
7   (3/3)  2.15  3.8  3.7  1228.1  406.5  24.9  8.2  39.8  40.5  9.3  5.4 
8   (3/3)  0.65  0.3  3.0  446.0  205.8  16.1  7.4  78.7  80.6  44.7  56.2 
9   (3/3)  1.04  1.0  3.0  885.5  322.0  24.1  8.8  43.4  54.3  22.6  21.9 
10  (3/3)  1.03 0.5  2.9 798.2  198.5  33.0 8.2 27.2 29.5 17.4 39.1 3. Development of a Novel Method to Determine VLDL1 Kinetics 
3.3.4 
3.3.5 
Effect of Increasing the Intralipid Infusion Rate 
For the 5 subjects who underwent Intralipid infusion at the Low (0.1 g.kg
-1.h
-1) and 
the High (0.2 g.kg
-1.h
-1) doses, there were no significant differences in the mean 
VLDL1-apoB production rates (Low dose: 23.8 ± 2.8 vs High dose: 22.0 ± 1.9 mg.h
-
1, P = 0.21) or VLDL1-TG production rates (Low dose: 813.8 ± 127.0 vs High dose: 
960.9 ± 136.8 mg.h
-1, P = 0.10) between both doses, although there was a tendency 
for the VLDL1-TG production rate to be higher at the High Intralipid dose.   
However, it was observed that separation of the large amount of Intralipid from 
plasma at the higher 0.2 g.kg
-1.h
-1 dose was technically quite difficult and it was 
suspected that the VLDL1 fraction in some samples may have become slightly 
contaminated with Intralipid at this dose (Figure 3.9).  This suggestion is supported 
by the substantially lower recovery of Intralipid in the Intralipid fraction at high 
Intralipid concentrations (see below).  Calculated FSRs for VLDL1-TG (Low dose: 
30.1 ± 8.8 vs High dose: 30.4 ± 8.1 pools.d
-1, P = 0.94) and VLDL1-apoB (Low dose: 
28.5 ± 8.7 vs High dose: 33.4 ± 14.6 pools.d
-1, P = 0.64) did not differ between the 
two doses.  In addition, FSRs for VLDL1-TG (r = 0.88, P = 0.05) and VLDL1-apoB 
(r = 0.95, P = 0.01) between the two doses correlated highly with each other and, 
when plotted, followed the line-of-equality (Figure 3.10). 
Furthermore, although a formal reproducibility test was not performed, the repeated 
two doses provided an opportunity to estimate the test/re-test reproducibility of 
VLDL1-TG and -apoB production rates.  Based on data from these 5 subjects, the 
within-subject CV for VLDL1-TG production was 20.1% and for VLDL1-apoB 
production was 12.7%. 
Intralipid Recovery 
Recovery of the Intralipid-TG in the Intralipid (Sf >400) fraction was 95 ± 7% (mean 
± SD) for the 1.5 mmol.l
-1 Intralipid-TG concentrations and 71 ± 4% for the ~4.0 
mmol.l
-1 Intralipid-TG concentrations. 
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Figure   3.9: [A] An example of Intralipid separation in the High dose of Intralipid infusion (0.2 
g.kg
-1.h
-1).  Intralipid separation is done by overlayering 2 ml of plasma with 4 ml of density 
solution 1.006 g.ml
-1 and centrifuged at 10,000 rpm for 30 min.   [B] A magnification of the 
bottom of the tube showing a thin layer of possible contamination of Intralipid at the top of 
plasma due to the high concentration of Intralipid. 
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Figure   3.10: Scatterplots (with the line of equality) illustrating the agreement between [A] 
VLDL1-TG FSR (pools.d
-1) and [B] Ln VLDL1-apoB FSR between the Low (0.1 g.kg
-1.h
-1) and 
High (0.2 g.kg
-1.h
-1) doses.  FSR is equivalent to FCR in the fasted state.  N = 5, r and P values 
are for Pearson product-moment correlations between variables.  VLDL1-apoB FSR was 
expressed in pools.d
-1 prior to log-transformation. 
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3.3.6 
3.3.7 
Interrelationships between VLDL1-TG and VLDL1-apoB Production 
and TG Clearance  
Intralipid-TG clearance rate and VLDL1-TG and -apoB production rates (expressed 
in mg.h
-1) were significantly inter-related (Figure 3.11) with the expected negative 
correlation between Intralipid-TG clearance and VLDL1-TG (r = -0.67, P = 0.04) 
and VLDL1-apoB (r = -0.69, P = 0.03) production rates and a positive correlation 
between VLDL1-TG and -apoB production rates (r = 0.85, P = 0.002).  There was 
also a very strong relationship between VLDL1-TG FSR (which equals the VLDL1-
TG FCR in the fasted state) and Intralipid-TG clearance rate (r = 0.90, P < 0.005).  
The positive correlation between VLDL1-TG and -apoB production rates remained 
significant between production rates when values were expressed in mg.kg
-1.d
-1 (r = 
0.73, P = 0.02).  However, the relationships between VLDL1-TG production rate 
expressed in mg.kg
-1.d
-1 and Intralipid-TG clearance (r = -0.46, P = 0.18) and 
between VLDL1-apoB production rate expressed in mg.kg
-1.d
-1 and Intralipid-TG 
clearance (r = -0.28, P = 0.44) were not statistically significant. 
Relationships between Kinetic Variables and Subjects Characteristics 
Figure 3.12 shows the relationships between the calculated kinetic variables and 
subjects characteristics, with VLDL1-TG and -apoB production rates expressed in 
mg.h
-1. VLDL1-TG and -apoB production rates (mg.h
-1) correlated strongly and 
significantly with waist circumference and fasting TG concentration.  VLDL1-TG 
production rate also correlated significantly with HOMAIR.  Similarly, Intralipid-TG 
clearance rate was significantly and inversely correlated with waist circumference, 
fasting TG concentrations and HOMAIR.  In addition, BMI correlated significantly 
and positively with VLDL1-TG (r = 0.83, P = 0.003) and VLDL1-apoB (r = 0.81, P = 
0.004) production rates and inversely with Intralipid-TG clearance rate (r = -0.60, P 
= 0.07).  Fasting NEFA concentrations were not significantly correlated with any of 
the kinetic variables.  The relationships between VLDL1-TG and -apoB production 
rates expressed in mg.kg
-1.d
-1 units with BMI, waist circumference, fasting TG 
concentration and HOMAIR are shown in Table 3.3.  The correlations between 
VLDL1-TG production and all of these variables remained strong and statistically 
significant, however the correlations between VLDL1-apoB production rate and 
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waist circumference and fasting TG were not statistically significant when the 
production rates were normalized for body mass.  
3.3.8  Relationships between Kinetic Variables and ALT Concentrations 
Figure 3.13 shows the relationships between serum ALT concentrations and kinetic 
variables.  Although all subjects had ALT concentrations within the normal range, 
one subject was on antibiotics shortly prior to participating in the study and was 
excluded from the following correlations.  ALT concentrations correlated 
significantly with VLDL1-apoB production rate (r = 0.73, P = 0.03) and Intralipid-
TG clearance rate (r = -0.79, P = 0.01).  This indicates that, within normal range, 
ALT concentrations explained 53% (0.73
2) and 62% (0.79
2) of the variance in 
VLDL1-apoB production rate and Intralipid-TG clearance rate, respectively.  There 
was a tendency toward a positive correlation with VLDL1-TG production rate, but it 
did not reach statistical significance (r = 0.59, P = 0.09). 
 
Table   3.3: Correlations between VLDL1-apoB and -TG production rates (expressed in mg.kg
-1.d
-
1) and subjects’ characteristics. 
  VLDL1-ApoB Production 
Rate 
Ln VLDL1-TG Production 
Rate 
BMI  r = 0.63 
P = 0.05 
r = 0.65 
P = 0.04 
WC  r = 0.45 
P = 0.19 
r = 0.70 
P = 0.02 
Ln Fasting TG  r = 0.54 
P = 0.11 
r = 0.79 
P = 0.01 
Ln HOMAIR  r = 0.40 
P = 0.25 
r = 0.79 
P = 0.01 
 
BMI, body mass index; HOMAIR,  HOMA-estimated insulin resistance; WC, waist circumference.  
N = 10, r and p values are for Pearson product-moment correlations between values. 
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Figure   3.11: Scatterplots (with linear-regression lines of ‘best-fit’) illustrating the 
interrelationships between [A] Ln Intralipid-TG clearance rate and Ln VLDL1-apoB 
production rate, [B] Ln Intralipid-TG clearance rate and Ln VLDL1-TG production rate, and 
[C] Ln VLDL1-apoB and Ln VLDL1-TG production rates.  N = 10, r and P values are for 
Pearson product–moment correlations between variables.  Production rates and Intralipid-TG 
clearance rate were expressed in mg.h
-1 and pools.d
-1 prior to log-transformation, respectively. 
©Iqbal A.R. AlShayji (2008)  883. Development of a Novel Method to Determine VLDL1 Kinetics 
 
  Ln VLDL1-ApoB 
Production Rate 
Ln VLDL1-TG 
Production Rate 
Ln Intralipid-TG 
Clearance Rate 
60
70
80
90
100
110
120
2.0 2.5 3.0 3.5 4.0 4.5
W
a
i
s
t
 
C
i
r
c
u
m
f
e
r
e
n
c
e
 
(
c
m
)
r = 0.74
p = 0.01
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
2.0 2.5 3.0 3.5 4.0 4.5
L
n
 
F
a
s
t
i
n
g
 
T
G
 
C
o
n
c
e
n
t
r
a
t
i
o
n
r = 0.80
p = 0.01
60
70
80
90
100
110
120
2.5 3.0 3.5 4.0 4.5 5.0 5.5
r = -0.74
p = 0.02
60
70
80
90
100
110
120
5.5 6.0 6.5 7.0 7.5 8.0 8.5
r = 0.90
p = 0.001
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
5.5 6.0 6.5 7.0 7.5 8.0 8.5
r = 0.87
p = 0.001
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
2.5 3.0 3.5 4.0 4.5 5.0 5.5
r = -0.86
p = 0.001
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
5.5 6.0 6.5 7.0 7.5 8.0 8.5
Ln VLDL1-TG Production Rate
r = 0.83
p = 0.003
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
2.0 2.5 3.0 3.5 4.0 4.5
Ln VLDL1-ApoB Production Rate
L
n
 
H
O
M
A
I
R
r = 0.59
p = 0.07
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
2.5 3.0 3.5 4.0 4.5 5.0 5.5
Ln Intralipid-TG Clearance Rate
r = -0.67
p = 0.03
 
Figure   3.12: Scatterplots (with linear-regression lines of ‘best-fit’) illustrating the relationships 
between the kinetic variables [Ln VLDL1-TG production rate (left), Ln VLDL1-apoB 
production rate (middle) and Ln Intralipid-TG clearance rate (right)] and subjects’ 
characteristics: waist circumference (top), Ln fasting TG concentrations (middle) and Ln 
HOMA-estimated insulin resistance (HOMAIR) (bottom).  N = 10, r and p values are for Pearson 
product-moment correlations between variables.  
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Figure   3.13: Scatterplots (with linear-regression lines of ‘best-fit’) illustrating the relationships 
between serum ALT concentration (mU.l
-1) and [A] Ln VLDL1-apoB production rate, [B] Ln 
Intralipid-TG clearance rate and [C] Ln VLDL1-apoB production rate.  N = 9, r and P values 
are for Pearson product-moment correlations between variables. 
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3.4  Discussion  
In the present study, a relatively straightforward method of determining TRL kinetics 
was developed.  The method relies on the fact that chylomicrons or chylomicron-like 
particles, such as Intralipid, compete with hepatically-derived large VLDL1 particles 
for clearance by a common saturable pathway – i.e. hydrolysis of their TG content by 
LPL (Bjorkegren et al., 1996; Karpe & Hultin, 1995) – and that chylomicrons or 
chylomicron-like particles are the preferred substrate for LPL (Fisher et al., 1995).  
Thus, the presence of a sufficient concentration of chylomicrons or chylomicron-like 
particles in the circulation will almost entirely prevent clearance of VLDL1 by LPL 
(Bjorkegren et al., 1996) and the rates of VLDL1-TG and -apoB production can 
therefore be calculated from their rates of rise in concentration.  The present work 
builds on the findings of Björkgren et al. who, in studies designed to evaluate the 
effects of Intralipid infusion on VLDL1 (Sf 60-400) and VLDL2 (Sf 20-60) kinetics, 
found that individual rates of VLDL1-apoB production calculated from the rate of 
rise of VLDL1-apoB during infusion were virtually identical to those calculated from 
the ‘gold-standard’ stable isotope method (see below) (Bjorkegren et al., 1996).  The 
‘Intralipid method’ described in the present study enables the determination of the 
rate of VLDL1-TG (i.e. VLDL1 lipid) and VLDL1-apoB (i.e. VLDL1 particle) 
production as well as the clearance rate of chylomicron-like particles. 
The Intralipid method specifically measures the production rate of large VLDL1 (Sf 
60-400) rather than total VLDL (i.e. Sf 20-400).  VLDL is a metabolically 
heterogeneous class of lipoproteins, and it is the larger VLDL1 subclass which 
competes with chylomicrons/chylomicron-like particles for LPL-mediated clearance 
and would have its clearance blocked by the presence of Intralipid (Bjorkegren et al., 
1996).  In contrast, catabolism of the smaller VLDL2 subclass would not be 
completely blocked by Intralipid as its clearance can occur via the action of hepatic 
lipase as well as LPL (Packard & Shepherd, 1997).  Indeed, as one source of VLDL2 
is from catabolism of VLDL1 (the other being direct hepatic production), and this 
process was blocked by Intralipid infusion, mean VLDL2-apoB concentrations 
decreased slightly during the infusion although individual responses were more 
heterogeneous than that observed in VLDL1-apoB; a finding also reported by 
Björkegren et al. (Bjorkegren et al., 1996).  This heterogeneity in individual VLDL2-
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apoB responses meant that it was not possible to perform any kinetic analyses using 
the VLDL2 data.  
To validate the calculation of VLDL1-TG and -apoB production rates using the 
‘Intralipid method’ it was necessary to consider a number of issues.  The first was to 
determine whether infusing a higher Intralipid dose would influence the calculated 
VLDL1-TG and -apoB production rates.  This was necessary to establish whether the 
proposed Intralipid infusion dose of 0.1 g.kg
-1.h
-1, was sufficient to saturate LPL and 
block clearance of VLDL1: if the 0.1 g.kg
-1.h
-1 dose was sufficient, infusing a higher 
Intralipid dose should not affect calculated production rates.  In agreement with the 
findings of Björkegren et al. (Bjorkegren et al., 1996), the calculated VLDL1-apoB 
production rate in the present study was not changed when a higher, 0.2 g.kg
-1.h
-1 
Intralipid infusion dose was used.  Similarly, FSRs, which correspond to the FCRs in 
the fasted state, for VLDL1-TG and -apoB did not differ between the two doses 
(Figure 3.10).  Although there was tendency for the calculated VLDL1-TG 
production rate to be higher with the 0.2 g.kg
-1.h
-1 dose, this was not statistically 
significant.  However, the author feels that the slightly higher apparent VLDL1-TG 
production rate at the High dose was a methodological, rather than a physiological, 
issue caused by the difficulty in separating Intralipid at the High dose, leading to the 
potential contamination of the VLDL1 fraction with Intralipid.  This is supported by 
the fact that Intralipid recoveries at high Intralipid doses were relatively low (71% at 
an Intralipid concentration of 4 mmol.l
-1).  This contrasts with the near complete 
recovery of Intralipid at lower Intralipid doses (95% at an Intralipid concentration of 
1.5 mmol.l
-1).  This, of course, would not influence the VLDL1-apoB production rate 
calculations, as Intralipid particles do not contain apoB.    
A further issue to consider is whether, following lipolysis by LPL, Intralipid 
‘remnant’ particles may have appeared in the VLDL1 fraction, thereby increasing the 
measured VLDL1-TG concentration and the apparent VLDL1-TG production rate.  
However, the author does not believe that this would have had a substantial effect on 
calculated VLDL1-TG production rates for a number of reasons.  Firstly, evidence 
from the literature suggests that for large TG-rich particles, particularly chylomicron-
like particles, lipolysis and particle removal from the plasma is likely to occur 
simultaneously, rather than by sequential mechanisms (Olivecrona & Olivecrona, 
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1998; Hultin et al., 1996), with the majority of particles removed from the plasma 
before conversion to smaller VLDL-sized remnant particles (Karpe et al., 1997).   
Secondly, as Intralipid contains TG but not apoB, appearance of Intralipid remnants 
in the VLDL1 fraction would lead to a disproportionate rise in VLDL1-TG compared 
with VLDL1-apoB, leading to an increase in the VLDL1 TG/apoB ratio.  There was 
no significant increase in this ratio during the infusion (P = 0.21). Thirdly, if the rise 
in VLDL1-TG was influenced by the appearance of Intralipid remnant particles, then 
a positive correlation between Intralipid clearance and VLDL1-TG production would 
be evident (i.e. increased Intralipid clearance would lead to increased VLDL1-TG 
production).  Instead, a negative relationship between Intralipid clearance and 
VLDL1-TG production (expressed in mg.h
-1) was observed (i.e. subjects with slow 
Intralipid clearance also had high VLDL1-TG production) (r = -0.67, P = 0.04).   
Furthermore, the relationship between VLDL1-apoB production, which would be 
unaffected by the presence of Intralipid remnant particles, and VLDL1-TG 
production was very strong, with 71% of the variance in the VLDL1-TG production 
rate explained by the VLDL1-apoB production rate (r = 0.85, P = 0.002).  
Furthermore, it is important to ascertain whether the results obtained are comparable 
with data obtained using the ‘gold standard’ stable isotope tracer method.  An 
internal validation of this method was previously undertaken by Björkegren and 
colleagues (Bjorkegren et al., 1996) in 3 subjects.  They reported VLDL1-apoB 
production rates of 20.0, 25.6 and 7.2 mg.h
-1 calculated from the Intralipid infusion 
method with corresponding rates calculated from a stable isotope method of 23.8, 
21.6 and 8.0 mg.h
-1, respectively, indicating that data obtained from the two methods 
were comparable.  In addition, from Table 3.4, it is clear that the values for VLDL1-
apoB production in the present study are of the same order as those obtained from a 
number of studies which determined VLDL1-apoB production using staple isotope 
techniques.  Determination of VLDL1-TG production rates using stable isotope tracer 
methods is technically more difficult than determination of VLDL1-apoB production, 
and the author is only aware of one group of workers who have evaluated this 
(Adiels et al., 2005a; Adiels et al., 2006b).  The values obtained for VLDL1-TG 
production in the present study are of the same order as those published by Adiels et 
al. (Adiels et al., 2005a; Adiels et al., 2006b). 
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This Intralipid method enabled the Intralipid-TG clearance rate to be calculated in 
two different ways: from the steady state concentration of Intralipid-TG during the 
infusion, which was defined in the present study as the mean of the final 3 values if 
these differed by less than 13.8% (i.e. two times the CV for the separation of the 
Intralipid fraction and measurement of the TG), and from the exponential decrease in 
Intralipid-TG post-infusion (Rossner, 1974).  In subjects where a steady-state 
Intralipid-TG concentration was achieved, the Intralipid-TG clearance rates 
calculated from the steady state concentration and from the post-infusion exponential 
decrease agreed closely (see Table 3.2).  However, not all subjects achieved a 
steady-state Intralipid-TG concentration in 75 min of infusion and it is not possible to 
determine whether a steady-state was achieved for a given subject until sample 
analysis was completed.  Therefore, in practice, it may be easier to use the post-
infusion values to determine Intralipid-TG clearance rates, as this ensures that the 
Intralipid infusion can be kept as short as is necessary to enable calculation of 
VLDL1-TG and -apoB production rates.  
Moreover, the author sought to determine whether this Intralipid method revealed the 
physiologically expected differences in TRL kinetics between subjects with differing 
physical and metabolic profiles.  As expected, there were strong positive correlations 
between fasting TG concentrations and VLDL1-TG production rates expressed in 
either absolute terms or normalized according to body mass and between fasting TG 
and VLDL1-apoB, production expressed in mg.h
-1 units, with a strong negative 
correlation between fasting TG and the Intralipid-TG clearance rates, indicating that 
those with high TG concentrations exhibited a combination of enhanced VLDL1 
production and diminished TG clearance.  VLDL1-TG FCR in the fasted state (i.e. 
with no Intralipid present) was ~45% of the Intralipid-TG clearance rate (30.2 ± 5.7 
pools.d
-1  vs. 66.2 ± 11.7 pools.d
-1, see Table 3.2) and there was a very strong 
correlation between the two variables (r = 0.90, P <0.0005), indicating that clearance 
rates for VLDL1 and chylomicron-like particles within an individual are very tightly 
linked, consistent with the fact that these particles are cleared by the same pathway.  
The expected positive correlations between indices of body fatness (waist 
circumference and BMI) and insulin resistance (HOMAIR) and VLDL1-TG and 
VLDL1-apoB production rates were also observed, in agreement with findings 
previously reported using stable isotope tracer methods (Gill et al., 2004a).  In 
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addition, significant negative relationships were observed between Intralipid-TG 
clearance and HOMAIR and waist circumference.  Thus, the Intralipid method 
appears to be sensitive enough to detect physiologically relevant differences in TRL 
kinetics between individuals across the normal and moderately hypertriglyceridaemic 
range.  
Finally, liver fat has been reported to be independently associated with insulin 
(Westerbacka et al., 2004) and predicted VLDL1 production (Adiels et al., 2006b).  It 
was proposed that insulin resistance induces an increase in the fatty acid flux from 
adipose tissue to the liver, which leads to the accumulation of fat in the liver, 
resulting in overproduction of VLDL1 particles (Adiels et al., 2006b).  As serum 
ALT concentrations, within normal range, have been shown to be a marker for liver 
fat (Westerbacka et al., 2004) and has been shown to predict the onsets of type 2 
diabetes (Sattar et al., 2004; Sattar et al., 2007), the metabolic syndrome 
(Schindhelm et al., 2007b) and CVD events (Schindhelm et al., 2007a), the author 
investigated whether serum ALT concentrations, would predict hepatic VLDL1 
production rate in the present study.  Indeed, ALT concentrations correlated 
significantly with VLDL1-apoB production rate and Intralipid-TG clearance rate, 
explaining 53% and 62% of their variance; respectively.  This suggests that ALT 
concentrations are significant predictors of hepatic VLDL1 production and further 
validates the sensitivity of the ‘Intralipid Method’. 
In conclusion, this chapter describes the development of a novel method to determine 
TRL kinetics.  The ‘Intralipid method’ provides a relatively straightforward and cost-
effective way of determining VLDL1-TG and VLDL1-apoB production rates, and the 
clearance rate of chylomicron-like particles, which does not require specialised 
equipment or skill in multicompartmental modelling.  The author believes that this 
method will increase the scope for the study of TRL kinetics, particularly in 
circumstances where issues related to funding or equipment availability preclude the 
use of more traditional isotopic tracer methods.  
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Table   3.4: Comparison of values for VLDL1-TG and VLDL1-apoB production rates (range) calculated in the present study (Intralipid Method) and in previously 
published studies using the stable-isotope method. 
Subjects Production  rates 
BMI  TG  VLDL1-ApoB VLDL1-TG  Study 
N (m/f) 
kg.m
-2  mmol.l
-1  mg.h
-1 mg.kg
-1.d
-1  mg.h
-1  mg.kg
-1.d
-1 
(Bjorkegren et al., 1996)  16 (m)  20.0 - 25.8  0.56 – 1.85  8.0 - 23.8      - 
(Demant et al., 1996)  6 (m)  -  1.00 – 2.40  21.2 - 51.8      - 
(Pietzsch et al., 1996)  6 (3/3)  20.5 - 25.0  0.70 – 1.46    22.9 - 50.7    - 
(Gill et al., 2004a)  16 (8/8)  19.6 - 32.9  1.00 – 3.15  8.5 - 67.8      - 
(Adiels et al., 2005a)  17  22.4 - 30.1  0.99 – 2.59    2.9 - 12.5    107 - 347 
(Zheng et al., 2006)  5 (f)  22.0 – 27.0  0.89 – 1.58    8.4 ± 5.6*   - 
(Adiels et al., 2006b)  18  22.0 – 30.0  0.67 – 3.14    2.9 - 12.5    107 - 352 
Intralipid Method  10 (7/3)  20.8 - 34.7  0.40 – 4.43  12.0 - 50.9  4.4 - 14.5  446.0 - 2563.2  199 - 610 
  *Data are mean ± SD. 
  
4.  Effects of Acute Hyperinsulinaemia and 
Hyperglycaemia on VLDL1-TG and VLDL1-
ApoB Production and Intralipid-TG 
Clearance in Normoglycaemic Subjects 
4.1  Introduction 
Diabetic dyslipidaemia is believed to be initiated by high concentrations of large 
VLDL1 particles, which, consequently, cause the accumulation of remnant 
atherogenic particles and the generation of small dense LDL and small dense HDL 
(Taskinen, 2003).  Interestingly, this profile of atherogenic lipoprotein abnormalities 
along with insulin resistance and hyperinsulinaemia is detectable in both the fasting 
(Tilly-Kiesi et al., 1996) and postprandial (Johanson et al., 2004) states years before 
the diagnosis of diabetes and appears to be related more to insulin resistance than 
hyperglycaemia.  Therefore, it is important to understand the role of insulin in the 
regulation of hepatic VLDL1 production. 
Insulin plays a pivotal role in the regulation of hepatic VLDL production and acute 
hyperinsulinaemia has been shown to suppress VLDL production in normal subjects 
(Lewis  et al., 1993; Malmstrom et al., 1997b).  Insulin directly inhibits VLDL 
assembly and secretion in the liver through a number of mechanisms; e.g. it enhances 
intracellular apoB degradation (Sparks & Sparks, 1990) and inhibits the maturation 
process of VLDL assembly (Brown & Gibbons, 2001).  In addition, it suppresses the 
NEFA flux to the liver, thereby reducing substrate availability for VLDL formation 
(Coppack et al., 1994).  However, these suppressive effects may be attenuated or lost 
in insulin resistant conditions. It has been reported that type 2 diabetic (Malmstrom 
et al., 1997a; Bioletto et al., 2000) and obese individuals (Lewis et al., 1993; Bioletto 
et al., 2000) fail to suppress hepatic VLDL production and concentrations (Bioletto 
et al., 2000) to the same extent as their normal-weight, non-diabetic counterparts. 
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It is important to recognise that VLDL is a heterogeneous particle consisting of at 
least two major subclasses - large TG-rich VLDL1 (Sf 60-400) and small, denser 
VLDL2 (Sf 20-40) (Packard & Shepherd, 1997) - which have been shown to be 
independently regulated (Packard & Shepherd, 1997; Malmstrom et al., 1998; Gill et 
al., 2004a).  Thus, the apparent effects of regulators on VLDL1 metabolism may be 
masked or attenuated in studies examining the kinetics of total VLDL without 
subdivision into VLDL1 and VLDL2 subclasses.  Indeed, VLDL1, but not VLDL2, 
particles have been shown to be the major determinant of plasma TG (Tan et al., 
1995) and the target for insulin-mediated VLDL suppression (Gill et al., 2004a; 
Malmstrom et al., 1998).  
Furthermore, it is important to differentiate between VLDL-apoB and VLDL-TG 
production rates.  As there is only one apoB molecule per VLDL particle (Elovson et 
al., 1988), VLDL-apoB reflects particle number, whereas VLDL-TG is a measure of 
the major lipid component of VLDL particle.  VLDL-apoB production rate may be 
dissociated from that of VLDL-TG (Kissebah et al., 1981), giving rise to variable 
TG-to-apoB ratios and, hence, VLDL particle size.  
To the best of the author’s knowledge, studies examining the effects of acute 
hyperinsulinaemia on VLDL have either (1) addressed VLDL heterogeneity but 
considered only the production of VLDL1-apoB, but not VLDL1-TG (Malmstrom et 
al., 1997b; Malmstrom et al., 1998; Bioletto et al., 2000; Annuzzi et al., 2001); (2) 
investigated both apoB and TG production rates, but in total VLDL (Lewis et al., 
1993; Lewis et al., 1994; Lewis & Steiner, 1996; Mittendorfer et al., 2003b; Lewis et 
al., 1995), rather than VLDL1 specifically; or (3) studied the composition of VLDL 
subfractions rather than production rates (Annuzzi et al., 2001; Bioletto et al., 2000).  
However, at the start of the present study, no information existed on the acute effects 
of insulin on both VLDL1-TG and -apoB production rates in normoglycaemic 
subjects.  Recently, a non-steady-state stable isotope study by Adiels et al. (Adiels et 
al., 2007) was published, which investigated the acute effect of insulin on the 
production rates and pool sizes of VLDL1-TG and -apoB in relation to liver fat 
content in normal and diabetic subjects.  
©Iqbal A.R. AlShayji (2008)  984. Effects of Hyperinsulinaemia & Hyperglycaemia on VLDL1 Production Rates  
Therefore, the aims of the present study initially were to investigate (1) whether 
acute hyperinsulinaemia inhibits VLDL1-TG and VLDL1-apoB production to the 
same extent and (2) factors that might influence the extent to which VLDL1 is 
suppressed in a group of normoglycaemic individuals with a wide range of adiposity, 
fasting TG and insulin resistance.  This was conducted using a novel, non-stable 
isotope method to determine VLDL1-TG and -apoB kinetics (Al-Shayji et al., 2007), 
the development of which was previously described in Chapter 3. 
4.2 
4.2.1 
4.2.2 
Subjects and Methods 
Subjects 
Eight non-smoking healthy subjects (6 men and 2 women) were included in this 
study after giving written informed consent.  All subjects had normal thyroid, liver 
and renal function and none had acute illness, a history of known cardiovascular 
disease or hypertension, nor were under medication known to influence carbohydrate 
or lipid metabolism.  The subject information sheet, consent form and health 
questionnaire were the same as those used for the ‘Intralipid Method’ study 
(Appendices A1 & B1).  Two subjects had the E3/2 phenotype, five had the E3/3 
phenotype and one had the E4/4 phenotype.  The subjects’ characteristics are shown 
in Table 4.1.  The study protocol was approved by the Research Ethics Committee of 
the North Glasgow University Hospitals NHS Trust. 
Study Design 
Each subject participated in 2 Intralipid trials (Control and Glucose) in random order 
at an interval of 2-3 weeks for men and 4 weeks (to control for menstrual cycle) for 
women.  In the Glucose trial, subjects were given an oral bolus of a glucose drink (30 
g in 120 ml) an hour before an Intralipid infusion (see below) followed by 10 g of 
glucose (in 40 ml) at 15-min intervals through out the duration of the trial.  This was 
substituted with equivalent volumes of water in the Control trial (Figure 4.1).  The 
dose and frequency of the glucose drink were previously determined, as explained in 
section 2.10, to elucidate sufficient suppression in NEFA concentrations, before 
administering the Intralipid infusion, and maintain, as far as possible, a steady state 
of hyperinsulinaemia and hyperglycaemia throughout the trial. 
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Subjects were requested not to exercise for three days before their study days as this 
is known to affect TRL metabolism (Gill & Hardman, 2003).  In addition, they were 
asked to weigh and record their dietary intake for two days prior to the first Intralipid 
test and this diet was replicated for the second trial. 
Table   4.1: Subjects' physical characteristics and mean fasting concentrations (n=8). 
 Mean  Range 
Age (years)  34  (22-55) 
Body Mass (kg)  73.9  (56.0-96.5) 
Body mass index (kg.m
-2) 25.8  (21.0-34.7) 
Waist circumference (cm)  83.8  (73.0-104.5) 
Waist/hip ratio  0.82  (0.77-0.88) 
ALT (U.l
-1) 20  (15-26) 
Triglycerides (mmol.l
-1)* 1.17  (0.52-2.36) 
Total cholesterol (mmol.l
-1)* 4.21  (3.37-5.65) 
HDL cholesterol (mmol.l
-1)* 1.37  (0.81-1.81) 
LDL cholesterol (mmol.l
-1)* 2.29  (1.47-3.63) 
Glucose (mmol.l
-1)* 5.32  (4.50-5.91) 
Insulin (mU.l
-1)* 7.15  (2.48-15.84) 
HOMAIR* 1.71  (0.50-3.59) 
NEFA (mmol.l
-1)* 0.50  (0.28-0.77) 
Fasting VLDL1-TG (mmol.l
-1)* 0.47 (0.12-1.31) 
Fasting VLDL1-apoB (mg.dl
-1)* 1.51 (0.38-4.04) 
*Values are the mean of Control and Glucose trials  
 
Time (min)
-60 -45 - 3 0 - 1 50 1 53 04 56 07 59 0 105 120 135 150
Intralipid Infusion
* * * * ** * *** * * ***
Blood sampling * Drink ingestion
Time (min)
-60 -45 - 3 0 - 1 50 1 53 04 56 07 59 0 105 120 135 150
Intralipid Infusion
* * * * ** * *** * * ***
Blood sampling * Drink ingestion
 
Figure   4.1: Study Protocol.  In the Glucose trial a bolus drink of 30 g of glucose in 120 ml water 
was given at -60 mins, followed by 10 g of glucose in 40 ml of water at 15-min intervals 
thereafter.  In the Control trial, equivalent volumes of water were given at the same intervals.  
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4.2.3  Intralipid Infusion 
TRL kinetics were determined using the ‘Intralipid Method’ (Al-Shayji et al., 2007) 
as previously described in Chapter 3.  Briefly, subjects reported to the Clinical 
Investigation Suite in the Department of Vascular Biochemistry in Glasgow Royal 
Infirmary after an overnight fast of 12 h where they were given a bolus dose of 0.1 
g.kg
-1 of 20% Intralipid followed immediately by an intravenous infusion of 0.1 g.kg
-
1.h
-1 of 10% Intralipid for 75 min.  Multiple EDTA blood samples were drawn at 
baseline, before and at 15-min intervals during infusion as well as at 2.5, 5, 10, 15, 
20, 30, 45, 60 and 75 min post-infusion.  
4.2.4  Analytical Methods 
Plasma total and HDL cholesterol concentrations were measured in the fasted state 
and glucose, TG and NEFA concentrations were measured in all time points.  LDL 
cholesterol was calculated in the fasted state using the Friedewald equation 
(Friedewald et al., 1972).  Plasma insulin concentrations were analysed in the fasted 
state and every 30 min throughout the trial.  Serum ALT concentrations were 
measured at screening and the apoE phenotype was determined for each subject.  All 
analyses were performed as previously described in sections 2.4.2 to 2.4.4. 
Intralipid (Sf >400) and VLDL1 (Sf 60-400) fractions were separated from whole 
plasma as previously described in sections 3.2.4 and 2.4.1, respectively (Al-Shayji et 
al., 2007).  TG concentrations (corrected for glycerol, section 3.2.7) were measured 
in the Intralipid and VLDL1 fractions in all time points and apoB concentrations were 
measured directly in the VLDL1 fraction by immunoturbidimetry as previously 
described in section 2.9.2.3. 
4.2.5  Calculations and Statistical Analyses 
VLDL1-TG and VLDL1-apoB productions rates were calculated from their linear 
rises in the VLDL1 fraction during infusion.  Intralipid-TG clearance rate was 
calculated from its exponential decay post-infusion as described in Chapter 3 (Al-
Shayji et al., 2007).  The production ratio of TG/apoB (mol:mol) was calculated as 
an index of the size of the VLDL1 particle being produced. 
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Time-averaged concentrations for glucose, insulin and NEFA were calculated from 
their respective areas under the curve from the start of the Intralipid infusion to 75 
min post-infusion. 
Statistical analyses were performed using MINITAB for Windows (Version 14.0, 
MINITAB Inc., State College, PA) and STATISTICA (Release 6.0, StatSoft, Inc, 
USA).  Normality was checked for all the data using the Anderson-Darling test. 
When data did not approximate a normal distribution, these were log-transformed, 
specifically fasting TG, kinetic data and the time-averaged concentrations of glucose 
and insulin. Time-trends were tested using two-way ANOVA (trial × time) with 
repeated measures on both factors.  Post hoc Fisher LSD tests were used to indentify 
exactly where any differences lay.  Paired t-tests were used to compare fasting 
concentrations and kinetic variables between the Glucose and Control trials.   
HOMAIR was used as a validated surrogate measure of insulin resistance (Matthews 
et al., 1985) and was calculated as insulin (mU.l
-1) × glucose (mmol.l
-1) / 22.5.  To 
determine factors which predicted the change in VLDL1-TG and -apoB production 
and Intralipid-TG clearance rates between Control and Glucose trials, Pearson 
product-moment correlations were performed between the changes (Control minus 
Glucose) in kinetic variables on one hand and HOMAIR, ALT, NEFA and the 
differences in the time-averaged concentrations of glucose and insulin on the other 
hand.  Significance was accepted at the P <0.05 level.  Data are presented as mean ± 
SEM unless otherwise stated.  There were no data available to base a formal power 
calculation on for the present study.  However, in a previous study investigating the 
effects of hyperinsulinaemia on VLDL1-apoB production using stable isotope 
methods, a significant effect was seen with five subjects (Malmstrom et al., 1998), 
suggesting that studying eight subjects in the present study would be sufficient to 
detect a significant effect of hyperinsulinaemia on VLDL1 metabolism, should such 
an effect exist.    
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4.3 
4.3.1 
4.3.2 
Results  
Fasting Plasma Concentrations 
There was no significant difference in fasting concentrations between the Glucose 
and Control trials.  Table 4.1 therefore shows the mean of fasting plasma lipid, 
glucose, insulin, HOMAIR and NEFA concentrations in both trials. 
Glucose, Insulin and NEFA Concentrations during and Post-
Infusion 
Mean plasma glucose concentrations were significantly higher throughout the 
Glucose trial compared with the Control trial (P = 0.005, Figure 4.2A).  In the 
Glucose trial, glucose concentrations increased significantly within 30 min of the 
initial glucose ingestion (i.e. 30 min prior to the Intralipid infusion) (from 5.35 ± 
0.18 to 7.92 ± 0.59 mmol.l
-1, P <0.001) and averaged 7.80 ± 0.12 mmol.l
-1 during 
infusion.  In the Control trial, glucose concentrations decreased slightly from 
baseline during the first hour before infusion (from 5.28 ± 0.15 to 5.06 ± 0.11 
mmol.l
-1, P = 0.01), but remained unchanged at an average of 5.08 ± 0.08 mmol.l
-1 
(P = 0.44) during infusion. 
As expected, insulin concentrations were significantly higher in the Glucose trial 
compared to the Control trial (P = 0.03, Figure 4.2B).  Like glucose concentrations, 
insulin concentrations increased significantly 30 min after the start of the glucose 
drinks in the Glucose trial (from 7.25 ± 1.80 mU.l
-1 to 47.61 ± 8.78 mU.l
-1, P = 0.02) 
and remained elevated (P = 0.47) throughout the trial with an average concentration 
of 64.91 ± 9.7 mU.l
-1.  This is in contrast to the Control trial, where plasma insulin 
concentrations did not change significantly from baseline (P = 0.91) with an average 
of 6.87 ± 0.17 mU.l
-1. 
In the hour prior to the start of the Intralipid infusion, mean plasma NEFA 
concentrations declined rapidly in the Glucose trial from 0.46 ± 0.07 at baseline to 
0.16 ± 0.04 mmol.l
-1 immediately before infusion (P <0.001, Figure 4.2C), but did 
not change significantly from baseline in the Control trial (0.55 ± 0.01 mmol.l
-1, P = 
0.27).   When  the  Intralipid  infusion  started  in  both  trials,  NEFA  concentrations 
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Figure   4.2: Mean [A] glucose, [B] insulin and [C] NEFA concentrations before and during 
Intralipid infusion (left panel) and post-infusion (right panel) between the Control (●) and 
Glucose (○) trials.  The dotted line represents the beginning of a bolus Intralipid dose of 0.1 
g.kg
-1 followed immediately by a constant Intralipid infusion of 0.1 g.kg
-1.h
-1.  Significant 
differences between the two trials were tested using two-way ANOVA with (*) representing P 
<0.05 and (**) P <0.001. 
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increased about 2.5-fold and leveled during infusion at an average concentration of 
0.85 ± 0.04 mmol.l
-1 in the Control trial and 0.34 ± 0.02 mmol.l
-1 in the Glucose trial.  
Overall, NEFA concentrations were significantly lower throughout the Glucose trial 
compared to the Control trial (P <0.001).  
4.3.3  The Change in Production and Clearance Rates 
Individual and mean VLDL1-TG and -apoB production and Intralipid-TG clearance 
rates in the Control and Glucose trials according to apoE phenotypes are shown in 
Figure 4.3.  The VLDL1-TG production rate was lower in the Glucose trial in 6 out 
of 8 subjects with an overall mean production rate of 805.7 ± 264.0 mg.h
-1 compared 
to 969.3 ± 181.6 mg.h
-1 in the Control trial (P = 0.05, Figure 4.3A).  Similarly, 
VLDL1-apoB production rate was lower in the Glucose trial in the same 6 subjects 
with an overall mean production rate of 21.8 ± 5.3 mg.h
-1 in the Glucose trial versus 
25.8 ± 4.1 mg.h
-1 in the Control trial (P = 0.04, Figure 4.3B).  Overall, there was a 
25.4% and 20.9% reduction in VLDL1-TG and -apoB production rates, respectively, 
in the Glucose trials. It is unclear why these two subjects responded differently.   
However, of note, one of them had the highest HOMAIR value (3.59) among all 
subjects. 
On the other hand, the Intralipid-TG clearance response differed widely amongst 
subjects (Figure 4.3C).  While four subjects showed a slight increase in Intralipid-
TG clearance rate in the glucose trial, one subject showed a dramatic increase and the 
remaining three subjects showed a decreased Intralipid-TG clearance rate.  The 
reason for these different responses is unclear.  However, it is possibly due to 
differences in insulin resistance: the subject who had the highest increase in 
Intralipid-TG clearance rate, had the lowest HOMAIR of 0.5 (mean between the 
Control and Glucose trials), while the three subjects who had decreased clearance 
rates in the glucose trial, exhibited the highest HOMAIR concentrations amongst the 
8 subjects (1.97, 3.47 and 3.59).  This suggestion is supported by a strong correlation 
between HOMAIR and the change in Intralipid-TG clearance rate (see below).  There 
was no significant difference in Intralipid-TG clearance between the Control and 
Glucose trials (69.4 ± 12.7 and 103.5 ±  49.8 pools.d
-1 respectively, P = 0.95), 
although clearance was 16.9% higher in the Glucose trial.  However, this numerical 
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increase in Intralipid-TG clearance was entirely due to one subject who showed a 
dramatic increase in Intralipid-TG clearance following glucose ingestion.  If this 
subject was excluded from analysis, the Intralipid-TG clearance rates between the 
Control and Glucose trials were almost identical (58.4 ± 7.3 and 54.8 ± 11.9 pools.d
-
1, respectively, P = 0.600).  
4.3.4 
4.3.5 
VLDL1 Particle Size 
The size of the VLDL1 particle being produced (estimated as TG/apoB molar ratio) 
in response to hyperinsulinaemia and hyperglycaemia varied widely among subjects: 
five subjects exhibited a decrease in VLDL1 particle size (range 7.4 - 50.6%), 
whereas 3 subjects showed an increased VLDL1 particle size (range 10.9 - 38.2%).  
Unlike the Intralipid-TG clearance rate, the reason for this variable response in 
VLDL1 particles size is unclear and could not be explained by differences in 
HOMAIR.  In total, there was a mean reduction of 7.6 ± 10.2% in VLDL1 particle 
size with glucose ingestion.  However, this change was not statistically significant (P 
= 0.29).  
Predictors of the Change in Production and Clearance Rates 
The change (Control minus Glucose) in NEFA concentrations at zero min (i.e. after 
the first hour of the start of the drink, and just before the Intralipid infusion) 
correlated significantly with the change in VLDL1-TG production rate (r = 0.79, P = 
0.02), but not with the change in VLDL1-apoB production rate (r = 0.59, P = 0.13, 
Figure 4.4A).  Overall, the change in NEFA concentrations explained 62% (0.79
2) of 
the variance in the change in VLDL1-TG production rate.  
In addition, the author investigated whether ALT concentrations within normal range 
would predict the change in hepatic VLDL1-TG and -apoB production in response to 
hyperinsulinaemia and hyperglycaemia.  It was noted that serum ALT concentrations 
correlated inversely and significantly with the change in VLDL1-TG (r = -0.83, P = 
0.01) and VLDL1-apoB (r = -0.74, P = 0.04) production rates, explaining 69% and 
55% of the variance in change in these responses, respectively (Figure 4.4B).  
HOMAIR did not correlate significantly with the change in VLDL1-TG and -apoB 
production rates.  However it correlated significantly with the change in Intralipid-
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TG clearance rates (r = 0.72, P = 0.04, Figure 4.4C), explaining 52% of the variance 
of the change in response.  This indicates that subjects who had the lowest HOMAIR 
(i.e. the more insulin sensitive individuals) had the biggest increase in Intralipid-TG 
clearance rate in response to hyperinsulinaemia. 
There was no apparent effect of apoE phenotype on the change in VLDL1-TG and 
VLDL1-apoB production rates or Intralipid-TG clearance rate (Figure 4.3).  
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Figure   4.3: Individual (according to apoE phenotype) and mean (bars) [A] VLDL1-TG and [B] 
VLDL1-apoB production rates and [C] Intralipid-TG clearance rate in the Control and Glucose 
trials  (n = 8).  (#) P = 0.05, (*) P <0.05. 
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Figure   4.4: Scatterplots (with linear-regression lines of ‘best-fit’) illustrating the relationships 
between the change (Control minus Glucose) in  [A] NEFA concentrations at 0 min (just before 
the start of the Intralipid infusion) and the change in VLDL1-TG (left) and VLDL1-apoB 
production rates (right); between [B] serum ALT concentrations and the change in VLDL1-TG 
(left) and VLDL1-apoB production rates (right); and [C] HOMAIR and the change in Intralipid-
TG clearance rate.  N = 8, r and P values are for Pearson product–moment correlations between 
variables. 
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4.4  Discussion 
This study aimed to investigate the acute effects of hyperinsulinaemia and 
hyperglycaemia on the production rates of both VLDL1-TG and -apoB and Intralipid-
TG clearance rate in healthy normoglycaemic subjects.  Firstly, the present results 
indicate that insulin acutely suppressed VLDL1-TG and -apoB production rates by 
25% and 21%, respectively.  However, as there was no significant difference in the 
size of the VLDL1 particle being produced (i.e. TG/apoB ratio), this suggests equal 
suppression of VLDL1-TG and -apoB production.  This is consistent with the recent 
findings of Adiels et al. (Adiels et al., 2007), who showed that insulin acutely 
induced a 60% suppression in both VLDL1-TG and VLDL1-apoB production rates in 
normal, non-diabetic subjects.  The work of Adiels et al. was concomitant with the 
present study and, to-date, these are the only two studies that specifically 
investigated the effect of hyperinsulinaemia on VLDL1-TG and VLDL1-apoB 
production rates.  
The suppression in VLDL1 production in response to insulin in the present study (at 
21-25%) was less than the 50-60% reduction reported in VLDL1-TG (Adiels et al., 
2007) and VLDL1-apoB (Malmstrom et al., 1997b; Malmstrom et al., 1998) 
production rates.  This could be due to the time of exposure to acute 
hyperinsulinaemia: in these studies, exogenous insulin was administered for 5-8.5 h, 
whereas in the present study, VLDL1 production rates were determined during the 
first 135 min of exposure to hyperinsulinaemia.  This is supported by Malmstrom et 
al. (Malmstrom et al., 1997b), who reported a significant detectable reduction in 
VLDL1-apoB synthesis after 0.5 h of insulin infusion at an average of ~9% per h 
(range 0% – 24%).   
Hepatic assembly of VLDL is a complex process (see section 1.3.2).  Briefly, it starts 
in the rough ER with the co-translational lipidation of apoB-100 forming a ‘lipid 
pocket’ and the subsequent interaction with MTP, which catalyses the transfer of TG 
to the continually synthesised apoB-100 and allowing apoB to fold on a core of 
neutral lipids.  This gives rise to a partially lipidated primordial particle (pre-VLDL), 
which is retained in the cell by interaction with chaperones and other ER proteins 
until it is further lipidated to form VLDL2 or sorted to degradation.  If apoB fails to 
be lipidated and misfolds, it is unfolded, retracted to the cytosol, ubiquinated, and 
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sorted to proteasomal degradation (Adiels et al., 2006a).  VLDL2 is converted to 
VLDL1 in the Golgi apparatus by the uptake of a defined lipid load from a fairly 
rapidly mobilised cytosolic TG pool (Gibbons et al., 2000).  Insulin controls a 
number of enzymatic steps in the assembly and secretion of VLDL by the hepatocyte 
(Gibbons  et al., 2002; Sparks & Sparks, 1994).  It downregulates MTP gene 
expression (Lin et al., 1995), enhances apoB degradation (Sparks & Sparks, 1990), 
inhibits the secretion of newly synthesised apoB as well as inhibiting VLDL 
maturation by suppressing transfer of cystosolic TG to pre-VLDL particles (Brown 
& Gibbons, 2001).  This is likely to explain the reduction in VLDL1-TG and - apoB 
production rates observed in the present study.  In addition, insulin decreases NEFA 
flux to the liver, likely due to inhibition of hormone-sensitive lipase (Lewis et al., 
1993) and adipose tissue triglyceride lipase (Kershaw et al., 2006).  This 
consequently decreases substrate availability for VLDL assembly (Coppack et al., 
1994), as the influx of NEFA from adipose tissue to the liver normally accounts for 
60-80% of hepatic TG (Donnelly et al., 2005).  Indeed, in this study, a rapid decrease 
in plasma NEFA concentrations occurred in the first hour, shortly after induction of 
hyperinsulinaemia in response to glucose ingestion, which correlated significantly 
and positively with the suppression in VLDL1-TG and -apoB production in response 
to insulin: subjects who had the biggest reduction in NEFA concentrations, had the 
biggest suppression in VLDL1-TG and -apoB production.  It should be noted that 
although NEFA concentrations were significantly lower throughout the Glucose trial 
compared to the Control trial in response to insulin, NEFA concentrations increased 
during Intralipid infusion in both trials due to the ‘spill-over’ from Intralipid 
produced by LPL-mediated TG hydrolysis taking place directly into the circulation 
(Evans et al., 1999).  Therefore, NEFA concentrations during the infusion were not 
included in the correlations with changes in VLDL1 production rates as they do not 
reflect the ‘true’ insulin-mediated suppression of NEFA.  
Secondly, in the present study, hyperinsulinaemia did not significantly influence 
Intralipid-TG clearance rate.  This is in contrast to the findings of Preiss-Landl et al. 
who reported that insulin upregulates LPL activity in adipose tissue (Preiss-Landl et 
al., 2002).  One likely explanation could be due to the heterogeneity of subjects’ 
insulin resistance in the present study as there was a significant correlation between 
HOMAIR and the change in Intralipid-TG clearance rate.  While glucose ingestion 
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caused an upregulation in clearance in the more insulin sensitive subjects, it induced 
a paradoxical downregulation of TG clearance in the more insulin resistant 
individuals.  Indeed, it was previously reported that the more resistant an individual 
is to insulin-mediated glucose uptake, the lower will be the plasma post-heparin LPL 
activity and adipose tissue LPL mRNA levels (Maheux et al., 1997). 
Finally, the author investigated whether serum ALT concentrations, a marker for 
liver function and hepatic fat accumulation (Westerbacka et al., 2004), would also 
predict the change in VLDL1 production in response to hyperinsulinaemia.  The 
present results demonstrate that serum ALT is a strong predictor of the suppression 
in VLDL1-TG and -apoB production, accounting for 69% and 55% of the variance in 
the change in production rates, respectively.  This finding was recently supported by 
Adiels et al. (Adiels et al., 2007) who showed that individuals with high liver fat 
failed to suppress VLDL1 production in response to insulin.  Whether this reduced 
suppression of VLDL1 production by insulin is a result of liver fat, a consequence of 
hepatic insulin resistance or both remains to be uncertain (Adiels et al., 2007).   
Similarly, it is unclear, in the present study, whether ALT (i.e. liver function) per se 
is the mediator of the change in VLDL1 production or whether ALT is just a marker 
for liver fat.  
In summary, this study demonstrated that, in normoglycaemic apparently healthy 
individuals, (1) insulin suppressed VLDL1-TG and -apoB production; and (2) the 
more insulin sensitive the subject is, the bigger the increase in Intralipid-TG 
clearance rates due to hyperinsulinaemia and hyperglycaemia.  In addition, ALT 
concentration – a marker of liver function and associated with liver fat content – 
strongly predicted individuals’ ability to suppress VLDL1-TG and -apoB in response 
to hyperinsulinaemia.  Not only do these findings help the basic scientific 
understanding of the effect of insulin on VLDL1 production, they may also help 
identifying individuals at higher risk of developing atherogenic dyslipidaemia which 
is believed to be initiated by insulin resistance, liver fat and hepatic overproduction 
of VLDL1 particles.  
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5.  Effects of Moderate Exercise on VLDL1 
Kinetics in Overweight/Obese Middle-Aged 
Men 
5.1  Introduction 
CVD is the main cause of death in the UK, with CHD, being the most common form, 
accounting for about 101,000 deaths each year (Allender et al., 2007).  Elevated 
plasma concentrations of TG are considered an independent risk factor for CHD 
(Cullen, 2000).  High concentrations of large very low density lipoprotein (VLDL1, 
Sf 60-400) are the major determinant of plasma TG levels (Tan et al., 1995; Hiukka 
et al., 2005) and believed to initiate a chain of reactions that generate the atherogenic 
lipoprotein phenotype associated with insulin resistance conditions (e.g. obesity, type 
2 diabetes and the metabolic syndrome) (Bloomgarden, 2007; Taskinen, 2003; 
Ginsberg et al., 2005).  Thus, reducing VLDL1 concentration is likely to induce 
clinically important changes to the atherosclerotic risk profile.  
While patient groups often undergo pharmacological treatments for these lipoprotein 
disorders, obesity and insulin resistance are growing problems in the population: 
over half of UK adults are overweight (BMI > 25 kg.m
-2) and over 20% are obese 
(BMI > 30 kg.m
-2) (Allender et al., 2006) and estimated prevalence of the metabolic 
syndrome in Scottish middle-aged men is ~25% (Sattar et al., 2003).  Therefore, it is 
unfeasible and probably undesirable to subject large sections of the population to 
long-term pharmacological therapies.  Moderate exercise is one potential non-
pharmacological therapy for elevated VLDL1 concentrations.  There is clear evidence 
that exercise of this nature can lower fasting and postprandial TG concentrations by 
20-25%, mostly in the VLDL1 fraction (Gill et al., 2006), in population groups at 
increased risk of cardiovascular disease, such as centrally obese middle-aged men 
(Gill et al., 2004b) and postmenopausal women (Gill & Hardman, 2000).  This effect 
is seen following a single exercise session, so is not mediated by weight loss (Gill et 
al., 2004b; Gill & Hardman, 2000; Gill et al., 2006).  However the mechanism(s) 
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responsible for this TG-reduction are unclear and require further elucidation as it 
could reflect reduced hepatic VLDL1 production and/or increased LPL-mediated 
VLDL1 clearance. Interestingly, a prior session of moderate exercise induces a larger 
TG-reduction in the VLDL1 fraction than the chylomicrons fraction (Gill et al., 
2001a; Gill et al., 2006).  Because chylomicrons are preferred substrates to LPL 
above VLDL1 (Karpe et al., 1993a; Fisher et al., 1995), this reduction in VLDL1 was 
hypothesised to be the result of an exercise-induced suppression of hepatic VLDL1 
production rather than increased clearance.  However, two recent stable-isotope 
kinetic studies have demonstrated that, in a group of lean recreationally active young 
men, a single session of a 90-120 min of moderate intensity exercise (at 60% of V
.
O2max) resulted in an increased clearance of total VLDL-TG (Magkos et al., 2006; 
Tsekouras et al., 2007) and a significant decrease in hepatic VLDL-apoB production 
(Magkos et al., 2006) with no significant change in hepatic VLDL-TG production 
(Magkos et al., 2006; Tsekouras et al., 2007).  However, studies investigating the 
effects of moderate exercise on large VLDL1 kinetics, especially in overweight/obese 
middle-aged men, a typical population at which exercise-for-health guidelines are 
targeted, are lacking.  This is important as moderate exercise may have a 
considerable potential to be used as a first-line therapeutic option for preventing and 
treating the primary defect in obesity/insulin resistance-related dyslipidaemia. 
Kinetics of VLDL are usually determined using stable-, or radio-, isotopic tracer 
methods, but these techniques are expensive and time-consuming which limits the 
scope of studies to which these methods can be applied.  Earlier in this thesis 
(Chapter 3) the development of a relatively easy method to determine VLDL1-TG 
and -apoB production and clearance rates, as well as Intralipid-TG clearance rate (as 
a surrogate measure of chylomicron-TG clearance) was described (Al-Shayji et al., 
2007), which is used in the present study to elucidate the mechanisms by which 
moderate exercise induces TG lowering. 
The aim of the present study was to investigate the effects of a 120-min session of 
prior moderate exercise on VLDL1-TG and -apoB kinetics and Intralipid-TG 
clearance rate in a group of overweight/obese middle-aged adults using the Intralipid 
method. 
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5.2 
5.2.1 
Materials and Methods 
Subjects  
Twelve overweight/obese, middle-aged men participated in this study; their 
characteristics are shown in Table 5.1.  All subjects were apparently healthy, 
normotensive, normoglycaemic, non-smokers who displayed no symptoms of 
coronary heart disease during a clinical exercise stress test (section 2.5).  None was 
taking any drugs known to affect lipid or carbohydrate metabolism.  The subject 
information sheet, consent form and health questionnaire are shown in Appendices 
A2 & B2.  One subject had E3/2 apoE phenotype, 4 had E3/3 phenotype, 5 had E4/3 
phenotype and 2 had E4/4 phenotype.  The study was conducted with the approval of 
North Glasgow University Hospitals NHS Trust Ethics Committee and subjects gave 
written informed consent prior to participation. 
Table   5.1: Characteristics of the participants (n=12). 
  Mean ± SD 
Age (years)  44 ± 8.4 
Body Mass (kg)  95.0 ± 17.1 
Body mass index (kg.m
-2)  31.3 ± 5.1 
Waist circumference (cm)  106.9  ± 13.2 
Waist/hip ratio  0.98  ± 0.05 
Maximal oxygen uptake (ml.kg
-1.min
-1)  37.9 ± 7.2 
ALT (U.l
-1)  39  ± 10 
 
5.2.2  Study Design 
Each subject underwent two Intralipid infusions (see below) within an interval of 2 
weeks. Preconditions (i.e. control and exercise) were different and administered in 
random order.  On the afternoon prior to one Intralipid infusion subjects walked 120 
min on a treadmill at an intensity of ~50% V
.
O2max (Exercise trial).  In the other trial, 
subjects performed no exercise on the day preceding the other Intralipid infusion 
(Control trial).  They were asked to weigh and record their dietary intake for two 
days prior to their first Intralipid infusion and replicate this prior to the second test 
and were instructed to refrain from alcohol consumption on those two days.  No 
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exercise other than the treadmill walk in the Exercise trial was performed during the 
three days prior to each Intralipid infusion.  
5.2.3  Treadmill Walk  
A preliminary submaximal incremental treadmill test was performed as previously 
described in section 2.6 at least 1 week prior to the first Intralipid test to estimate     
V
.
O2max and determine the speed and gradient required to elicit 50% V
.
O2max.  The 
120-min walk in the Exercise trial was completed ~16-18 h prior to the Intralipid 
test.  Heart rate, O2 uptake and CO2 production were measured as previously 
described in section 2.8.  Ratings of perceived exertion (Borg, 1973) were obtained 
at 15-min intervals during the walk.  
5.2.4  Intralipid Infusion 
VLDL1 kinetics were determined using the 'Intralipid Method' as previously 
described in Chapter 3 (Al-Shayji et al., 2007) with a slight modification in the 
frequency of blood sampling during infusion.  Briefly, subjects reported to the 
Clinical Investigation Suite in the Department of Vascular Biochemistry at Glasgow 
Royal Infirmary in the morning after an overnight fast of 12 h and they were given a 
bolus dose of 0.1 g.kg
-1 of 20% Intralipid followed immediately by an intravenous 
infusion of 0.1 g.kg
-1.h
-1 of 10% Intralipid for 75 min.  Multiple EDTA blood 
samples were drawn at baseline, before and at 10-min intervals during infusion as 
well as at 2.5, 5, 10, 15, 20, 30, 40 and 60 min post-infusion.  The post-infusion 
period was reduced from 75 to 60 min when it became clear that 60 min was 
sufficient to calculate the Intralipid-TG clearance rate.  
5.2.5  Analytical Methods 
Plasma glucose, insulin, total and HDL cholesterol and apos C-II, C-III and E 
concentrations were analysed in the fasted state.  TG and NEFA concentrations were 
analysed in all time points. LDL cholesterol was calculated using the Friedewald 
equation (Friedewald et al., 1972).  Serum ALT concentrations were measured at 
screening.  ApoE phenotype was determined for each subject by isoelectric focusing 
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using Western blot techniques.  All analytical methods were performed as previously 
described in sections 2.4.2 to 2.4.4. 
Intralipid (Sf >400) was separated from whole plasma as previously described in 
section 3.2.4 with a minor modification.  In the present subjects (typical candidates 
for hyperlipidaemia), it was found that the Intralipid fraction was technically easier 
to separate at 23
o C instead of 4
o C.  The VLDL1 (Sf 60-400) fraction was separated 
as previously described in section 2.4.1.  TG concentrations were measured in the 
Intralipid and VLDL1 fractions in all time points and were corrected for glycerol as 
described in section 3.2.7 (Al-Shayji et al., 2007). 
The composition of the VLDL1 fraction (i.e. TG, cholesterol, FC and PL) was 
measured as described in section 2.4.2.  Total protein content was measured 
manually using a modified Lowry assay (section 2.4.5).  CE concentration was 
determined by multiplying the difference between total cholesterol and free 
cholesterol concentrations (in mg.dl
-1) by 1.68 to account for the difference in mass 
between cholesterol and CE. VLDL1 concentration was calculated by summing the 
concentrations of these components in mg.dl
-1 (i.e. TG, FC, CE, PL and protein).  
ApoB concentrations were measured directly in the VLDL1 fraction by automated 
immunoturbidimetry (see section 2.9.2.3).   In four subjects, where VLDL1-apoB 
was not detectable by the immunoturbidimetry method, apoB concentrations were 
measured manually, as described in section 2.9.2.2 by precipitation with Isopropanol 
and subsequent protein measurement by Lowry method (section 2.4.5). 
5.2.6  Calculations and Statistics 
VLDL1-TG and -apoB production rates and FCRs, as well as Intralipid-TG clearance 
rates were determined as previously described in Chapter 3 (Al-Shayji et al., 2007).  
Net energy expenditure during the 120-min walk was calculated using indirect 
calorimetry assuming no protein oxidation (Frayn, 1983).  HOMA was used as a 
validated surrogate measure of insulin resistance (IR) (Matthews et al., 1985).  
The number of apoC-II, apoC-III and apoE molecules per VLDL1 particle were 
calculated, in the fasted state, by dividing the apolipoprotein concentrations in 
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mmol.l
-1 by the apoB concentration in mmol.l
-1.  In addition, VLDL1 TG/apoB ratio 
(mol:mol), representing the size of the particle in the circulation; CE/TG ratio 
(mol:mol), representing the composition of its core; CE/apoB ratio (mol:mol), 
representing the CE content per VLDL1 particle; and FC/PL ratio (mg:mg), 
representing the composition of its surface layer, were also calculated in the fasted 
state.  
Statistical analyses were performed using MINITAB for Windows (Version 14.0, 
MINITAB Inc., State College, PA) and STATISTICA (Release 6.0, StatSoft, Inc, 
USA).  Normality was checked for all the data using the Anderson-Darling test.  
When data did not approximate a normal distribution, these were log-transformed, 
namely insulin, HOMAIR, VLDL1-apoB fasting concentrations, TG/apoB ratios, 
FC/PL ratio,  Intralipid-TG clearance rate, VLDL1-apoB FCR and production rate, 
VLDL1-TG production rate, and the exercise-induced change in VLDL1-apoB FCR 
and production rate required transformation.  Comparisons of fasting values, 
summary responses and kinetic data between Control and Exercise trials were made 
using paired t-tests and changes over the trial period were assessed by two-way 
ANOVA (trial × time) with repeated measures on both factors.  Post hoc Fisher LSD 
tests were used to indentify exactly where any differences lay.  Significance was 
accepted at the P <0.05 level.  Data are presented as mean ± SEM unless otherwise 
stated. 
To determine factors which predicted the change in VLDL1-TG and -apoB 
production and clearance rates as well as Intralipid-TG clearance rates between 
Control and Exercise trials, Pearson product-moment correlations were performed 
between the exercise-induced changes in kinetic variables on one hand and ALT, the 
exercise-induced changes in glucose, insulin, HOMAIR and NEFA on the other hand.  
5.2.7  Power Calculations 
The pilot data from 5 subjects who underwent two Intralipid infusions at the 0.1g.kg
-
1.h
-1 Intralipid and 0.2 g.kg
-1.h
-1 Intralipid doses (described in Chapter 3), indicate 
that the standard deviation for the within-subject variability in VLDL1-apoB and 
VLDL1-TG production are 12.7% and 20.1%, respectively, when preceding diet, 
exercise and alcohol intake are well-controlled.  Based on these data, 12 subjects 
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would enable detection of an 11% difference in VLDL1-apoB production and an 18% 
difference in VLDL1-TG production, with 80% power at the 0.05 level.  Groups of 8-
12 subjects clearly show significant effects of a single moderate exercise session on 
postprandial TG metabolism where a 20-25% reduction in plasma TG concentration 
is typically observed (Gill & Hardman, 2003).  
5.3 
5.3.1 
5.3.2 
Results 
Treadmill Walk 
Subjects walked at a speed of 4.5 ± 0.2 km.h
-1 up a gradient of 6.0 ± 0.6%.  All 
subjects completed the 120-min walk without difficulty, with an average perceived 
exertion of 12.2 ± 0.4 (between ‘fairly light’ and ‘somewhat hard’) on the Borg scale 
of 6-20 (Borg, 1973).  Mean V
.
O2 was 18.6 ± 0.8 ml.kg
-1.min
-1 (49.2 ± 0.7% V
.
O2max), 
mean heart rate was 123 ± 3 beat.min
-1 and net energy expenditure for the walk was 
3.5 ± 0.1 MJ (837 ± 35 kcal). 
Fasting Concentrations in the Control and Exercise Trials 
Mean plasma and VLDL1 composition and concentrations in the fasted state are 
shown in Table 5.2.  In four subjects, VLDL1-apoB was not detectable directly using 
the immunoturbidimetry method in at least one trial, and, therefore, was measured 
manually for both the Control and Exercise trials.  In addition, fasting apoE 
concentrations were below limits of detection in 2 subjects in one or two trials, and, 
therefore, these two subjects were omitted from all apoE calculations.  Exercise 
significantly (P <0.05) reduced fasting plasma TG and glucose concentrations by 
21.9 ± 6.0% and 3.0 ± 1.0%, respectively, and increased NEFA by 23.8 ±  12.1%.  
There was a reduction of 12.6 ± 6.7% in insulin concentrations and of 14.8 ± 6.9% in 
HOMAIR post-exercise, but these did not reach statistical significance (P = 0.080 and 
0.059, respectively).  Fasting VLDL1 concentrations were significantly lower by 32.6 
± 9.7% after exercise (P = 0.006), as were fasting concentrations of VLDL1-TG (29.6 
± 9.3%), VLDL1-Cholesterol (43.7 ± 11.4%), VLDL1-apoB (38.2 ± 9.8%), VLDL1-
apoC-II (28.0 ± 10.7%), VLDL1-apoC-III (25.0 ± 12.1%) and VLDL1-apoE (27.6 ± 
11.4%, n = 10), all P <0.05.  There were no significant differences in fasting 
concentrations of total, HDL- and LDL-cholesterol (Table 5.2). 
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5.3.3 
5.3.4 
TRL Kinetics in Responses to Exercise  
Figure 5.1 shows the mean percentage changes in VLDL1-TG and -apoB kinetics 
and Intralipid-TG clearance rate and Figure 5.2 shows the absolute mean and 
individual production and clearance rates in response to exercise according to apoE 
phenotypes.  There was a significant increase after exercise in Intralipid-TG 
clearance rate (Control: 47.6 ± 6.8, Exercise: 68.1 ± 9.7 pools.d
-1,  P  <0.001), 
VLDL1-TG FCR (Control: 16.0 ± 2.1, Exercise: 29.1 ± 4.4 pools.d
-1, P = 0.002) and 
VLDL1-apoB FCR (Control: 10.4 ± 2.0, Exercise: 25.6 ± 5.1 pools.d
-1, P = 0.015).  
However, there was no significant difference between the Control and Exercise trials 
in the production rates of VLDL1-TG (Control: 1271.5 ± 155.7, Exercise: 1431.7 ± 
148.3 mg.h
-1, P = 0.104) and VLDL1-apoB (Control: 37.2 ± 7.4, Exercise: 41.5 ± 5.4 
mg.h
-1, P = 0.335).  
VLDL1 Compositional Responses to Exercise 
Table 5.3 shows the exercise-induced compositional changes in VLDL1 in the fasted 
state – reflecting the composition of circulating VLDL1 particles.  There was a 
tendency for a bigger VLDL1 particle (TG/apoB ratio) in the circulation in the 
Exercise trial (Control: 15392 ± 2178, Exercise: 19449 ± 3150).  However, this did 
not reach statistical significance (P = 0.059).  On the other hand, the CE/TG ratio, 
reflecting the neutral lipid composition of the VLDL1 core, was significantly lower in 
the Exercise trial (Control: 0.17 ± 0.02, Exercise: 0.12 ± 0.02, P = 0.007). 
Consequently, the CE/apoB ratio, reflecting CE content per VLDL1 particle, was not 
significantly different between both trials (Control: 2487 ± 353, Exercise: 2276 ± 
564, P = 0.537).  PL was not detectable for one subject and, consequently, the FC/PL 
ratio in both trials for this subject were not included.  There was no significant 
difference in the FC/PL ratio, which reflects the composition of the VLDL1 surface 
layer, between the Control (0.32 ± 0.01) and Exercise (0.32 ± 0.02) trials (P = 0.606, 
n = 11).  
Moreover, there was no significant difference in the fasting ratios of apoC-II/apoB 
(Control: 32.6 ± 5.0, Exercise: 42.8 ± 8.6, P = 0.23), apoC-III/apoB (Control: 64.1 ± 
7.9, Exercise: 83.8 ± 13.9, P = 0.10) or apoE/apoB (Control: 0.83 ± 0.20, Exercise: 
1.12 ± 0.33, P = 0.409, n = 10).  
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Table   5.2: Plasma and VLDL1 concentrations in the fasted state 
 Control  Exercise  P-Value 
Plasma TG (mmol.l
-1)  1.54 ± 0.16  1.21 ± 0.15  0.004 
Total Cholesterol (mmol.l
-1)  5.17 ± 0.25  5.14 ± 0.24  0.843 
HDL Cholesterol (mmol.l
-1)  1.05 ± 0.06  1.08 ± 0.07  0.233 
LDL Cholesterol (mmol.l
-1)  3.38 ± 0.31  3.48 ± 0.29  0.409 
Glucose (mmol.l
-1)  5.76 ± 0.09  5.58 ± 0.09  0.010 
Insulin (mU.l
-1)  6.99 ± 1.30  6.29 ± 1.46  0.080 
HOMAIR  1.81 ± 0.35  1.58 ± 0.37  0.059 
NEFA (mmol.l
-1)  0.55 ± 0.04  0.64 ± 0.03  0.026 
VLDL1 concentration (mg.dl
-1)  94.9 ± 14.1  62.9 ± 11.4  0.006 
VLDL1-TG (mmol.l
-1)  0.67 ± 0.10  0.46 ± 0.08  0.007 
VLDL1-C (mmol.l
-1)  0.47 ± 0.07  0.28 ± 0.06  0.006 
VLDL1-apo B (mg.dl
-1)  2.77 ± 0.44  1.55 ± 0.30  0.004 
VLDL1-apo CII (mg.dl
-1)  1.22 ± 0.18  0.88 ± 0.16  0.017 
VLDL1-apo CIII (mg.dl
-1)  2.52 ± 0.40  1.84 ± 0.37  0.031 
VLDL1-apo E (mg.dl
-1)*  0.16 ± 0.06  0.11 ± 0.05  0.049 
* n = 10. All values are mean ± SEM. P values are for the difference between the Control and 
Exercise trials 
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Figure   5.1: The mean percentage change in VLDL1-TG and VLDL1-apoB production rates (PR) 
and fractional catabolic rates (FCR) and Intralipid (IL)-TG clearance rate (CR) in response to a 
single session of 120-min brisk walking at ~50% VO2max. (* P <0.05, ** P <0.001). 
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Figure   5.2: Individual (according to apoE phenotype) and mean (bars) VLDL1-TG and VLDL1-
apoB production rates (top panel) and fractional catabolic rates (FCR, middle panel) and 
Intralipid-TG clearance rate (bottom) in response to a single session of 120-min brisk walking at 
~50% VO2max (* P <0.05, ** P <0.001 for the difference in mean response between the Control 
and Exercise trials). 
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Table   5.3: Exercise-induced compositional changes to circulating VLDL1 particles 
 Control  Exercise  P-Value 
TG/apoB ratio (mol:mol)  15392 ± 2178  19449 ± 3150  0.059 
CE/TG ratio (mol:mol)  0.17 ± 0.02  0.12 ± 0.02  0.007 
CE/apoB ratio (mol:mol)  2487 ± 353  2276 ± 564  0.537 
FC/PL ratio (mg:mg)*  0.32 ± 0.01  0.32 ± 0.02  0.606 
* n = 11. All values are mean ± SEM.  
 
5.3.5  Predictors of the Exercise-Induced Changes in TRL Kinetics 
There was a significant correlation (r = 0.61, P = 0.035) between the exercise-
induced change in Intralipid-TG clearance rate and the exercise-induced change in 
VLDL1-TG FCR (Figure 5.3A), which suggests that a single mechanism (likely 
LPL- mediated clearance) was likely to be responsible for both effects. 
Although there was no statistically significant effect of exercise on fasting insulin 
concentrations and HOMAIR, a significant inverse relationship was found between 
the exercise-induced change in VLDL1-apoB FCR and the exercise-induced change 
in insulin concentrations (r = -0.65, P = 0.022), the exercise-induced change in 
glucose (r = -0.58, P = 0.049), and, consequently, with the exercise-induced change 
in HOMAIR (r = -0.68, P = 0.016, Figure 5.3B).  This shows that those who had the 
biggest reduction in HOMAIR had the biggest increase in VLDL1-apoB FCR. 
No significant correlations were found between ALT or the exercise-induced change 
in NEFA and any of the exercise-induced changes in VLDL1-TG and -apoB FCR or 
production rates or Intralipid-TG clearance rate (all P > 0.05).  In addition, there was 
no significant effect of apoE phenotype on the response of the above kinetics to 
moderate exercise.  
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Figure   5.3: Scattergrams indicating the relationships between the exercise-induced changes 
(Exercise minus Control) in [A] Intralipid-TG and VLDL1-TG FCR (pools.d
-1) and [B] VLDL1-
apoB FCR (pools.d
-1) and HOMAIR. 
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5.4  Discussion 
To the best of the author’s knowledge, this is the first study to investigate the 
possible mechanism(s) underlying the hypotriglyceridaemic effect of a prior session 
of moderate exercise (120-min brisk walk at ~50% V
.
O2max) in overweight/obese 
middle-aged men, a group typically targeted in exercise-for-health guidelines. 
The results of the present study confirm and expand on earlier observations that a 
prior session of moderate exercise induces a significant reduction in plasma TG and 
influences VLDL1 to a greater extent than chylomicrons (Gill et al., 2006).  Indeed, 
in the present study, the change in VLDL1-TG clearance was greater than the change 
in Intralipid change (91.0% vs. 43.3%, respectively).  Because chylomicrons are 
preferred substrates for LPL (Fisher et al., 1995) and, therefore, compete with 
VLDL1 particles for a LPL-mediated clearance (Karpe et al., 1993b), it was 
hypothesised earlier that the exercise-induced TG reduction was likely to be the 
result of a reduced hepatic VLDL1 production rather than increased clearance 
(Malkova & Gill, 2006).  However, this does not seem to be the case. The present 
results demonstrate that this exercise-induced reduction in TG is due to a significant 
91% increase in VLDL1-TG FCR (i.e. clearance), with no significant effect on 
VLDL1-TG production rate. This is consistent with two recent stable-isotope studies 
by Magkos et al. (Magkos et al., 2006) and Tsekouras et al. (Tsekouras et al., 2007) 
who reported an increased total VLDL-TG clearance, rather than decreased VLDL-
TG production following a session of 120-min cycling and 90-min walking (at 60% 
V
.
O2max), respectively. 
The novelty of this study, however, is that it allowed the simultaneous measurements 
of VLDL1-TG FCR and Intralipid-TG clearance rate in response to a prior session of 
moderate exercise.  This is important in providing a better understanding of the 
major possible mechanism(s) involved in the exercise-induced hypotriglyceridaemia 
as it was difficult to measure the clearance of VLDL1-TG in the presence of 
chylomicrons/Intralipid because of their competition for the same catabolic pathway 
(Bjorkegren et al., 1996; Karpe & Hultin, 1995).  Importantly, the present results 
show a significant correlation (r = 0.61, P = 0.035) between the exercise-induced 
©Iqbal A.R. AlShayji (2008)  1255. Effects of Moderate Exercise on VLDL1 Kinetics 
changes in Intralipid-TG and in VLDL1-TG indicating that exercise is upregulating 
their clearance by the same mechanism/pathway (i.e. LPL).  However, it is unclear 
why VLDL1 appears to develop a higher affinity following exercise for clearance by 
LPL relative to Intralipid, but this could be due to the compositional changes in the 
VLDL1 particle post-exercise: the particles in the circulation tended to be ~26% 
bigger following exercise and more TG-enriched, which may render them more 
favourable substrates for LPL-mediated lipolysis (Fisher et al., 1995).  There are two 
possible explanations as to why this might be the case.  Firstly, the liver might be 
producing a bigger, more TG-enriched VLDL1 particle following exercise. 
Consistant with this, circulating NEFA concentrations were 16% higher in the 
exercise trial than the Control trial, increasing fatty acid availability to the liver, 
which could lead to larger secreted VLDL1 particle.  Secondly, under normal 
conditions, once in the circulation, the TG content of the newly secreted VLDL1 
particle, and consequently its size, are being reduced rapidly by hydrolysis by LPL 
(Karpe et al., 2007) and the action of CETP, which promotes the transfer of TG from 
apoB-containing particles (VLDL and LDL) in exchange for CE from HDL (Barter, 
2002).  The present results show a significant ~29% reduction in VLDL1 CE/TG 
ratio in the Exercise trial, which is supported by a similar 18% post-exercise 
reduction in CE/TG ratio reported by Gill et al (Gill et al., 2006).  This may be 
suggestive of a reduced in vivo CETP activity following moderate exercise, 
rendering the VLDL1 particle more TG-enriched.  However, this explanation is less 
likely to occur as the CE/apoB ratio, representing the CE content per VLDL1 particle, 
in the present study was not significantly different between the two trials (Control: 
2487 ± 353, Exercise: 2276 ± 564, P = 0.537).  Unfortunately, conclusive results 
about the effect of moderate exercise on CETP activity or mass are currently lacking 
in the literature. While some studies found an increase in CETP mass following 
exercise (Thomas et al., 2001), others reported an exercise-induced decrease in 
CETP mass (Magkos et al., 2006).  Two other studies found no significant difference 
in CETP activity post-moderate exercise (Thomas et al., 2004) even after 24 h 
(Zhang et al., 2002).   
Furthermore, although there was no significant difference in the number of apos C-II, 
C-III and E per VLDL1 between the Exercise and Control trials in this study, a 
reduced apoC-III and apoE enrichment of VLDL1 was reported in a similar group of 
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participants following moderate exercise (Gill et al., 2006).  These apolipoproteins 
are acquired by VLDL from circulating HDL and apoC-III (Wang et al., 1985) and 
apo E (Jong et al., 1997) both act to inhibit lipolysis by LPL.  This could conceivably 
have increased the potential of post-exercise VLDL1 particle as an LPL substrate.  It 
is unclear why the present findings differ from the earlier report. 
The present results also show a significant 43% increase in Intralipid-TG clearance 
rate post-exercise, which is likely to reflect increased LPL activity and/or mass.   
Although early studies of prolonged and vigorous exercise, such as marathon 
running, clearly demonstrated that this type of exercise increased LPL-mediated TG-
clearance (Sady et al., 1986), recent studies of a more moderate exercise are 
conflicting. While some studies show no significant difference in muscle (Herd et al., 
2001) or post-heparin plasma LPL activity (reflecting overall LPL activity from all 
body tissues) ~16h after a moderate session of exercise (Gill et al., 2003), others 
reported a significant increase in plasma (Zhang et al., 2002), muscle and adipose 
tissue LPL activity post-exercise (Perreault et al., 2004).  In addition, although 
Magkos et al. (Magkos et al., 2006) found no significant difference in muscle LPL 
mass, the group reported a significant ~20% increase in plasma LPL concentrations 
in response to acute moderate exercise.  It should be noted, though, that even in the 
absence of a significant increase in post-heparin LPL activity, the exercise-induced 
changes in LPL activity was reported to correlate significantly with the exercise-
induced changes in fasting and postprandial TG (Gill et al., 2003).  Furthermore, if 
exercise increased the affinity of VLDL1 for clearance, this could have occurred 
without an increase in measured LPL action using a standard substrate.  This further 
highlights the importance of LPL as a mediator of the TG-lowering effect of 
moderate exercise. 
In addition to increased VLDL1-TG FCR, exercise significantly increased VLDL1-
apoB FCR by 211% with no significant influence on VLDL1-apoB production rate.  
This is in contrast with Magkos et al. (Magkos et al., 2006) who reported a 
significant reduction in total VLDL-apoB production rate with no significant change 
in VLDL-apoB clearance.  A likely explanation for these different findings could be 
due to the different characteristics of participants.  Unlike the normal weight subjects 
who participated in Magkos et al. study (Magkos et al., 2006), the participants in the 
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present study were overweight/obese men with increased abdominal obesity, which 
makes them likely candidates for insulin resistance and high liver fat content  (Karpe 
& Tan, 2005; Haffner, 2007; Després, 2007; Adiels et al., 2006b).  Similar group of 
subjects with increased liver fat failed to suppress VLDL1 production in response to 
insulin (Adiels et al., 2007).  Indeed, the participants in the present study had higher 
insulin concentrations compared with the study subjects of Magkos et al. (Magkos et 
al., 2006) (7.0 vs. 5.4 mU.l
-1, respectively) and no significant reductions in insulin or 
HOMAIR concentrations were observed following exercise in the present study.   
Interestingly, however, there was a significant correlation in the present study 
between the exercise-induced change in HOMAIR and the exercise-induced change in 
VLDL1-apoB FCR, indicating that subjects who had a bigger decrease in HOMAIR 
following exercise had a bigger increase in VLDL1-apoB FCR (clearance).  These 
exercise-induced changes in insulin sensitivity may augment changes in VLDL1-
apoB clearance, but this relationship was not observed for VLDL1-TG.  
In summary, a single session of moderate intensity exercise significantly reduced 
fasting plasma TG, mainly in the VLDL1 fraction, by increasing the VLDL1-TG and 
VLDL1-apoB FCR (i.e. clearance).  The increase in VLDL1 was greater than the 
increase in Intralipid clearance, suggesting that exercise may have increased the 
affinity of VLDL1 for LPL-mediated lipolysis (Figure 5.4).  In contrast, exercise did 
not decrease hepatic VLDL1-TG or VLDL1-apoB production.  However, further 
studies are needed elucidate the mechanism(s) underlying this increased affinity for 
clearance of VLDL1, such as in vitro studies investigating the affinity of VLDL1 for 
LPL as well as the change in CETP activity both under control and exercise 
conditions.  This may help improve understanding of the nature of these exercise-
induced changes.  
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6.  General Discussion 
6.1  Summary 
There is a growing body of evidence implicating elevated VLDL concentrations, 
particularly the larger VLDL1 (Sf 60-200) particles, as the primary cause of the 
atherogenic lipoprotein phenotype in insulin resistance conditions; such as type 2 
diabetes (Taskinen, 2003), metabolic syndrome (Grundy, 2006), obesity (Aguilera et 
al., 2008) and, eventually, coronary heart disease (Abbasi et al., 2002; Tanaka et al., 
2001).  The fact that this atherogenic dyslipidaemia is detectable years before the 
onset of the disease (Tilly-Kiesi et al., 1996; Johanson et al., 2004) makes the 
measurement and regulation of hepatic VLDL1 production of great importance.   
However, mere measurements of VLDL1 concentrations provide limited information 
and do not reflect the dynamics of the continual synthesis and clearance of VLDL1 
particles. Radioactive and stable-isotope tracers have been successfully used to 
measure the kinetics of different lipoproteins, including VLDL1.  Although such 
methods yield a large amount of useful information, they are expensive, labour-
intensive, time consuming and require the use of specialised laboratories, equipment 
and skills in multicompartmental modelling.  Of note, these methods measure 
generally either total VLDL-TG and -apoB, or VLDL1- and VLDL2-apoB, but not 
VLDL1- or VLDL2-TG.  It is only recently that Adiels and colleagues (Adiels et al., 
2005a) have developed a multicompartmental stable-isotope method to determine 
both VLDL1- and VLDL2-TG and -apoB kinetics.  Thus, this thesis was designed to 
develop and validate a simpler and cost-effective method – the ‘Intralipid Method’ – 
to determine VLDL1 kinetics and use this method to study the effects of insulin and 
moderate exercise on the regulation of hepatic VLDL1 kinetics.  
The method builds on the work of Björkegren et al. (Bjorkegren et al., 1996) and 
relies on the fact that Intralipid (chylomicron-like particles) compete with VLDL1 for 
the same catalytic pathway (Bjorkegren et al., 1996; Karpe & Hultin, 1995), which 
allows the accumulation of VLDL1 in the circulation (Bjorkegren et al., 1996) during 
a constant Intralipid infusion.  By measuring the linear rise in VLDL1-TG and -apoB 
concentrations, it is possible to determine their production rates.  In addition, because 
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the method is employed in the fasted state in which there is a steady state where 
production equals clearance, it is also possible to determine the fractional catabolic 
rate (FCR, i.e. clearance) of VLDL1-TG and -apoB by dividing their linear rises 
during the Intralipid infusion by their fasting concentrations.  Furthermore, the 
Intralipid method combines the findings of Rössner (Rossner, 1974), who showed 
that Intralipid is cleared following first-order kinetics, which allows the 
determination of Intralipid-TG clearance rate as a surrogate measure of chylomicron-
TG clearance.  
In addition to the fact that the kinetic data obtained using the Intralipid method are 
similar to that obtained by the ‘gold standard’ stable-isotope method (Bjorkegren et 
al., 1996), this newly developed method has a number of strengths. First, it provides 
valuable information about TRL kinetics: both VLDL1-TG and VLDL1-apoB 
production rates and Intralipid-TG clearance rate. In addition, under steady state 
conditions, it allows the simultaneous determination of large VLDL1-TG (rather than 
total VLDL-TG) and Intralipid-TG clearance rates.  This is important for two 
reasons: (1) it is the high concentrations of large VLDL1 particles that are implicated 
in atherogenic dyslipidaemia and the progression of atherosclerosis (Taskinen, 2003; 
Packard, 2003) and, unlike VLDL2, VLDL1 are the target for insulin-induced hepatic 
suppression (Gill et al., 2004a); (2) due to the fact that Intralipid/chylomicrons and 
VLDL1 compete for the same LPL-mediated catalytic pathway, it has previously 
been difficult to determine the clearance rate of VLDL1 in the presence of Intralipid 
or chylomicrons.  As a result, the Intralipid method helped to elucidate the 
hypotryglyceridaemic effects of exercise on TRL kinetics (Chapter 5).  Second, the 
Intralipid method is sensitive enough to detect physiological changes in hepatic 
VLDL1 production and Intralipid-TG clearance, such as the effect of insulin on TRL 
kinetics (Chapter 4).  Third, the method is relatively easy and simple enough to be 
used in any laboratory equipped with only one ultracentrifuge without the need for 
any other specialised equipment (such as a mass spectrometer).  Fourth, estimation of 
production and clearance rates using the Intralipid method is relatively easy to carry 
out and can be automated using Excel.  Fifth, the protocol for the Intralipid method 
takes less time to complete than the stable-isotope method, which is beneficial both 
for the subject and the researcher.  While a standard stable-isotope method to 
measure VLDL1 kinetics requires ~48 h of the subject’s time, the Intralipid infusion 
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and post-infusion period of the present method lasts only for about 3.5 h.  In 
addition, unlike the time required (at least 2 weeks) for laboratory techniques and 
sample and kinetic analyses using the stable-isotope method, the Intralipid method 
protocol, including lipoprotein separation, sample analysis and kinetic calculations, 
takes approximately 2-3 days.  Sixth, the Intralipid method is cheaper than the stable-
isotope method and suitable for laboratories with limited funding or resources as 
each trial (including investigator/technician time at £20 per hour) costs 
approximately £750 and 2-3 days to complete compared to the ~£2500 and about two 
weeks using the stable-isotope method.  Finally, because the Intralipid method is safe 
as well as both time- and cost-effective, it can be used for a large number of subjects, 
with even multiple trials for each subject. 
As a first application, the Intralipid method was used to study the effect of 
hyperinsulinaemia and hyperglycaemia on VLDL1-TG and -apoB production rates in 
8 normoglycaemic subjects (Chapter 4).  This was done using a simple frequent oral 
administration of glucose to provide a pseudo-steady hyperinsulinaemic state as the 
use of a conventional hyperinsulinaemic normoglycaemic clamp was not possible 
due to lack of constant medical cover.  The result demonstrated that insulin acutely 
suppressed VLDL1-TG and -apoB production, a finding recently supported by Adiels 
et al. (Adiels et al., 2007).  Although hyperinsulinaemia had no apparent effect on 
Intralipid-TG clearance rate, the change seemed to be related to insulin sensitivity, 
i.e. the more insulin sensitive the subject was, the biggest the increase in Intralipid-
TG clearance rate.  One possible limitation of this study is the number of subjects, 
especially with such a wide range of insulin resistance, which may have diluted the 
effect of insulin on Intralipid-TG clearance rate.  However, the technique would 
make it very easy to increase the numbers in future studies. 
Because moderate exercise has been shown to decrease plasma TG by 20-25%, 
mostly in the VLDL1 fraction (Gill et al., 2006), the second application of the 
Intralipid method was to investigate whether this decrease is due to decreased hepatic 
VLDL1 production, increased clearance or a combination of both (Chapter 5).  The 
present results showed that a session of moderate exercise significantly increased the 
clearance of VLDL1-TG and -apoB rather than suppress their hepatic production.  
Although there is no information in the literature about the effect of exercise on 
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VLDL1 kinetics specifically, these results are consistent with recent findings using 
stable-isotopes which investigated the effect of moderate exercise on total VLDL-TG 
(Magkos et al., 2006; Tsekouras et al., 2007) and VLDL-apoB (Magkos et al., 2006) 
using the stable-isotope method.  In addition, because of the nature of the Intralipid 
method, it provided the opportunity to simultaneously study both Intralipid and 
VLDL1 clearance, which was previously unfeasible.  As a result, a novel finding is 
observed that this increased exercise-induced clearance of VLDL1 is likely to be the 
result of increased affinity of VLDL1 to LPL-mediated lipolysis.  Furthermore, this 
study is the first to investigate the kinetics of such effects of exercise in 
overweight/obese middle-aged men, a group typically targeted in exercise-for-health 
guidelines.  
Adequate liver function is important for VLDL1 homeostasis.  Serum ALT 
concentrations are used clinically as an indication of liver function and, within 
normal range, have been shown to be a marker for liver fat (Westerbacka et al., 
2004).  It was recently shown that hepatic overproduction of VLDL1 particles is 
driven by liver fat accumulation (Adiels et al., 2006b).  Results from this thesis show 
a significant relationship between serum ALT concentrations and hepatic VLDL1 
production and regulation.  Even within normal range, ALT concentrations 
correlated significantly with VLDL1 production (Chapter 3) and inversely with the 
extent to which VLDL1 is suppressed in response to hyperinsulinaemia and 
hyperglycaemia (Chapter 4): subjects who had higher ALT concentrations, produced 
more VLDL1 particles and failed to suppress VLDL1 secretion in response to insulin.  
It is unclear, however, whether this correlation with ALT concentrations reflects liver 
function per se or hepatic fat content, as ALT is a marker for both. 
In all studies described in this thesis, 3 subjects were E2/3 phenotype, 11 subjects 
were E3/3 phenotype, 6 subjects were E3/4 phenotype and 3 subjects were E4/4 
phenotype.  Previous studies showed that apoE phenotypes influence plasma lipids 
(Eto et al., 1986) and particularly large VLDL1 concentrations (Bioletto et al., 1998) 
as well as VLDL-apoB kinetics (Watts et al., 2000; Welty et al., 2000; Demant et al., 
1991).  However, no apparent effect of apoE phenotype on VLDL1-TG and -apoB 
production rates or Intralipid-TG clearance rate was observed in this thesis 
(Appendix C).  It is uncertain, however, whether this is a true lack of influence of 
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apoE on VLDL1-TG and -apoB production rates and Intralipid-TG clearance rate or 
whether it may be due to lack of sufficient numbers for each phenotype.  Fortunately, 
because of the relative ease and cost-effectiveness of the Intralipid method, a bigger 
study can be conducted which may have not been feasible otherwise using the stable-
isotope method. 
6.2  Limitations of the Intralipid Method 
There are two main limitations to the Intralipid method.  The first is that it only 
allows the determination of VLDL1 kinetics but not VLDL2.  This is because VLDL2 
is hydrolysed by HL; i.e. Intralipid does not compete with VLDL2 for LPL-mediated 
lipolysis and, consequently, VLDL2 will not accumulate in the circulation like 
VLDL1 particles.  Although VLDL1 and VLDL2 are regulated independently 
(Packard & Shepherd, 1997; Gill et al., 2004a), it has been recently reported that 
while insulin acutely reduced VLDL1 secretion, it increased VLDL2 secretion (Adiels 
et al., 2007).  Although this acute suppression of VLDL1 secretion by insulin was 
detected using the Intralipid method, it was not possible to investigate this effect on 
VLDL2.  Thus, the addition of VLDL2 kinetics might have helped to complete the 
picture of the effect of insulin on total VLDL hepatic regulation.  The second 
limitation of the Intralipid method is that the FCR can only be calculated if the 
subject is in a steady state.  For example, it was not possible to determine VLDL1-TG 
and VLDL1-apoB FCRs in Chapter 4 where VLDL1 production was investigated in 
response to hyperinsulinemia and hyperglycemia.  This is because the steady state 
value used for FCR calculation is made in the fasted state before the glucose 
ingestion, which does not represent the steady state value for VLDL1 concentration 
during glucose ingestion. 
Furthermore, the lack of direct comparison with either the stable-isotope or 
radioactive tracer methods within the same subjects represents a limitation to the 
validation of the method.  Although Björkegren et al. (1996) reported a close 
agreement between the two methods, ideally, further studies on a larger scale should 
be performed in the future to validate the Intralipid method against the currently used 
‘gold-standard’ methods. 
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6.3  Future Experiments and Applications of the Method 
Results from Chapter 5 suggest that moderate exercise is likely to increase VLDL1 
clearance by increasing its size and TG-enrichment, thereby increasing its affinity for 
LPL-mediated lipolysis.  Reports from the literature with respect to the effect of 
moderate exercise on LPL and CETP activities, which are responsible for VLDL1 
TG-enrichment, are conflicting.  Therefore, it would be helpful to conduct the 
following two studies.  The first is an in vitro study investigating the suggested 
higher affinity of VLDL1 to LPL post-exercise.  This could possibly be done by 
incubating LPL (obtained commercially or post heparin from a donor) with different 
concentrations (and possibly at different durations) of the subject’s native VLDL1 
particles separated from the Control and Exercise trials.  VLDL1 lipolysis is then 
determined by measuring the released NEFA from VLDL1 by LPL over time.  In 
addition, Intralipid could also be incubated with native VLDL1 and LPL to 
investigate the relative competition between Intralipid and VLDL1 particles for LPL-
mediated lipolysis in both the Control and Exercise trials.  
Secondly, it is important to compare the activity of CETP in control and post-
exercise as data from Chapter 5 suggest an increased TG-enrichment of VLDL1 
particles post-exercise.  However, current commercial methods that measure CETP 
activity use the same concentration for donor and accepter particles in both exercise 
and control trials, which does not necessarily reflect physiological conditions as in 
vivo concentrations of VLDL particles differ between both conditions.  Therefore, it 
would be better to measure CETP activity in an assay in which native VLDL1 from 
the Exercise and Control trials are used as donor and accepter particles.  
These two experiments would aid a better understanding of the effect of exercise on 
VLDL1 and test the hypothesis that the increased clearance of VLDL1 post-exercise 
is due to the increased size and TG-enrichment of the VLDL1 particle. 
Finally, previous studies have shown that the relationships between obesity, insulin 
resistance, metabolic syndrome and risk for cardiovascular disease are subject to 
ethnic variations (Joshi et al., 2007; Lear et al., 2003; Whincup et al., 2002).  For 
example, compared with Caucasian men, South Asian men have excess subcutaneous 
abdominal adiposity, in spite of similar BMI, which renders them more susceptible to 
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insulin resistance than white men (Chandalia et al., 2007).  In addition, although 
Afro-Caribbean men in the United Kingdom are reported to be as insulin-resistant as 
South Asian men, they have been found to be less susceptible to the dyslipidaemia 
that accompanies insulin resistance (Zoratti et al., 2000).  Interestingly, Zoratti et al. 
(2000) reported that this favourable lipoprotein profile in Afro-Caribbean may relate 
to an effective VLDL metabolism.  However, there is currently no information 
available on the effect of ethnicity on VLDL1 kinetics.  Therefore, an important 
application of the Intralipid method would be to investigate VLDL1 kinetics in a 
different ethnic population. In addition, the method could be used to study VLDL1 
kinetics in response to moderate exercise in Kuwaiti subjects and compare that with 
results from those obtained in Scottish men. Kuwait (the author’s homeland) has a 
high prevalence of obesity (Al-Kandari, 2006), insulin resistance (Al-Shaibani et al., 
2004) and type 2 diabetes (Al-Adsani et al., 2004) and ischemic heart diseases are a 
major cause of death in the country (El-Shazly et al., 2004). 
6.4  Conclusion 
In conclusion, this thesis describes the development and validation a novel method to 
determine the kinetics of large VLDL1, and the application of this method to 
investigate the effects of hyperinsulinaemia/hyperglycaemia and moderate exercise 
on VLDL1 kinetics.  The method is relatively straightforward and cost-effective 
which means it has potential for future widespread use in situations where isotopic 
tracer methods are not feasible because of technical or cost limitations. 
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Appendix A1: Subject Information Sheet and Consent Form – 
Chapters 3 & 4 
 
 
 
Version 3, 18
th March 2004               
 
 
 
 
 
 
 
VOLUNTEER INFORMATION SHEET 
 
 
Title: Development of novel method to determine very low 
density lipoprotein kinetics 
Lay title: A new method of measuring the metabolism of blood fats 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
 
 
 
 
 
 
 
    Institute 
of Biomedical 
and Life Sciences   
Please reply  to :  Division of Neuroscience and Biomedical Systems, 
                             Institute of Biomedical and Life Sciences,  
                             University of Glasgow, West Medical Building, 
                             University Avenue, Glasgow G12 8QQ  
     Tel: 0141-330-2916     Fax: 0141-330-2915     E-mail: j.gill@bio.gla.ac.uk 
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Frequently Asked Questions 
 
What is the purpose of the study? 
The aim of this study is to develop a new method of measuring how fast your liver 
produces fatty particles (called lipoproteins) and how fast these particles are cleared 
from your bloodstream. This will help us to determine how effective different 
treatments are at influencing fat metabolism in future studies. 
 
Why have I been chosen? 
You have been chosen because you are a healthy adult aged between 18 and 65 
years. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
What will happen to me if I take part? 
In the first instance you will be asked to attend for a screening visit in which we will 
discuss with you and complete confidential questionnaires regarding your health and 
family history, measure your blood pressure and provide an opportunity for you to 
ask questions about the study. We will then ask you to help us in one of two different 
ways:  
 
To provide a fasting blood sample: We will ask you to come to the Clinical 
Investigation Suite after an overnight fast and provide a simple blood sample.  We 
will take up to 60 ml (4 tablespoons) of blood from you. Your blood will be used to 
help us to develop laboratory methods for analysing the fat in your bloodstream.   
 
OR 
 
To help us to develop a new method for assessing the metabolism of blood fats: We 
will ask you to perform either one, two or three experimental trials to help us to 
develop a new method for assessing the metabolism of lipoproteins.  Each trial will 
involve coming to our Clinical Investigation Suite after an overnight fast.  We will 
then introduce two small plastic tubes called cannulas into a vein in your arms (one 
in each arm).  This is no more painful than giving a normal blood sample.  We will 
take blood from one cannula and use the other to pump small amounts of a fatty 
substance called Intralipid® into your blood stream.  Intralipid® is used in hospitals 
to feed people through a ‘drip’ when they are unable to eat normally.  The 
Intralipid®  we give you will cause the level of fat in your blood to rise about the 
same amount as it does after you eat a fatty meal and it will be pumped into your 
bloodstream for between one and three hours. We will take two blood samples from 
the cannula before giving you the Intralipid® and then take blood samples at 
intervals during the Intralipid® infusion and for a maximum of two hours after the 
Intralipid® pump is stopped.  We may ask you to sip small amounts of a glucose 
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drink throughout the trial. We will take a maximum of 250 ml of blood during each 
trial – this is half the amount of blood that you give when you donate a ‘pint’ of 
blood. During the experimental trial you will only be able to drink water (or the 
glucose drink), but we will provide you with some food to eat when the trial is 
finished.  The total duration of each trial will vary between 2
1/2 and 6 hours but we 
will tell you specifically how long each of your own trials will take. You will be able 
to watch TV or videos, listen to music or read to keep yourself occupied during the 
experiment. 
   
What do I have to do? 
We will ask you to weigh and record everything that you eat and drink and to avoid 
alcohol and planned exercise for the two days before each Intralipid® test.  We will 
provide you with scales and record sheets to enable you to record your diet easily.  If 
you do more than one test, we will ask you to eat the same diet on the two days 
leading up to each test. (You will not need to do this if you are just giving us a 
fasting blood sample). 
 
What are the possible disadvantages and risks of taking part? 
Blood sampling via the cannula may cause minor bruising, an inflammation of the 
vein or haematoma (a small accumulation of blood under the skin). Good practice, 
however, minimises this risk.  Some people may feel faint when they give blood. 
There is a small risk that you could have an allergic reaction to Intralipid®  (less than 
one chance in a million). This usually only occurs in people are allergic to soya 
protein or eggs, so if you have these allergies you will not be able to participate in 
this study.  In the unlikely event that you do have an allergic reaction to Intralipid® , 
the appropriate medicines and equipment are in place for you to be treated 
immediately. 
There is a small possibility that taking part in this study will reveal a health problem 
that you already have such as high cholesterol or high blood pressure. If such a 
problem is revealed, we will inform your GP to ensure that you receive appropriate 
treatment.   
 
What are the possible benefits of taking part? 
The purpose of this study is to develop a new method of determining how fast 
lipoprotein particles are produced by the liver and how fast they are broken down 
and cleared from the bloodstream. We will be able to use this method in future 
research to help to determine how effective different treatments are at improving the 
way in which the body handles fat. 
 
What if something goes wrong? 
The chances of something going wrong are extremely small. All of the procedures 
involved in this study are low risk and our screening tests are designed to ensure that 
you will only participate if it is safe for you to do so. In the unlikely event that you 
are harmed due to someone's negligence, then you may have grounds for a legal 
action but you may have to pay for it. Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints 
mechanisms may be available to you. 
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Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the University 
or hospital will have your name and address removed so that you cannot be 
recognised from it. 
 
Who has reviewed the study? 
This study has been reviewed and approved by the North Glasgow NHS Trust 
Research Ethics Committee. 
 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you have 
any doubts or questions, please ask for further explanations by contacting either: 
 
Iqbal AlShayji 
Mobile: 07799353689     E-mail: ialshayji@yahoo.com 
Tel: 0141 2114595      
 
 
Dr Jason Gill 
Tel: 0141 3302916       E-mail: j.gill@bio.gla.ac.uk
 
 
  
You will be given a copy of this information sheet and a signed 
consent form to keep for your records. 
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Volunteer Identification Number for this trial: __________ 
 
 
 
CONSENT FORM 
 
Title of Project: Development of novel method to determine very low 
density lipoprotein kinetics 
 
Lay title: A new method of measuring the metabolism of blood fats 
 
 
Name of Researcher: ___________________________________________ 
 
 
Please initial box 
 
1. I confirm that I have read and understand the information 
sheet dated 18 March 2004 (version 3) for the above study 
and have had the opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected. 
 
3.  I agree to take part in the above study.   
 
 
 
 
 
      
           
Name of Patient  Date  Signature 
 
    
Name of Person taking consent  Date  Signature 
(if different from researcher) 
 
   
Researcher Date  Signature 
 
 
 
 
 
Blue for patient 
Pink for researcher 
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Appendix A2: Subject Information Sheet and Consent Form - 
Chapter 5 
 
 
 
 
 
 
 
 
 
 
VOLUNTEER INFORMATION SHEET 
 
 
Title: Effects of Moderate Exercise on Very Low Density 
Lipoprotein Kinetics 
 
Lay title: How does exercise affect the metabolism of the liver’s fatty 
particles? 
 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
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What is the purpose of the study? 
Heart disease is the leading cause of death in Scotland and being even slightly 
overweight, particularly when fat is stored in the tummy region, increases your risk. 
Many factors contribute to a person’s risk of heart disease, but it is thought that the 
ability to cope with fat contained in food plays a role.  A single session of moderate 
exercise decreases blood fat concentrations following a meal, but is unclear whether 
this is due to an increase of the clearance of fatty particles by the blood, or their 
reduced production from the liver. This study will help to investigate the effects of a 
single brisk walking session lasting from 90 to 120 minutes on the production and 
clearance of fatty particles. This is important as exercise could be used as a treatment 
option, rather than drugs, to prevent and treat disturbances in blood fat metabolism. 
 
Why have I been chosen? 
You have been chosen because you are a man or a postmenopausal woman aged 
between 30-60 years who is heavier than the ideal weight for your height.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide, you will be 
given this information sheet to keep and be asked to sign a consent form. If you do 
this you are still free to withdraw at any time and without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
What will happen to me if I take part? 
In the first instance you will be asked to attend for a screening visit in which we will: 
  discuss with you and complete confidential questionnaires regarding your 
health, family history and physical activity level 
  measure your blood pressure 
  take your height, weight and waist measurements 
  take two small blood samples (20 ml or 4 teaspoons) to check the fat and 
sugar levels in your blood.  We will also check if you are anaemic or have 
any abnormalities in the function of your liver, kidneys and thyroid gland   
  provide an opportunity for you to ask questions 
 
These preliminary procedures will enable us to determine whether you fall into the 
group of people we wish to study and will also ensure that it is perfectly safe for you 
to take part. In addition, we will inform your GP of your participation in the study 
and send them a copy of your screening results. 
 
Experimental procedures 
 
A. Preliminary Exercise Test 
At the beginning of the study, an exercise test will be undertaken.  This will involve 
walking on a motorised treadmill.  If you are not used to walking on a treadmill, we 
will familiarise you with this before any ‘real’ sessions are performed. The test is 
designed to estimate your body’s ability to use oxygen and enables us to find the 
correct speed and gradient for you to walk at during your treadmill walks. This will 
not require a maximal effort and the test will last for about 20 minutes.  Heart rate 
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will be monitored and recorded throughout using a heart rate monitor and expired air 
will be collected at intervals using a mouthpiece and respiratory valve.  For safety 
reasons, the test will be stopped if your heart rate exceeds 85% of your predicted 
maximum. 
 
B. Body Composition  
The amount and distribution of your body fat will be determined by measuring body 
girths and by using callipers to measure skin fold thickness at four different sites (a 
sophisticated version of "pinch an inch"). Your height, weight and waist and hip 
circumferences will also be recorded. You will need to wear only underclothing for 
these measurements which will be made in private.  These measurements only take a 
few minutes and can be made on the same day as other tests. 
 
C. Main Trials 
We will ask you to undertake 2 Intralipid tests, approximately 1-2 weeks apart, in 
random order. On the day prior to one Intralipid test, a controlled exercise session of 
90- to 120-minutes walk will be undertaken (Exercise test). Other than this, 
conditions (such as alcohol consumption, food eaten, etc) in the days leading up to 
each trial will be EXACTLY the same. This is explained in detail in the “What do I 
have to do?” section. 
 
  Control Test – We will ask you to come to our Clinical Investigation Suite at 
Glasgow Royal Infirmary after an overnight fast (i.e. having eaten nothing 
and with only water to drink for 12 hours). We will then introduce two small 
plastic tubes called cannulas into a vein in your arms (one in each arm).  This 
is no more painful than giving a normal blood sample.  We will take blood 
from one cannula and use the other to pump small amounts of a fatty 
substance called Intralipid into your blood stream.  Intralipid is used in 
hospitals to feed people through a ‘drip’ when they are unable to eat 
normally. This is a quick way for us to give you a fatty meal. The Intralipid 
we give you will cause the level of fat in your blood to rise about the same 
amount as it does after you eat a fatty meal and it will be pumped into your 
bloodstream for 60 to 75 minutes. We will take a maximum of 250 ml of 
blood during each trial – this is half the amount of blood that you give when 
you donate a ‘pint’ of blood. During the test you will not be able to eat or 
drink anything except water, but we will provide you with some food to eat 
when the trial is finished.  The total duration of each test will be about 3 
hours. You will be able to watch TV or videos, listen to music or read to keep 
yourself occupied during the experiment. 
 
  Exercise Test – This will be identical to the control test, except that we will 
ask you to come to the University to walk on the treadmill for 90 to 120 
minutes on the day before the test. 
 
What do I have to do? 
We also ask you to maintain your usual lifestyle (i.e. don’t change your diet or 
exercise habits) for the duration of this study. However, before each Intralipid test, 
we ask you to do the following: 
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1.  For 3 days before each Intralipid test, refrain from planned or strenuous 
exercise, other than for personal transportation and the 90- to 120-minute 
treadmill walk in our laboratory.. 
2.  Weigh and record everything you eat and drink for 2 days before each test.  
We will provide you with weighing scales and diet sheets to do this.   
3.  Refrain from alcohol consumption on the day before each test. 
4.  For the 2 days leading up to the second test, we will ask you to eat the same 
diet as you did on the two days leading up to the first test. Therefore, we 
would advise you to eat meals that you will be able to easily repeat during the 
days preceding both tests.  
 
What are the possible disadvantages and risks of taking part? 
  Exercise testing will not be at a maximal level but the possibility exists that, very 
occasionally, certain changes may occur during or shortly after the tests. They 
include abnormal blood pressure, fainting or a change in the normal rhythm of 
the heartbeat.  
  Blood sampling via the cannula may cause minor bruising or an inflammation of 
the vein. Good practice, however, minimises this risk.  Some people may feel 
faint when they give blood. 
  There is a small risk that you could have an allergic reaction to Intralipid (less 
than one chance in a million). This usually only occurs in people who are allergic 
to soya protein or eggs, so if you have these allergies you will not be able to 
participate in this study.  In the unlikely event that you do have an allergic 
reaction to Intralipid, the appropriate medicines and equipment are in place for 
you to be treated immediately. 
  There is a small possibility that taking part in this study will reveal a health 
problem that you already have such as high cholesterol or high blood pressure. If 
such a problem is revealed, we will inform your GP to ensure that you receive 
appropriate treatment.   
 
What are the possible benefits of taking part? 
There may be no benefits to you but as a result of being involved in this study you 
will receive health and fitness information about yourself including fitness tests, 
dietary assessment, body fat measurement and your cholesterol and blood sugar 
levels.  This study will help us to determine how exercise can improve risk factors 
for heart disease and diabetes. The findings will be published in scientific journals so 
that understanding of the way in which exercise decreases the risk of heart disease 
and diabetes can be increased.  This information may help make up better exercise 
guidelines, particularly for people who are overweight or obese.   
 
We will provide you with feedback about the main study findings and also about 
your own results and would be delighted to explain results and discuss the 
implications with you. 
 
What if something goes wrong? 
The chances of something going wrong are extremely small. We have recently 
conducted a similar project and there were no problems. All of the procedures 
involved in this study are low risk and our screening tests are designed to ensure that 
you will only participate if it is safe for you to do so. In the unlikely event that you 
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are harmed due to someone's negligence, then you may have grounds for a legal 
action but you may have to pay for it. Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints 
mechanisms may be available to you. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the University 
or hospital will have your name and address removed so that you cannot be 
recognised from it. In addition, your records, samples and results will be identified 
by a number and not your name.  
 
What will happen to the results of the research study? 
The results from this study will be presented at scientific meetings and published in 
scientific journals. A copy of the published results will be sent to you upon request. 
You will be informed which part of the study you were in, as this information will be 
confidential and no one else will know your name and which part you participated in. 
 
What will happen to my samples after the study has finished? 
The blood samples that you provide for this study may be useful for future research 
into the prevention and treatment of diabetes and heart disease; this may involve 
investigating new biochemical markers that are not yet identified. Samples will be 
analysed anonymously and will require a new ethics application before they would 
be used for future research. If you do not wish your samples to be used for future 
research, please indicate this on the consent form. 
 
Who has reviewed the study? 
This study has been reviewed and approved by the North Glasgow NHS Trust 
Research Ethics Committee. 
 
Who is organising and funding the research? 
This study is being funded by the British Heart Foundation and the Glasgow Royal 
Infirmary R&D Endowment Fund (Chest, Heart and Stroke).  
 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you have 
any doubts or questions, please ask for further explanations by contacting either: 
 
Iqbal AlShayji 
Mobile: 07799353689     E-mail: i.alshayji.1@research.gla.ac.uk
Tel: 0141 211 4595 or 4596      
 
Dr Jason Gill 
Tel: 0141 3302916       E-mail: j.gill@bio.gla.ac.uk
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You will be given a copy of this information sheet and a signed 
consent form to keep for your records. 
 
 
 
Thank You for Your Time and Participation 
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Volunteer Identification Number: ___________ 
 
 
CONSENT FORM 
 
Title of Project: Effects of moderate exercise on very low density lipoprotein 
kinetics 
 
Lay title: How does exercise affect the metabolism of the liver’s fatty particles? 
 
 
Name of Researcher: ____________________________________________ 
 
Please initial box 
 
1.  I confirm that I have read and understand the information sheet 
dated 21/02/2006 (Version 3) for the above study and have had 
the opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
3.  I agree to take part in the above study. 
 
4.  I agree that my GP is to be informed of my participation in this 
study. 
 
5.  I agree for my samples to be used for future research into the 
prevention and treatment of diabetes and heart disease. This 
may involve analysis of new biochemical markers not yet 
identified. 
Yes  
  
 No 
 
 
      
           
Name of Subject  Date  Signature 
 
    
Name of Person taking consent  Date  Signature 
(if different from researcher) 
 
   
Researcher Date  Signature 
 
 
 
Copy for subject 
Copy for researcher 
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Appendix B1: Health Screen Questionnaire – Chapters 3 & 4 
 
HEALTH SCREEN FOR STUDY VOLUNTEERS 
 
Name: _____________________________________________________ 
It is important that volunteers participating in research studies are currently in good health 
and have had no significant medical problems in the past.  This is to ensure (i) their own 
continuing well-being and (ii) to avoid the possibility of individual health issues 
confounding study outcomes. 
 
Please complete this brief questionnaire to confirm fitness to participate: 
 
1.  At present, do you have any health problem for which you are: 
(a)  on medication, prescribed or otherwise      yes [  ]  no [  ] 
(b) attending your general practitioner       yes [  ]  no [  ] 
(c)  on a hospital waiting list        yes [  ]  no [  ] 
 
2.  In the past two years, have you had any illness which required you to: 
(a)  (a)  consult  your  GP      yes  [  ]  no  [  ] 
(b) attend a hospital outpatient department      yes [  ]  no [  ] 
(c)  be admitted to hospital          yes [  ]  no [  ] 
 
3.  Have you ever had any of the following: 
(a)  Convulsions/epilepsy      yes  [  ]  no  [  ] 
(b) A s t h m a         y e s   [   ]   n o   [   ]  
(c)  E c z e m a         y e s   [   ]   n o   [   ]  
(d) Diabetes       yes  [  ]  no  [  ] 
(e)  A  blood  disorder      yes  [  ]  no  [  ] 
(f)  Digestive  problems      yes  [  ]  no  [  ] 
(g) Hearing  problems      yes  [  ]  no  [  ] 
(h) Disturbance of balance/co-ordination    yes  [  ]  no  [  ] 
(i)  Numbness in hands or feet        yes [  ]  no [  ] 
(j)  Disturbance  of  vision      yes  [  ]  no  [  ] 
(k) Thyroid  problems      yes  [  ]  no  [  ] 
(l)  Kidney or liver problems        yes [  ]  no [  ] 
(m) Chest pain or heart problems        yes [  ]  no [  ] 
(n) Any other health problems        yes [  ]  no [  ] 
(o) An allergy to soya protein or eggs      yes [  ]  no [  ] 
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4.  For female volunteers only 
(a)  Are you pregnant or think that you might be pregnant  yes [  ]  no [  ] 
(b) Do you take the contraceptive pill or other hormone-based contraceptives   
         y e s   [   ]   n o   [   ]  
(c)  Are you postmenopausal        yes [  ]  no [  ] 
(d) Are you receiving Hormone Replacement Therapy (HRT) 
        y e s   [   ]   n o   [   ]  
 
5.  Have any of your family (parents, grandparents, brothers, sisters, children, aunts, 
uncles, cousins) ever had any of the following: (if yes please give details including age 
of first diagnosis) 
(a)  Any  heart  problems      yes  [  ]  no  [  ] 
(b) Diabetes       yes  [  ]  no  [  ] 
(c)  S t r o k e         y e s   [   ]   n o   [   ]  
(d) Any other family illnesses        yes [  ]  no [  ] 
 
6.  Do you currently  smoke       yes [  ]  no [  ] 
Have you ever smoked          yes [  ]  no [  ] 
  
If so, for how long did you smoke and when did you stop? …………………… 
 
7.  How many units of alcohol do you typically drink in a week? …………………. 
 
If YES to any question, please describe briefly if you wish (e.g. to confirm whether 
problem was short-lived, insignificant or well controlled.) (Use a separate sheet if 
necessary) 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………….….…………………………………………………………...………………
………………………………………………………………………………….……………… 
 
Name and address of GP 
………………………………………………………………………………… 
…………………………………………………………………………………  
 
Blood pressure measured at screening…………………..mm Hg 
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Appendix B2: Health Screen Questionnaire – Chapter 5  
 
HEALTH SCREEN FOR STUDY VOLUNTEERS 
 
Name: _____________________________________________________ 
 
It is important that volunteers participating in research studies are currently in good health 
and have had no significant medical problems in the past.  This is to ensure (i) their own 
continuing well-being and (ii) to avoid the possibility of individual health issues 
confounding study outcomes. 
 
Please complete this brief questionnaire to confirm fitness to participate: 
 
1.  At present, do you have any health problem for which you are: 
(a)  on medication, prescribed or otherwise      yes [  ]  no [  ] 
(b) attending your general practitioner       yes [  ]  no [  ] 
(c)  on a hospital waiting list        yes [  ]  no [  ] 
 
2.  In the past two years, have you had any illness which required you to: 
(a)  consult  your  GP       yes  [  ]  no  [  ] 
(b) attend a hospital outpatient department      yes [  ]  no [  ] 
(c)  be admitted to hospital          yes [  ]  no [  ] 
 
3.  Have you ever had any of the following: 
(a)  Convulsions/epilepsy      yes  [  ]  no  [  ] 
(b) A s t h m a         y e s   [   ]   n o   [   ]  
(c)  Diabetes       yes  [  ]  no  [  ] 
(d) A  blood  disorder      yes  [  ]  no  [  ] 
(e)  Digestive  problems      yes  [  ]  no  [  ] 
(f)  Disturbance of balance/co-ordination    yes  [  ]  no  [  ] 
(g) Numbness in hands or feet        yes [  ]  no [  ] 
(h) Disturbance  of  vision      yes  [  ]  no  [  ] 
(i)  Thyroid  problems      yes  [  ]  no  [  ] 
(j)  Kidney or liver problems        yes [  ]  no [  ] 
(k) Chest pain or heart problems        yes [  ]  no [  ] 
(l)  Any other health problems        yes [  ]  no [  ] 
(m) An allergy to soya protein or eggs      yes [  ]  no [  ] 
(n) An allergy to nuts 
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4.  For female volunteers only 
(a)  Are you pregnant or think that you might be pregnant  yes [  ]  no [  ] 
(b) Do you take the contraceptive pill or other hormone-based contraceptives   
         y e s   [   ]   n o   [   ]  
(c)  Are you postmenopausal        yes [  ]  no [  ] 
(d) Are you receiving Hormone Replacement Therapy (HRT) 
        y e s   [   ]   n o   [   ]  
 
5.  Have any of your family (parents, grandparents, brothers, sisters, children, aunts, 
uncles, cousins) ever had any of the following: (if yes please give details including age 
of first diagnosis) 
(a)  Any  heart  problems      yes  [  ]  no  [  ] 
(b) Diabetes       yes  [  ]  no  [  ] 
(c)  S t r o k e         y e s   [   ]   n o   [   ]  
(d) Any other family illnesses        yes [  ]  no [  ] 
 
6.  Do you currently  smoke       yes [  ]  no [  ] 
Have you ever smoked          yes [  ]  no [  ] 
  
If so, for how long did you smoke and when did you stop? …………………… 
 
7.  How many units of alcohol do you typically drink in a week? …………………. 
8.  Have you taken part in a research study in the last 3 months? yes [  ]  no [  ] 
 
If YES to any question, please describe briefly if you wish (e.g. to confirm whether 
problem was short-lived, insignificant or well controlled.) (Use a separate sheet if 
necessary) 
…………………………………………………………………………………………………
…………………………………………………………………………………………………
………………….….…………………………………………………………...………………
………………………………………………………………………………….……………… 
 
Name and address of GP 
………………………………………………………………………………… 
…………………………………………………………………………………  
 
Blood pressure measured at screening…………………..mm Hg 
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Appendix C: Kinetic Results For All Subjects According To ApoE 
Phenotypes 
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Figure   8.1: Production rates of [A] VLDL1-TG and [B] VLDL1-apoB and [C] Intralipid-TG 
clearance rate for all subjects (n = 23) according to apoE phenotypes: E2/E3 (n = 3), E3/E3 (n = 
11) and E4+ (n = 9).  P > 0.05 for differences between phenotypes. 
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